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1 Introduction 
1.1 Neuronal cell death mechanisms 
Regulated cell death (RCD), a well-defined sequence of genetically encoded or biochemically 
determined events for the elimination of cells, is a central aspect of cellular homeostasis, tissue 
sculpting during embryogenesis, maturation of the immune system and disease control. In 
1842, Carl Vogt was the first to describe primal features of programmed cell death [198] and 
since then apoptosis, coined in 1972 [96], became the best-characterized form of regulated cell 
death. RCD has expanded from simple descriptive microscopic characterization to genetic and 
biochemical definition, giving rise to a variety of well-defined heterogeneous cell death 
pathways, for instance apoptosis, autophagy or regulated necrosis (Figure 1). Despite 
significant efforts to determine the unique characteristics on a genetic and biochemical basis in 
vitro, cell death pathways in vivo should be regarded as an interconnected network rather than 
individual mechanisms as they are mostly found in parallel or in succession [50,58,59,221]. 
Over the past decades, RCD comprising massive accumulation of reactive oxygen species (ROS) 
and disturbed calcium homeostasis [69] has been implicated in a variety of chronic 
neuropathologies such as Alzheimer’s disease (AD) [28,166], Parkinson’s disease (PD) 
[181,187], Huntington’s disease (HD) [108,197], and in acute brain injury induced by cerebral 
ischemia [128,176], hemorrhagic insults [76,145] or brain trauma [70,119,149].  
Figure 1. Cell death mechanisms 
Cell death mechanisms can be subdivided into three major classes of regulated apoptosis, necrosis and the “recycling”
mechanism autophagy. These major classes itself include a variety of subgroups, such as intrinsic and extrinsic apoptosis
or necroptosis, oxytosis, ferroptosis parthanatos and many others. 
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Mounting evidence has linked imbalanced calcium signaling and the accumulation of ROS, 
such as lipid peroxides, hydrogen peroxide or hydroxyl and nitric oxide radicals, to excessive 
mitochondrial damage, and hence is considered to provoke impairments of mitochondrial 
morphology and function [109]. Since the brain relies on a high metabolic turnover, it crucially 
depends on a functional energy metabolism by mitochondrial respiration and glycolysis, thus, 
rendering it vulnerable to oxidative stress and mitochondrial dysfunction. 
Moreover, recent findings suggest that inflammation severely contributes to 
mitochondrial dysfunction and neurodegenerative cell death [139,193]. In this regard, strong 
microglial activation has been demonstrated to affect mitochondrial dynamics and impair 
mitochondrial energy metabolism, thus, provoking neurodegenerative processes. Vice versa, 
harmed mitochondria of microglia amplify the inflammatory response by ROS production and 
release of damage-associated molecular patterns (DAMPs) [139]. Despite that several events, 
which are attributed to apoptotic or necrotic events, were found to underlie neuronal 
degradation, the exact biochemical mechanisms of cell death in neurons remain to be 
elucidated for the precisely targeted and ideally curative therapy of neuronal diseases.  
1.1.1 Apoptosis 
The best-studied molecular cell death pathway is apoptosis and occurs not only in pathological 
conditions upon cell damage but also during tissue development, homeostasis and ageing 
[47,156]. Typical hallmarks include cytoplasmic shrinkage, chromatin condensation, DNA 
degradation, nuclear fragmentation and membrane blebbing with the formation of apoptotic 
bodies, and caspase-dependency as a biochemical feature [75,79,96]. Apoptosis is further 
subdivided depending on its initiation by either intracellular (intrinsic) or extracellular 
(extrinsic) stimuli (Figure 2). 
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Extrinsic apoptosis requires external death signaling via death receptors at the plasma 
membrane, such as FAS/CD95, tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
receptor (TRAIL1/2) or TNF receptor 1 (TNFR1) [7]. After ligand binding, death receptors 
form oligomers and death domains to activate the initiator caspase-8, thereby activating a 
cascade of effector caspases and provoking rapid cell death [160]. Caspase-8 is also capable of 
cleaving and activating the pro-apoptotic B-cell-lymphoma-2 (BCL-2) protein BID (BH3 
interacting-domain death agonist) to truncated BID (tBID) [48,74,104,111], thereby 
connecting extrinsic and intrinsic apoptotic pathways [177].  
Figure 2. Apoptosis 
Extrinsic apoptosis (left) induced by extracellular death ligands (TNF, FasL) leads to the rapid activation of the initiator
caspase-8 and effector caspases-3/7 causing cell death. Caspase-8 links extrinsic to intrinsic apoptosis via cleavage of full-
length BID to truncated BID, which translocates to the mitochondria. Intrinsic mitochondria-dependent apoptosis (right) 
is activated upon harsh intracellular stimuli, e.g. ROS, radiation, calcium overload or ER stress, and results in detrimental
mitochondrial damage. BAX/BAK and BID/tBID provoke MOMP (mitochondrial outer membrane permeabilization)
thereby releasing AIF and cytochrome C into the cytosol. Cytc, APAF-1 and caspase-9 form the so-called apoptosome, 
which triggers a caspase activation cascade finally executing cell death. 
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In contrast to death receptor signaling, intrinsic apoptosis is induced by a wide array of 
intracellular stimuli including oxidative stress, radiation, hypoxia, DNA damage, endoplasmic 
reticulum (ER) stress or increased intracellular calcium concentration [58].These diverse 
stimuli converge at the level of mitochondria where they trigger mitochondrial outer 
membrane permeabilization (MOMP)[57] by pore formation [12,57,154] through the 
recruitment of the pro-apoptotic BCL-2 family proteins BCL-2 associated x protein (BAX) 
[73,206] and BCL2 antagonist killer 1 (BAK) [202] to the mitochondrial outer membrane 
(OMM). Upon mitochondrial permeabilization, pro-apoptotic factors such as Apoptosis-
inducing-factor (AIF), Endonuclease G (EndoG), high temperature acquired protein A2 
(OMI/HrtA2) or second mitochondria-derived activator of caspases (SMAC/DIABLO) and 
cytochrome c (Cytc) [74,111,153,154] are released from the mitochondrial intermembrane 
space (IMS). Released Cytc, APAF-1 (apoptotic protease-activating factor 1) [110,229] and 
caspase-9 [105] activate a caspase cascade in the cytosol via formation of the so-called 
apoptosome ternary-complex [134,188], whereas SMAC/DIABLO [46] and OMI/HtrA2 [78] 
promote caspase activation through neutralizing the inhibitory effects of IAPs (inhibitors of 
apoptosis proteins). Eventually, the apoptosome initiates the auto-activation of caspase-9 and 
subsequent activation of caspase-3 [105,229].  
Over the past decades a caspase-independent form of intrinsic apoptosis  has been 
introduced where mitochondrial damage is regarded as the point of no return in the cell’s 
commitment to die [127,177,223]. Alterations in mitochondrial morphology and function 
ultimately result in disruption of the mitochondrial membrane potential and energy supply, 
ROS formation and sudden opening of the mitochondrial permeability transition pore (mPTP). 
This mPTP, is observed at the inner mitochondrial membrane rendering it permeable for small 
molecules and proteins with less than 1500 Da [16]. Finally, nuclear DNA fragmentation occurs 
through interaction of AIF with phosphorylated cyclophilin A (CypA) and histone H2AX 
[6,11,43,163] or the nuclease macrophage migration inhibitory factor (MIF) [200]. Owing to 
increasing research recognizing significant morphological overlap with necrosis, this form of 
cell death should rather be allocated to regulated necrosis than to apoptosis [182]. 
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1.1.2 Regulated necrosis 
Necrosis, which was originally defined as random and irreversible rapid death forced by harsh 
mechanical, chemical or temperature stimuli, is recently accepted as genetically controlled and, 
consequently, is termed regulated necrosis [30,196]. Necrosis is an acute form of cell death 
morphologically characterized by cytoplasmic swelling, early plasma membrane rupture, 
cellular leakage, and dilatation of cellular organelles causing inflammation in surrounding 
regions [58]. Additional aspects, such as ROS formation, mitochondrial damage, necrosome 
formation or inhibition by several pharmacological inhibitors, define a number of distinct 
subclasses of regulated necrosis, for instance necroptosis, parthanatos, oxytosis or ferroptosis 
[59] which all have been implicated in various age-related and/or neurodegenerative diseases. 
1.1.2.1. Oxytosis  
In immortalized mouse hippocampal HT22 cells, a model system to study regulated oxidative 
neuronal cell death has been established which is known as oxytosis [185]. A special feature of 
these HT22 cells, originally derived from neural HT4 cells [34,123], is their deficiency in 
ionotropic NMDA (N-methyl-D-aspartate) receptors. Consequently, upon exposure to 
millimolar glutamate concentrations, oxidative cell death occurs independently of excitotoxic 
NMDA receptor-activated calcium overload or caspase activation (1.1.3) [54]. Independence 
of caspases, calpains and cathepsins is further confirmed by the fact that neither the pan-caspase 
inhibitor z-VAD-FMK, caspase-8 inhibitor IETD-FMK nor calpain or cathepsin inhibitors are 
protective in this paradigm of cell death [54,103]. Instead, oxytosis is induced through direct 
inhibition of the cystine/glutamate antiporter system (XC-) at the cell surface [9,125] which 
consists of the disulfide bond-linked cell surface antigen heavy chain (4F2) and the solute 
carrier family 7 member 11 (xCT or SLC7A11) light chain [155].  
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Physiologically, XC- transports glutamate out of the cell in exchange for cystine [155] (Figure 
3). However, upon high extracellular glutamate concentrations or direct inhibition of the 
transporter, this exchange is shut off thereby reducing cysteine pools required for glutathione 
(GSH) synthesis as part of the cell’s redox defense [2,184]. GSH depletion in turn leads to 
compromised function of glutathione peroxidase 4 (GPX4), which is essentially responsible for 
the maintenance of a proper redox state by reduction of hydrogen peroxide, organic 
hydroperoxides as well as lipid peroxides as products of 12/15 lipoxygenases (LOX) (e.g. 
oxidized polyunsaturated fatty acids: PUFA-OOH and phospholipids: PL-OOH) at the expense 
of reduced glutathione [4,45,114]. In addition, GPX4 inhibition is correlated to enhanced 
12/15-LOX activity through accumulated ROS giving rise to a chain reaction of massive soluble 
and lipid ROS production [162], which can be blocked using the antioxidants vitamin E [159], 
Trolox and the LOX inhibitors baicalein or PD146176 [106,186]. Subsequent to increased ROS 
formation, the dynamin-related protein 1 (DRP1) and the pro-apoptotic BCL-2 family protein 
BID translocate to the OMM, where they mediate fission of the mitochondrial network, 
mitochondrial ROS production, and loss of mitochondrial membrane potential and ATP 
production through electron leakage from the electron transport chain [103,186]. Notably, 
depending on their subtype and differentiation state, neurons exclusively inherit an 
alternatively spliced, BH3 domain-only form of BAK (N-BAK) with strong translational arrest 
of the mRNA, thus not being a substitute for BAX or a target for BID at the mitochondrial site 
during oxidative cell death [86,189]. Sequential release of pro-apoptotic proteins, for instance 
the mitochondrial flavoprotein AIF anchored at the inner mitochondrial membrane, mediate 
final cell death execution upon translocation to the nucleus [72,186], nuclear condensation and 
DNA cleavage [163] presumably through interaction with cytosolic CypA [43] or MIF nuclease 
[200]. Despite this pro-death signaling upon mitochondrial release, AIF is believed to play an 
important role in the regulation of mitochondrial morphology and mitochondrial energy 
metabolism [163]. In this context, AIF was shown to stabilize mitochondrial complex I and vice 
versa. Interestingly, AIF depletion-induced complex I degradation resulted in protection 
against glutamate toxicity through preconditioning effects, such as reduced mitochondrial 
membrane potential and enhanced mitochondrial stability [23,24,133]. 
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Despite a lack of initial calcium overload as found in excitotoxicity, during oxytosis calcium 
enters the cell in a delayed manner through the calcium release-activated calcium channel 
protein 1 (ORAI1) [80]. Therefore, glutamate toxicity in HT22 cells is considered as an 
adequate model system to study oxidative neuronal cell death in vitro as it combines oxidative 
stress, mitochondrial BID-transactivation, mitochondrial damage, AIF release and enhanced 
intracellular calcium levels. 
Figure 3. Oxytosis and ferroptosis 
Glutamate and erastin inhibit the Xc--antiporter at the cell’s surface in paradigms of oxytosis and ferroptosis, respectively, 
resulting in decreased cystine and GSH levels. Subsequently reduced GPX4 activity and correlated activation of 
12/15-LOX mediate significant formation of reactive oxygen species (ROS). In erastin-induced ferroptosis cell death is 
defined to be induced through oxidative stress and independently of mitochondrial demise. In neuronal HT22 cells, 
oxytosis-induces transactivation of BID to the mitochondria and causes mitochondrial ROS formation that is associated
with irreversible morphological and functional damage, e.g. loss of membrane potential, decline of ATP levels and release 
of apoptosis inducing factor (AIF), which mediates final cell death. 
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1.1.2.2. Ferroptosis  
Recently, an iron-dependent form of regulated oxidative cell death attracted much attention. 
The term ferroptosis is derived from the word apoptosis to emphasize the strict regulation of 
this type of cell death, and ferrum, the Latin word for “iron” due to the biochemical contribution 
of iron metabolism and iron-containing enzymes to impaired redox homeostasis [38]. Iron is 
crucial to a variety of redox enzymes involved in respiration, which use iron-sulfur (Fe-S) 
clusters as cofactors, for instance nicotinamide adenine dinucleotide (NADH) dehydrogenase 
and coenzyme Q (Cytc reductase). Heme iron is used in oxygen transport as hemoglobin and 
myoglobin, and by catalase and superoxide dismutases (SODs) for detoxification of ROS [49]. 
Death from ferroptosis has been defined as the fatal combination of iron toxicity, 
antioxidant depletion due to disruption of GPX4 and membrane damage through autoxidation 
of polyunsaturated phospholipids (PU-PLs) [38,41,90,180] and enhanced 12/15-LOX activity, 
and, as such, is implicated in several human pathological conditions [30]. In this regard, one of 
the best-studied pathologies is neurodegeneration. To date, GPX4 impairment and lipid 
peroxidation as key features of ferroptosis have been described in models of traumatic brain 
injury [204], cerebral ischemia [175], AD [21,88,115,205], PD [35,77,217], Friedreich’s ataxia 
[1] and HD [29,137]. In addition, ferroptosis is emerging in acute renal failure, hepatic and 
heart ischemia/reperfusion injury, in T-cell immunity and as a curative therapeutic mechanism 
in tumor pathology [49,207,219]. In this regard, NAD phosphate (NADPH) abundance was 
proposed as a biomarker for ferroptosis sensitivity useful for predictions about cancer cell 
sensitivity towards chemotherapy using novel ferroptosis inducing-compounds [168,169]. 
Mechanistically, oxidative cell death by ferroptosis can be induced by either indirect 
disturbance of redox homeostasis through inhibition of system Xc-, subsequent cysteine and 
GSH depletion and reduced GPX4 activity by erastin [42,185], or in a direct manner through 
RSL3-induced covalent GPX4 binding and inactivation [211] (Figure 3). In the following, 
increasing 12/15-lipoxygenase activity gives rise to excessive PEBP1-dependent enzymatic 
[170,204] and iron-catalyzed non-enzymatic lipid peroxide formation (mostly oxidized 
arachidonic [20:4] and adrenic [22:4] phosphatidylethanolamines, Figure 4) [162,195,213], 
which changes lipid bilayer architecture and rapidly leads to cell death.  
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For the synthesis of polyunsaturated phospholipids, the fusion of polyunsaturated fatty acids 
with CoA is required, which is catalyzed by the enzyme acyl-CoA synthetase long chain family 
member 4 (ACSL4) thus facilitating their esterification into phospholipids accomplished by 
LPCAT3 (lysophospholipid acyltransferase 5) [40,90]. In MEF and Pfa1 cells genetic deletion 
or pharmacological inhibition of ACSL4 by triacsin C were both effective in protecting against 
ferroptosis at an early stage before lipid ROS occur [41,90,90]. In this paradigm of oxidative 
death, inhibition of iron supply, ROS formation and LOX inhibition provides therapeutic 
potential against neuronal loss. At the level of iron metabolism, chelators such as deferoxamine 
and the lipid ROS scavenger liproxstatin aim to reduce iron-dependent ROS formation and 
prevent downstream ferroptotic cell death in vitro and in in vivo, e.g. in models of acute renal 
failure and hepatic ischaemia/reperfusion injury [38,53]. Another encouraging strategy is the 
pharmacological inhibition of lipid peroxidation through inhibitors of lipid autoxidation, so-
called radical-trapping antioxidants (RTAs), for instance liproxstatin-1 [53] and ferrostatin-1 
[38,171,227], which were identified using high-throughput screens; or recently described 
diarylamines derived from petroleum degradation inhibitors [164]. Despite a considerable 
increase in studies on oxidative cell death, the exact chronological and molecular pattern of the 
events accompanying ferroptosis and the final cell death execution following lipid peroxidation 
particularly in neurons remains elusive.  
1.1.3 Excitotoxicity 
During ischemic and hypoglycemic episodes, presynaptic neurons massively release the 
excitatory neurotransmitter glutamate up to millimolar concentrations in the synaptic cleft 
(Figure 5) resulting in overstimulation of postsynaptic NMDA or AMPA (α-amino-3-hydroxy-
5-methy-4-isoxazole propionic acid) glutamate receptors and subsequent excitotoxic cell death 
initially proposed by Olney et al. in 1969 [129].  
Figure 4. Phosphatidylethanolamine scaffold 
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Upon rapid calcium influx and secondary activation of voltage-gated calcium channels as well 
as calpain-mediated cleavage of the plasma membrane Na+/Ca2+ exchanger (NCX), 
homeostatic mechanisms are inactivated and calcium levels dramatically rise. Mitochondria are 
massively overloaded with calcium causing permeability transition, ATP depletion, ROS 
generation, such as superoxide and nitric oxide, and release of AIF and Cytc. In addition, the 
activation of cathepsins, calpains and caspases is observed orchestrating the final steps of cell 
death [3,25,142,143,201]. Regardless of unique biochemical features it is still under debate 
whether the paradigm of excitotoxicity should be considered as a sole form of cell death as it 
has been linked to both the activation of apoptosis and regulated necrosis [116]. 
 
Figure 5. Excitotoxicity 
Excitotoxicity is initiated upon massive glutamate release from pre-synaptic neurons. This neurotransmitter binds to
post-synaptic glutamate receptors, e.g. NMDA and AMPA receptors, provoking excessive calcium influx. Mitochondria
take up a significant amount of calcium leading to ROS formation, disturbed ATP synthesis and membrane
depolarization. Upon opening of the mitochondrial permeability transition pore, Cytc and AIF are released, which leads
to caspase-activation, nuclear DNA damage and cell death. The ER contributes to calcium overload by release of stored
calcium thereby promoting caspase and calpain-cleavage induced detrimental effects. Inside the cell calcium-induced 
ROS formation through NO synthase (NOS) and lipid peroxidation further harms the cell and leads to the disruption of
membranes at the cell surface and at the mitochondria driving the neuron to death. 
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1.2 BCL-2 family proteins 
The family of BCL-2 proteins plays a major regulatory role in mitochondrial permeabilization 
and thereby promote pro- and anti-apoptotic events in the cytosol and in mitochondria. As 
such, BCL-2 protein activity is implicated in the regulation of mitochondrial morphology and 
metabolism such as carbon substrate utilization, electron transport and metabolite import [66]. 
Moreover, BCL-2 family proteins are involved in tumor pathology, neurodegenerative and 
autoimmune diseases as well as in tissue development and maturation of blood cells [62,118]. 
In mammalian cells, at least 12 core BCL-2 proteins are known which are subdivided in three 
classes according to their properties of either promoting or inhibiting cell death and their BCL-
2 homology (BH) domains (Figure 6). The first group includes all pro-survival BCL-2 proteins 
(BCL-2, BCL-XL, BCL-W, MCL-1, A1), whereas the apoptosis initiators are subdivided in 
multi-domain (BAX, BAK, BOK) and BH3-only proteins (BID, BIM, BIK, BAD, PUMA, 
NOXA). Pro-apoptotic signaling can be achieved by either direct activation of cell death, 
known as activators (BID, BIM) or by antagonizing anti-apoptotic proteins, the so-called 
sensitizers (NOXA, BIK) [101,218]. The multi-domain pro-apoptotic proteins BAX and BAK 
most prominently mediate MOMP by their incorporation into the OMM once truncated BID 
is translocated to the OMM and mediates BAX/BAK oligomer pore formation. At the MOM, 
the pores release Cytc and other pro-apoptotic factors which can be circumvented by direct 
interaction with prosurvival BCL-2 proteins [138]. In turn, a caspase cascade is activated and 
the apoptosome is formed representing the point of no return in intrinsic apoptosis (1.1.1.). 
Figure 6. BCL-2 family proteins 
BCL2-family proteins are subdivided into three major groups according to their anti-apoptotic or pro-apoptotic 
properties and their BH domains. 
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1.2.1 The BH3-only protein BID 
Among the BCL-2-family proteins the cytosolic 22 kDa BH3-only protein BID is a key 
regulator of mitochondrial apoptosis by activating BAX and BAK to promote MOMP, thereby 
linking extrinsic to intrinsic apoptosis pathways [199]. In contrast to other BH3-only proteins, 
BID appears as a highly structured protein with conserved regions of sequence homology and 
similar predicted secondary structure to the core multi-BH3 domain BCL-2 family members 
(Figure 7). According to the NMR spectroscopy structural 3D models [26,120], BID contains 
eight α-helices, two of which build a hydrophobic core (α6 and α7), an unstructured N-
terminus and an intramolecular unstructured loop with several distinct cleavage sites for 
caspases, calpains, cathepsins, granzyme B and c-Jun N-terminal kinases (JNK) activated 
protease [18]. As suggested by Kvansakul et al. [102], BID may contain a redefined BH4 region 
at the N-terminus, which was originally found in anti-apoptotic BCL-2 proteins. Further 
attempts to clarify the 3D structure included generation and purification of novel recombinant 
mouse Bid constructs lacking unstructured parts of the protein to facilitate crystal growth for 
X-ray crystal analysis, however, reproducible crystallization could not be achieved so far[132]. 
In response to apoptotic stimuli, the full-length protein is proteolytically cleaved by caspase-8 
(or by granzyme B, calpains, cathepsins and more rarely other caspases) into an N-terminal p7 
fragment, so-called nBID and a C-terminal p15 fragment, so-called truncated BID (tBID or 
cBID) containing the BH3 domain (amino acids 90-98) (Figure 8) [74,104,111].  
Figure 7. NMR mouse BID protein structure (1DDB) 
The NMR solution structure of mouse BID [112] depicts eight α-helices, two of which build a core unit, an unstructured
N-terminus and an intramolecular unstructured loop 
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When still bound, the fragment-complex (also termed cBID: cleaved BID) is masking the BH3 
domain and translocates to the mitochondria. At the mitochondria, the BID-complex breaks 
apart, adopts an extended conformation [55] and tBID helices α4-α7 associate with the OMM 
[165] (Figure 9) thereby recruiting BAX [73,206] and BAK [202][203] with its unmasked 
hydrophobic BH3 domain.  
Figure 9. Proposed tBID association with mitochondrial membranes 
Human: MDCEVNNGSSLRDECITNLLVFGFLQSCSDNSFRRELDALGHELPVLAPQWEG--YDELQ
Mouse: MDSEVSNGSGLGAEHITDLLVFGFLQSSG--CTRQELEVLGRELPVQA-YWEADLEDELQ
58 TDGNRSS-HSRLGRIEADSESQEDIIRNIARHLAQVGDSMDRSIPPGLVNGLALQLRNTS
57 TDGSQASRSFNQGRIEPDSESQEEIIHNIARHLAQIGDEMDHNIQPTLVRQLAAQFMNGS
Casp-8 BH3 domain
RSEEDRNRDLATALEQLLQAYPRDMEKEKTMLVLALLLAKKVASHTPSLLRDVFHTTVNF
LSEEDKRNCLAKALDEVKTAFPRDMENDKAMLIMTMLLAKKVASHAPSLLRDVFHTTVNF
INQNLRTYVRSLARNGMD 195
INQNLFSYVRNLVRNEMD 195
Figure 8. Human/mouse BID protein sequence alignment 
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BAX and BAK, in turn, insert and form oligomers mediating MOMP to release pro-apoptotic 
proteins such as Cytc [12,74,111,154,202] and AIF [5] from the IMS. The presence of a 
mitochondria specific negatively charged phospholipid at the IMM, namely cardiolipin, was 
demonstrated to be required for tBID binding and BAX oligomerization [68,112]. In addition, 
the presence of mitochondrial carrier homolog 2 (MTCH2) at the mitochondria has been 
shown to further increase tBID recruitment and is discussed as a second tBID receptor 
[71,92,146,222]. Apart from direct pro-apoptotic function, BID is also able to bind and inhibit 
anti-apoptotic BCL-2 family proteins such as BCL-2 and BCL-XL, thus indirectly promoting 
apoptosis [199]. Moreover, BID is upregulated by the tumor suppressor and apoptosis initiator 
p53 and promotes p53-regulated apoptosis [157]. Additionally, BID is located in the nucleus 
where it is known to participate in a mitosis checkpoint and maintenance of genomic stability 
possibly functioning as a sensor of DNA damage through ATM (ataxia-telangiectasia mutated 
serine/threonine kinase)-mediated phosphorylation [91,228]. 
Functional studies on BID deficiency in vitro found significant protection against 
oxidative stress in neuronal HT22 cells [103], oxygen-glucose deprivation (OGD) in neurons 
[117,140] and against MNNG-induced necroptosis in BID−/− MEFs (mouse embryonic 
fibroblasts) [19]. In mice, loss of BID has little effect on developmental apoptosis but provokes 
resistance to Fas-induced hepatocyte apoptosis [215]. A study on middle cerebral artery 
occlusion (MCAO) as a model of cerebral ischemia confirmed BID-cleavage by caspase-8 
in vivo and revealed BID-deficient mice to obtain attenuated infarction size [140,216] and 
reduced inflammation [117] suggesting BID to contribute to nerve cell demise upon ischemia. 
Improved outcome of BID-deficient mice was additionally demonstrated in a model of renal 
ischemia reperfusion injury where Bid knockout ameliorated renal failure [203].  
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The BCL-2 family protein BID was also found to be a mediator of astrocyte activation in 
neuroinflammation through NF-κB signaling analyzed in wildtype (WT) and BID-deficient 
mice [100]. In a controlled cortical impact (CCI) model for traumatic brain injury, BID-
deficient mice showed decreased early posttraumatic brain cell death and tissue damage, 
however, their functional outcome deficits were not reduced [15]. Finally, excitotoxic BID 
cleavage was detected in a rat model of seizures evoked by kainic acid injection into the 
amygdala [81] and in human temporal lobe epilepsy [209]. 
1.2.2 The BID-inhibitor BI-6c9 
One of the best-studied inhibitors of oxytosis is the BID inhibitor BI-6c9 [13,14] (Figure 10), 
which was developed in order to provide neuroprotection in conditions of BID-mediated 
mitochondrial cell death. The molecular design of BID inhibitors was based on the mouse BID 
NMR structural data from 1999 (1DDB) [120] which indicated a hydrophobic groove at the 
surface of the protein and led to the lead structures BI-11A7 and BI-6c9 being protective in 
vitro [13,14,72,98,103,186]. However, further optimization of small-molecule BID inhibitors 
requires improved affinity and water solubility for increased bioavailability upon oral 
application and would be facilitated by high-resolution crystal BID structures for 3D modeling 
of lead structures. 
Figure 10. BID inhibitor BI-6c9 
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1.3 CRISPR/Cas9 genome engineering 
Genetic abnormalities are responsible for a variety of neurodegenerative disorders as they often 
result in the accumulation of mutated and/or misfolded proteins as found in for instance AD, 
HD or PD [17]. Latest research has established CRISPR (Clustered Regularly Interspaced Short 
Palindromic Repeats)/Cas9 (CRISPR-associated protein) gene editing as a versatile tool [63,87] 
to knock out or repair certain genetic material providing new therapeutic options for the 
treatment of genetic neurological diseases lacking effective treatment options. Editing genomic 
DNA using CRISPR marks the beginning of a new era and may be used to reduce or even halt 
disease progression but has to be tightly controlled for precise gene manipulation in the affected 
area. Due to the complexity of editing human genomes, CRISPR is also widely established for 
the generation of animal models [210] for investigating the pathogenic mechanisms underlying 
neurodegenerative processes and to reveal novel treatment strategies. So far, various other gene 
editing tools, for instance TALEN (transcription activator-like effector nucleases) [89] and zinc 
finger nucleases (ZFNs) [190] have been established, however, the CRISPR/Cas technology 
seems most promising being faster and more efficient [56]. 
CRISPR/Cas editing techniques have evolved from a microbial adaptive immune 
mechanism to fend off foreign nucleic acids upon viral invasion (Figure 11) [122,144]. A 
CRISPR locus contains a sequence encoding the endonuclease Cas and unique so-called spacer 
motifs derived from viral nucleic acids delineated by short, repeated, palindromic sequences. 
Upon transcription and translation of the bacterial CRISPR-DNA, the spacers, which are 
homologous to the viral nucleic acids, become guide RNAs leading the endonuclease Cas9 to 
the target viral sequences for degradation. In case of reinfection, bacteria utilize this system to 
destroy pathogenic viral nucleic acids.  
  
  1 Introduction 
 
17 
 
 
Figure 11. CRISPR/Cas process 
(1) Infection of a bacterial cell and release of bacteriophage nucleic acids leads to the incorporation of viral DNA/RNA in
the bacterial genome delineated by short repeated sequences (CRISPR-DNA). (2) Transcription and translation of
bacterial CRISPR DNA results in various guide-RNA/tracr-RNA sequences targeting the original viral DNA by Cas9. 
(3) Bacterial CRISPR-RNA and Cas9 eliminate invading viral genomic material. 
  1 Introduction 
 
18 
 
Since the early discovery of CRISPR sequences in 1987 [85] and viral defense mechanisms in 
2005 [122,144], the system has been adapted for use as gene editing tool in eukaryotes in 2012 
(Figure 12) [63,87]. Meanwhile, the number of new applications and improved gene editing 
protocols increased dramatically [56]. One of the most applicable gene editing techniques using 
CRISPR/Cas9 is simple gene knockout by frameshift or stop codon mutation. Here, a target-
specific guide RNA including a PAM (protospacer adjacent motif, mostly NGG for S. pyogenes 
derived Cas9) sequence combined with Cas9 is exploited to perform double-strand breaks 
(DSB) in the genomic DNA. Subsequently, DNA repair mechanisms are activated in an attempt 
to repair DNA strand breaks by non-homologous end joining (NHEJ) or homology-directed 
repair (HDR) [83]. The predominant repair mechanism NHEJ, however, is error-prone leading 
to addition or deletion of nucleotides named indel mutations ultimately resulting in non-sense 
protein mutation or knockouts. In contrast, HDR results in full DNA restoration but requires 
a homologous DNA sequence for insertion. This rare repair mechanism can be taken advantage 
of if targeted introduction of specifically mutated genetic material is desired (knock-in) 
although the successful mutation rate is as little as ~8-10 % [8] if not enhanced by suppressing 
NHEJ using for instance KU70 knock down [191]. 
 
Figure 12. CRISPR timeline 
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CRISPR/Cas9 is not only useful to permanently alter genetic material but is also applicable for 
gene regulation purposes [64]. To do so, an enzymatically inactive Cas9 (dCas9) is employed to 
repress or activate gene transcription when combined with a proper guide RNA and repressor 
or activator proteins. Variations of dCas9 can also be targeted to the transcriptional promoter 
regions of specific genes to activate or block their transcription initiation or elongation [51]. 
Current attempts in the development of CRISPR-based therapy in neurodegenerative 
diseases address, for instance, AD and PD. In particular, early-onset familial AD is genetic in 
origin leading to accumulation of amyloid β plaques (Aβ). Mutations were found in genes 
encoding for proteins that enhance the accumulation of Amyloid beta (Aβ) protein such as 
presenilin 1/2 (PSEN1/2) or amyloid precursor protein (APP), and alterations in 
apolipoprotein E (APOE) which increase the risk for late-onset AD. In order to study AD, 
human induced pluripotent stem cells (iPSCs) have been created, which display certain 
phenotypes according to their genotype (CRISPR-derived APP and PSEN mutations [135]). 
Further, CRISPR applications might be enhancing pathogenic Aβ-clearance or repressing 
mutant APP production. Moreover, animal models of CRISPR can be used to predict 
therapeutic and/or adverse effects of pharmacological drugs by repression of certain enzymes 
targeted by pharmacological inhibitors and to halt detrimental neuronal loss by the 
identification of key proteins involved in nerve cell death. 
A major concern in the field of CRISPR research remains the precise control for off-
target effects as gRNAs are limited to 17-24 base pairs length often targeting genetic sequences 
other than the target site [158]. The chance for off-target effects depends on the succession and 
number of mismatched nucleotides [83,84,113]. For example, mismatches at the 5’ end and at 
gRNA sequences with high GC content are more likely to be tolerated. Thus, gRNAs should be 
chosen carefully and CRISPR knockout attempts should be controlled for off-target effects. In 
addition, nickases are useful to reduce off-targets. Here, Cas9 is altered in a way, that it is only 
capable of cleaving one DNA strand and requires a second guide RNA to bind at the opposite 
side of the target sequence to achieve a complete DSB [97]. Additional approaches are reducing 
the Cas9 concentrations and limiting the half-life by using Cas9 protein delivered via cell-
derived membrane vesicles (CMV) instead of Cas9 plasmid DNA [82,192]. 
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1.4 Aims of the thesis 
Over the last decades, the crucial involvement of BID-mediated mitochondrial damage in 
various cell death paradigms involved in neurodegeneration has become evident. Upon 
activation through excessive (lipid) ROS formation, BID translocates to mitochondria where it 
fatally harms mitochondrial morphology and function thereby disrupting the bioenergetic 
homeostasis. As neuronal computation is energetically expensive, loss of the brain’s limited 
energy supply and mitochondrial damage-associated release of pro-death factors drive neurons 
to death. Based on this fatal contribution to neuronal loss by mediating mitochondrial death 
signaling, impeding BID function as a novel therapeutic strategy should be a promising chance 
to protect brain tissue in neurodegenerative diseases.  
In the first part of this thesis the precise biochemical mechanisms and time-dependent 
progression underlying ferroptotic oxidative cell death by erastin were analyzed. Assuming 
mechanistic similarity to already existing cell death paradigms, for instance oxytosis, the 
pathways of ferroptosis in neurons downstream of lipid peroxidation and potential 
mitochondrial involvement at the point of no return in the cell’s commitment to die were 
elucidated. The study focused on the role of BID in linking oxidative stress to mitochondrial 
injury. Therefore, genetic (CRISPR/Cas9 knockout) and pharmacological BID inhibition (BI-
6c9) were exploited to evaluate the role of BID on erastin- and RSL3-induced ferroptotic cell 
death processes. 
In the second part of the thesis, novel targeted antioxidant treatment options for 
neurodegenerative disorders were addressed with respect to mitochondrial protection. For this 
purpose, the mitochondria-targeted ROS scavenger MitoQ was assessed for potential neuronal 
protection against RSL3-induced GPX4 inhibition and subsequent ferroptotic cell death in 
order to elucidate mitochondrial damage in the context of ferroptosis. Due to the fact that 
MitoQ is already commercially available as a dietary supplement, potential interference with 
mitochondrial energy metabolism were investigated. 
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Finally, neuroprotective approaches could be assisted by structure-guided ligand design 
demanding high-resolution protein structures of the target protein. To date, two NMR 
structures for BID have been published [26,120] but no high-resolution X-ray data are available. 
In previous attempts [132], different constructs of recombinant mouse BID were expressed and 
purified in high amounts by GSH-affinity and size exclusion chromatography. In an attempt to 
crystallize these, promising experimental conditions could already be identified as a basis for 
further optimization. Hence, the primary aim of this part of the study was to optimize BID 
crystallization by creating and purifying appropriate protein constructs followed by identifying 
optimal crystallization conditions for an optimal elucidation of the structure of BID using X-
ray analysis. 
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2 Materials and methods 
2.1 Chemicals, reagents and kits 
2.1.1 Standard chemicals and reagents 
All standard chemical reagents commercially available were acquired from Sigma-Aldrich 
(Taufkirchen, Germany) or Roth (Karlsruhe, Germany) if not stated differently. All buffers and 
solutions were prepared with demineralized, ultrapure water that was obtained from the SG 
Ultra Clear UV plus pure water system (VWR, Darmstadt, Germany). Ultrapure, 
demineralized water for aseptic preparation of solutions and for media used in the cell culture 
was sterilized either using a steam autoclave (Systec V-40, Systec GmbH, Wettenberg, 
Germany) or by filtration using 0.22 μm filter sets (Sarstedt, Nümbrecht, Germany). All Kits 
used in this study (Table 1) were applied according to the manufacturer’s protocol: 
Table 1. Kits 
Kit Purpose Company 
Annexin-V-FITC Detection Kit Apoptosis/Necrosis detection Promokine, Heidelberg, Germany 
Attractene Transfection Reagent Plasmid transfection Qiagen GmbH, Düsseldorf, 
Germany 
BODIPY (581/591 C11) Measurement of lipid 
 peroxidation 
Invitrogen, Karlsruhe, Germany 
Bradford Determination of protein content AppliChem, Darmstadt, Germany 
CM-H2DCFDA Measurement of soluble ROS Invitrogen, Karlsruhe, Germany 
GSH Assay Kit GSH detection Cayman Chemical, Ann Arbor, 
US 
InviTrap® Spin Universal RNA Mini Kit DNA/RNA extraction Stratec Molecular GmbH, Berlin, 
Germany 
Lipofectamine RNAiMax 
Transfection Reagent 
siRNA transfection Life Technologies, Carlsbad, US 
ZymoPURE™ Plasmid  Plasmid DNA isolation Zymogen, Irvine USA 
MitoPTTM TMRE Kit Mitochondrial membrane 
 potential detection 
Immunochemistry Technologies, 
Hamburg, Germany 
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Kit Purpose Company 
MitoSOXTM Mitochondrial ROS detection Invitrogen, Karlsruhe, Germany 
Pierce BCA Kit Determination of protein content Perbio Science, Bonn, Germany 
REDTaq® ReadyMixTM PCR Reaction Mix PCR Sigma-Aldrich, Taufkirchen, 
Germany 
SelenoMet DreamTM Media Kit Recombinant protein expression 
with heavy atom exchange 
Molecular Dimensions, Suffolk, 
UK 
SuperScript III One Step RT-PCR System 
with Platinum® Taq 
RT-PCR Invitrogen, Karlsruhe, Germany 
ViaLightTM ATP Plus-Kit ATP detection Lonza, Verviers, Belgium 
Wizard® SV Gel and PCR Clean-Up 
System  
DNA Gel extraction Promega, Madison, US 
XF Cell Mito Stress Kit Measurement of respiratory 
function  
Seahorse Biosciences, North 
Billerica, US 
2.1.2 RSL3 synthesis 
The four RSL3 diastereoisomers were synthesized by the group of Prof. W.E. Diederich 
(Philipps-University, Marburg, Germany) according to Yang et al. [211] as depicted in Figure 
13 for the 1S, 3R-RSL3 isomer. Analytical data were in agreement to those published before. 
Reaction of 3a, an advanced intermediate in the RSL3 synthesis, with acetyl chloride afforded 
the des-chloro derivative 1S, 3R-RSL3-Cl in 45% yield. 
Reagents and conditions: a, b: [211]; c: acetyl chloride, NaHCO3, CH2Cl2, 0 °C - RT, 45 %. 
 
Figure 13. RSL3 synthesis 
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2.2 Cell culture 
2.2.1 HT22 and MEF cell system 
2.2.1.1. Cell culture plastic ware: 
Cell culture sterile plastic ware was used as listed in Table 2: 
Table 2. Cell culture: Sterile plastic ware 
Plastic ware Company 
T75 flasks Greiner, Frickenhausen, Germany 
T175 flasks Greiner, Frickenhausen, Germany 
6-well plates Greiner, Frickenhausen, Germany 
24-well plates Greiner, Frickenhausen, Germany 
96-well plates Greiner, Frickenhausen, Germany 
96-well plates for BCA Greiner, Frickenhausen, Germany 
96-well plates (white) for ATP Greiner, Frickenhausen, Germany 
96-well xCELLigence E-plates Roche, Applied Science, Penzberg, Germany 
XF96-well microplates and cartridges Seahorse Biosciences, North Billerica, MA 
IbiTreat 8-well plates Ibidi, Munich, Germany 
6 cm dishes Sarstedt, Nümbrecht, Germany 
10 cm dishes Sarstedt, Nümbrecht, Germany 
15 mL tubes Greiner, Frickenhausen, Germany 
50 mL tubes Greiner, Frickenhausen, Germany 
0.2, 0.5, 1.5, 2.0 mL Eppendorf tubes Sarstedt, Nümbrecht, Germany 
0.22 μm Whatman PuradiscTM sterile filter Whatman, Dassel, Germany 
0.45 μm filter Whatman, Dassel, Germany 
Cell scraper Sarstedt, Nümbrecht, Germany 
1, 5, 10 mL syringes Braun, Melsungen, Germany 
Cannulae Braun, Melsungen, Germany 
Nalgene Rapid-Flow Bottle-Top Filter 0.2 μm filter ThermoFisher Scientific, Schwerte, Germany 
Pipette tips Gilson, Middleton, USA 
StarLab, Hamburg, Germany 
 
  2 Materials and methods 
 
25 
 
2.2.1.2. Cultivation of HT22 and MEF cells 
HT22 cells were derived from Gerald Thiel (Homburg/Saar, Germany) with kind permission 
of David Schubert (Salk Institute, San Diego, US). HT22 cells are derived from parent HT4 cells 
that were originally immortalized from primary mouse hippocampal neuronal culture with a 
temperature-sensitive SV40 T-antigen [34,123]. MEF cells were a kind gift from Prof. Axel 
Methner (Johannes-Gutenberg University, Mainz, Germany). 
HT22 and MEF cells were cultured in Dulbecco’s modified Eagle medium from 
Capricorn (DMEM, Ebsdorfergrund, Germany) supplemented with 10 % heat-inactivated fetal 
calf serum (Biochrom, Berlin, Germany), 100 U/mL penicillin, 100 μg/mL streptomycin and 
2 mM L-Alanyl-L-glutamine (Capricorn, Ebsdorfergrund, Germany). For standard cultivation 
cells were kept in 75 cm2 culture flasks (T75) in a standard unified incubator at 37 °C and 5 % 
CO2. Cells were split twice per week in a ratio of 1:10-1:20.  
Splitting of cells was performed as follows: Growth medium was removed and cells were 
washed once with 10 mL phosphate buffered saline (1x PBS, Table 3) to fully remove the growth 
media and FCS. For detachment of cells from the bottom of the flasks, 2 mL of trypsin/EDTA 
solution (Table 4) was added and cells were incubated 2-5 minutes at 37 °C. After detachment 
of the cells, the protease activity was stopped by adding the 5-fold amount of DMEM growth 
medium (Table 5). Thereafter, the cell suspension was centrifuged at 1,000 rpm for 5 minutes 
and the cell pellet resuspended in fresh growth medium. For the quantification of cell numbers, 
a counting chamber (Neubauer Zählkammer, Brand, Wertheim, Germany) was utilized. 
Afterwards, cells were seeded into the appropriate culture dishes with a cell density of 6 x103–
6 x104 cells per well or 5 x105–1.5 x106 cells per dish depending on the respective experiments 
(Table 6). 
Table 3. Phosphate buffered saline (PBS), pH 7.4 
NaCl 9 g 
Na2HPO4 0.527 g 
KH2PO4 0.144 g 
HCl (0.1 M) q.s. for pH 7.4 
Aqua demin. up to 1 L 
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Table 4. Standard Trypsin/EDTA solution (TE) 
Trypsin 7,500 U/mg 100 mg 
Ethylene diamine-tetra-acetic acid (EDTA) 40 mg 
1x PBS up to 200 mL 
Table 5. HT22 and MEF standard growth medium 
DMEM medium with 4.5 mg/L glucose and 110 mg/L sodium pyruvate 440 mL 
Heat-inactivated fetal calf serum (FCS)  50 mL 
L-Alanyl-L-glutamine 200mM 5 mL 
Penicillin 10,000 U/mL, Streptomycin 10,000 μg/mL (Pen/Strep) 5 mL 
Table 6. Cell densities for HT22 and MEF cell seeding 
Format Cell density [~ cells per well or dish)  
96-well plate 6,000-10,000 
24-well plate 40,000-60,000 
6-well plates 100,000-200,000 
Ibidi 8-well plate 12,000-16,000 
6 cm dish 500,000 
10 cm dish 1,000,000-1,500,000 
XF96-well microplates 6,000-10,000 
96-well xCELLigence E-plates 5,000-10,000 
2.2.2 Primary mouse and rat embryonic neurons 
Primary cortical neurons were cultured in PEI-coated dishes. Therefore, cell culture dishes were 
coated with 5 % polyethylenimine (PEI, Table 7). Coating was achieved by incubation of the 
dishes with 5 % PEI for 2-3 hours at 37 °C. Afterwards the dishes were washed three times with 
sterile bidest. water and allowed to dry for 30 minutes under UV-light exposure.  
Table 7. Polyethylenimine 5% (PEI) 
Boric acid 3.1 g 
Borax 9.0 g 
PEI 5 % 1 mL  
Aqua demin. ad 0.8 L 
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Cortices were obtained from embryonic day 14-16 wild type C57BL/6 mice (Charles River 
Laboratories, Sulzfeld, Germany) and split by trypsinization and trituration as follows: Isolated 
cortices were incubated in Hank’s balanced salt solution (HBSS, diluted from 10x HBSS, 
Invitrogen, Karlsruhe, Germany, Table 8) containing 1 mg/mL trypsin (Sigma- Aldrich, 
Taufkirchen, Germany) for 15 minutes at 37 °C. Afterwards, DNAse was added for 30 seconds 
and the cortices were washed with HBSS and then mixed with HBSS containing 2 mg/mL 
trypsin inhibitor (Sigma-Aldrich, Taufkirchen, Germany). The cell suspension was then 
incubated for a further 2 minutes at room temperature. Afterwards, the cortices were washed 
once with HBSS, and triturated. The triturated cells were centrifuged at 2,000 rpm for 5 minutes 
at room temperature and the supernatant was removed, and the cells cultured in neurobasal 
medium supplemented with 2 % (v/v) B-27 (Table 9). Afterwards, the cells were counted in a 
cell counting chamber (Neubauer Zählkammer) and seeded into 96-well plates with a density 
of 5.5 x104 cells. On day 5 and 7 after seeding of cells, half of the medium was exchanged with 
fresh neurobasal medium, respectively. As cultures of primary neurons develop functional 
NMDA receptors after 6 to 8 days in culture and therefore are sensitive to glutamate-induced 
excitotoxicity, experimental treatments were performed with 7 to 9 day old cultures. All media 
were obtained from Invitrogen (Karlsruhe, Germany) and chemical substances were obtained 
from Sigma-Aldrich (Taufkirchen. Germany) if not specified differently. 
Primary rat embryonic cortical neurons were obtained from wild type Sprague–Dawley 
rats (Charles River Laboratories) at embryonic day 18 and cultured similarly to primary mouse 
neurons. 
Table 8. Hank's balanced salt solution (HBSS), pH 7.2 
10x HBSS 50 mL 
HEPES 1.2 g 
Pen/Strep 1 % (v/v) 5 mL 
Aqua demin. up to 500 mL 
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Table 9. Neurobasal medium 
Neurobasal medium (Gibco®) 480 mL 
B-27 (Gibco®) 2 % (v/v) 10 mL 
L-glutamine 1 % (v/v) 5 mL 
Pen/Strep 1 % (v/v) 5 mL 
2.2.3 DNA/RNA transfection  
Transfection of HT22 and MEF cells was performed in either 96-well, 24-well, 6-well, ibidi 8-
well plates or in 6 or 8 cm2 dishes according to which experiment was carried out. Plasmids 
were transfected 24 hours after cell seeding, whereas siRNA was applied prior to cell seeding 
(reverse transfection). 
2.2.3.1. Transfection reagents 
For the formation of DNA transfection complexes of plasmid vectors with Attractene 
transfection reagent (Qiagen, Hilden, Germany), Opti-MEM I medium (Invitrogen, Karlsruhe, 
Germany) was utilized.  
For siRNA transfection, Lipofectamine RNAiMax transfection reagent (Invitrogen, 
Karlsruhe, Germany) was used in antibiotic-free Dulbecco’s modified Eagle medium (DMEM, 
Invitrogen, Karlsruhe, Germany) supplemented with 10 % heat-inactivated fetal calf serum and 
2 mM L-Alanyl-L-glutamine (all from PAA Laboratories GmbH, Germany). 
2.2.3.2. Plasmid transfection 
For the purpose of plasmid transfection, HT22 or MEF cells were seeded as stated in Table 10 
24 hours in advance and grown under normal growth conditions (37 °C, 5 % CO2). Prior to 
transfection, the normal growth medium was replaced completely by fresh standard growth 
medium and enriched with pre-treatment substances as may be necessary at given time points. 
The plasmids were dissolved in Opti-MEM I and Attractene transfection reagent was 
added. To allow for complex formation, the solutions were incubated for 15 to 20 minutes at 
RT before the transfection mixture could be finally added to the cell’s growth medium. 
Afterwards, cells were cultivated under normal conditions for 24 to 48 hours until further 
experimental steps were performed. 
  2 Materials and methods 
 
29 
 
Table 10. Plasmid transfection 
Format  Cells/well seeded DNA/well Attractene/well Opti-MEM I/well 
96-well 5,000-8,000 100-200 ng 0.75 μL up to 15-20 μL 
24-well 30,000-40,000 400 ng-2 μg 1.5-4.5 μL up to 60 μL 
6-well 100,000-150,000 500 ng-5 μg 4.5-8 μL up to 200-250 μL 
Ibidi 8-well 16,000 1 μg 1 μL up to 50 μL 
2.2.3.3. Plasmid vectors 
In this thesis the following plasmid vectors (Table 11) were used: 
Table 11. Plasmid vectors 
Gene/Purpose Vector names Company/Origin 
Control vector pcDNA 3.1(+) Invitrogen (Karlsruhe, Germany) 
Control vector eGFP pIRES-EGFP PT3267-5, #60296-1 BD Biosciences 
Clontech (US) 
Mouse tBid pcDNA3 Bid p15 
or pcDNA3 tBid 
Plasmid #8808, Addgene (Cambridge, 
US) 
Mouse full-length Bid pcDNA3 Bid p22 
or pcDNA3 Bid 
Plasmid #8774, Addgene (Cambridge, 
US) 
Mouse full-length Bid pcDNA3 Bid p22 mut Mutated from Addgene Plasmid #8774 
Mouse tBid, eGFP pIRES-tBid-EGFP Previously described in [93] 
Mouse Bid 
CRISPR/Cas9 
U6-gRNA/CMV-Cas9-GFP  
target: GTCAGCAACGGTTCCGGCCTGG 
Sigma-Aldrich (Taufkirchen, Germany) 
Mouse full-length Bid pET15b Bid p22 Plasmid #8784, Addgene (Cambridge, 
US) 
Mouse tBid pET15b Bid p15 Plasmid #8782, Addgene (Cambridge, 
US) 
 
All plasmids were amplified in either self-made DH5α-competent E.coli, supercompetent 
DH5α and isolated using the ZymoPURE™ Plasmid kit according to the manufacturer’s 
protocol. Prior to use, the DNA concentration was quantified using the NanoPhotometerTM 
(Implen, Munich, Germany). All plasmids cloned were verified by sequencing afterwards 
(EurofinsGenomics, Ebersberg, Germany). 
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2.2.3.4. SiRNA transfection 
SiRNA transfection was performed in a reverse way immediately before seeding of cells. For 
transfection, Lipofectamine RNAiMax transfection reagent was used according to the 
manufacturer’s protocol.  
The respective siRNA and Lipofectamine RNAiMax were diluted in antibiotic-free 
growth medium to a concentration appropriate to yield a final concentration of 20 to 80 nM 
siRNA and 2 μL/mL transfection reagent in the cell culture plate or dish, and were then allowed 
to equilibrate for 10 minutes at RT. Afterwards, the siRNA solution was combined with the 
Lipofectamine RNAiMax solution and mixed gently. For normal siRNA transfection the cell’s 
growth medium was exchanged for antibiotic-free growth medium and after 20 minutes of 
incubation at RT the prepared siRNA mixture was added dropwise. For reverse transfection, 
the siRNA mixture was filled into the cell culture plates or dishes where it was allowed to form 
siRNA complexes for 20 minutes at RT prior to addition of antibiotic-free cell suspension. 
Controls were treated similarly with either control siRNA or transfection reagent in antibiotic-
free growth medium exclusively. Gene silencing was verified by RT-PCR and Western blot 
analysis after 24 and 48 hours, respectively. 
2.2.3.5. SiRNAs 
For the deletion of BID, two siRNAs and a non-functional control siRNA were acquired from 
Sigma-Aldrich (Taufkirchen, Germany) according to Table 12: 
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Table 12. SiRNAs 
siRNA Sequence 
SASI_Mm01_00115198 “Bid siRNA #1” 5´-GAGUGUAUCUAAGAGUUU[dT][dT]-3´ 
SASI_Mm01_00115200 “Bid siRNA #2” 5´-AAACUCUUCAGAUACACUC[dT][dT]-3´ 
MISSION® siRNA Universal Negative Control #1 
(SIC001) 
Not specified 
siAIF 2.2 5´-AUGUCACAAAGACACUGCA-3´ 
Eurofins control siRNA 5´-AAGAGAAAAAGCGAAGAGCCA-3´ 
2.2.4 Induction of cell death 
Induction of cell death was performed 24 to 48 hours after seeding of HT22 or MEF cells with 
either glutamate, erastin, H2O2, RSL3, tBID or staurosporine when the cells had reached 70 to 
80 % confluency.  
2.2.4.1. Glutamate, erastin, RSL3and staurosporine induced toxicity 
Glutamate was applied at a final concentrations of 1 to 10 mM, erastin at 0.25 to 2 μM, RSL3 at 
0.001-100 μM and staurosporine at 0.1 to 5 μM to initiate cell death. For the preparation of the 
glutamate stock solution, D, L-glutamic acid monohydrate (Sigma-Aldrich, Taufkirchen, 
Germany) was dissolved in DMEM (PAA Laboratories GmbH; Cölbe, Germany) to a stock 
concentration of 1 M and the pH was subsequently adjusted to pH 7.2 with sodium hydroxide 
solution of 1 or 5 M, respectively. The stock aliquots were stored at -20 °C until use. Erastin, 
RSL3 and staurosporine were dissolved in DMSO to a stock concentration of 1 mM. 
For treatment, the stock solutions were diluted in normal growth medium prior to use. 
Cell growth medium was removed and replaced with the prepared glutamate/erastin/RSL3/ 
staurosporine solution. For the investigation of neuroprotective effects of several inhibitors, 
these inhibitors were additionally applied to the glutamate/erastin/RSL3/staurosporine 
solution either before the treatment (pre-treatment, 1-7 hours), simultaneously (co-treatment) 
or after the treatment (post-treatment, 1-8 hours). Four to 24 hours after treatment cells were 
analyzed according to the indicated protocols for RNA, DNA or protein analysis, cell viability, 
flow cytometry, epi- and confocal microscopy, immunoprecipitation, ATP, Seahorse or GSH 
assay. 
  2 Materials and methods 
 
32 
 
2.2.4.2. H2O2 induced cell death 
H2O2 was used to provoke oxidative stress induced cell death independent of oxytosis or 
ferroptosis. Therefore, H2O2 was applied to HT22 cells at a final concentration of 1 mM and 
incubated over-night. 
2.2.4.3. TBID induced toxicity 
TBID mediated cell death was initiated 24 hours after seeding of 5,000-8,000 HT22 cells per 
well in a 96-well format according to 2.2.3.1 with 0.25 to 0.75 μg plasmid/well, and 0.75 μL 
Attractene/well or in 24-well format with 2 μg plasmid/well and 4.5 μL Attractene/well. 
Seventeen to 24 hours after transfection cell viability, morphology or other cell parameters were 
assessed. 
2.2.5 Inhibition of cell death 
2.2.5.1. BID inhibitor BI-6c9 
For the inhibition of oxidative cell death during oxytosis in HT22 cells, the BID inhibitor BI-
6c9 (Sigma-Aldrich, Taufkirchen, Germany; Figure 14) was dissolved in DMSO to a stock 
concentration of 10 mM and stored at -20 °C until further use. With final concentrations of 
10 μM in normal growth medium as co-treatment a complete protection can be achieved. 
 
 
Figure 14. BID inhibitor BI-6c9; Mw: 471.59 g/mol 
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2.2.5.2. Liproxstatin-1 (Lip-1) 
For the inhibition of oxidative cell by lipid peroxidation during ferroptosis [53], the small 
molecule liproxstatin-1 (a kind gift of Marcus Conrad, Helmholtz-Zentrum Munich, Germany; 
Figure 15) was used dissolved in DMSO (stock concentration of 100 μM) and was further 
diluted in growth medium to a final concentration of 1 nM to 2 μM (co- or post-treatment) 
depending on the respective purpose. 
 
2.2.5.3. Ferrostatin-1 (Fer-1) 
Ferrostatin-1 (Sigma-Aldrich, Taufkirchen, Germany; Figure 16) was used as an inhibitor of 
oxidative cell death during ferroptosis to control lipid soluble ROS [227]. Therefore, 
ferrostatin-1 was dissolved in DMSO to a stock concentration of 10 mM and diluted to a final 
concentration of 10 μM in normal growth medium to protect against ferroptotic cell death. 
N
HN
NH
NH Cl
Figure 15. Liproxstatin-1, Mw: 340.85 g/mol 
Figure 16. Ferrostatin-1, Mw: 262.35 g/mol 
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2.2.5.4. Iron chelator deferoxamine 
Deferoxamine (Figure 17) was used as an iron chelating ferroptosis inhibitor [38,53] dissolved 
in DMSO to a stock concentration of 10 mM and stored at -20 °C until usage. Prior to use 
deferoxamine was diluted in normal growth medium to a final concentration of 10 μM. 
2.2.5.5. Mitoquinone (MitoQ) 
In order to specifically block mitochondrial ROS formation the mitochondria-targeted 
ubiquinone derivative mitoquinone (MitoQ; Figure 18) was used [94,95]. MitoQ was diluted in 
DMSO to a stock concentration of 10 mM and stored at -20 °C. Prior to use MitoQ was diluted 
in normal growth medium to final concentrations of 0.1-2 μM. 
2.2.6 CRISPR/Cas9 Bid gene knockout 
2.2.6.1. Plasmid transfection 
HT22 Bid KO cells were generated using a ready-to-use Bid CRISPR plasmid (U6gRNA-Cas9-
2A-GFP; MM0000220718, Sigma Aldrich, Germany). As control, the ordered plasmid was 
digested with XbaI to ensure working with the correct plasmid. The following reaction mix was 
prepared: 
Figure 17. Deferoxamine 
Figure 18. MitoQ 
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Table 13. XbaI digest 
CRISPR plasmid DNA 1 μg 
Tango buffer 10x 2 μL 
XbaI enzyme 1 μL 
Bidest. H2O ad 20 μL 
 
The mix was incubated at 37 °C for 1.5 hours and, together with an undigested sample, loaded 
on a 1 % agarose gel to check for the correct size of cleaving products. 
In order to achieve knockout, cells were seeded in 6-well plates with a density of 1.0 x105 
cells per well and incubated for 24 hours under normal growth conditions (37 °C, 5 % CO2). 5 
μg DNA was diluted in OptiMEM I and mixed with Attractene as stated in section 2.2.3.1 and 
given into the respective well. Cells were transfected for 48 hours before harvesting with trypsin. 
To do so, cells were washed once with PBS and incubated with trypsin until floating. After 
centrifugation at 1,000 rpm for 3 minutes cells were re-suspended in PBS and kept on 37 °C for 
FACS sorting.  
2.2.6.2. FACS sorting 
In order to increase CRISPR efficacy successfully transfected GFP-positive cells were sorted by 
FACS. For elimination of dead cells, cells were stained with DAPI (200 μg/mL). Afterwards, 
cells were filtered through an 80 μm filter to exclude cell clusters. GFP-positive and DAPI-
negative cells were automatically seeded in 96-well plates with either 1, 2 or 5 cells per well, 
respectively, and grown in HT22 standard growth medium (Table 5).  
2.2.6.3. Mutation detection 
Growing cell colonies from single wells were picked and allowed to proliferate in either 6-well 
plates or T75 flasks in HT22 standard growth medium for genomic DNA analysis or Western 
blot.  
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For Western blot analysis, cells were trypsinized, centrifuged at 1,000 rpm and washed once 
with PBS. After a second centrifugation step, cells were lysed in Western blot lysis buffer and 
put in liquid nitrogen. After thawing on ice cells were centrifuged at 10,000 rpm for 15 min at 
4 °C to eliminate cell debris. The supernatant containing proteins was either stored at -20 °C or 
directly used for BCA protein amount determination (542.8.2). For Western blot analysis 50-
80 μg protein were loaded on a 12.5 % 1.5 mm SDS-gel and blotted onto a PVDF-membrane 
(2.8.4). Incubation with primary anti-BID antibody (Cell signaling, US) was performed 
overnight at 4 °C. After incubation with a secondary HRP-labeled anti-rabbit antibody (Vector 
Laboratories, US), Western blot signals were detected via chemiluminescence with Chemidoc 
software (Bio-Rad, Germany).  
For genomic DNA sequencing, cells were trypsinized, centrifuged at 1,000 rpm and 
washed once with PBS. After a second centrifugation step cells were put in liquid nitrogen and 
either stored at -80 °C or directly used for genomic DNA extraction using InviTrap® Spin 
Universal RNA Mini Kit. The cell pellet was lysed in 700 μL Lysis buffer containing 1:100 β-
mercaptoethanol and immediately put onto a DNA-Binding Spin Filter. After incubation for 1 
minute at room temperature and DNA binding to the filter, the filter was centrifuged for 2 
minutes at 11,000 rpm. Afterwards, the filter was washed once with Wash buffer 1 and twice 
with Wash buffer 2 and allowed to dry by centrifugation for 4 minutes at maximum speed. 
Finally, genomic DNA was eluted using 40 μL of Elution buffer and DNA amount was 
determined at 260 nm using a NanoPhotometerTM (Implen, Munich, Germany) (2.9.3). For 
PCR amplification of the CRISPR target region the following reactions were prepared: 
Table 14. Genomic DNA PCR 
DNA 200 ng 
Primer fwd/rev (Table 40) 1 μL each 
REDTaq® ReadyMix™ PCR Reaction Mix 6 μL 
RNAse free H2O ad 20 μL 
 
For genomic DNA PCR the following protocol was used: 
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Table 15. Genomic DNA PCR cycler program 
Initial denaturation 94°C 3 min 
Denaturation 94°C 30 sec 
Annealing 62°C 30 sec                  40 x 
Elongation 72°C 30 sec 
Final elongation 72°C 5 min 
Cooling 4°C ∞ 
 
After PCR amplification according to section 2.9.4, the PCR samples were loaded onto a 1 % 
agarose gel stained with ethidium bromide and electrophoresis was performed at 80 V for 30-
45 minutes. Under UV light for visualization of the respective PCR products, the 1028 bp band 
was cut out and DNA purified using the Wizard® SV Gel and PCR Clean-Up System Kit. After 
determination of DNA amount, 150 ng purified DNA were mixed with 1 μL of forward primer 
and filled up with RNAse-free water to 15 μL and send for DNA sequencing to Eurofins 
Genomic (Ebersberg, Germany). 
2.2.6.4. Off-target analysis 
Most potential off-targets were calculated with web-based tools from the Zhang group [225] 
and the University of Heidelberg (Germany) [178,179]. 
Table 16: Genomic DNA PCR program Off-target analysis 
Initial denaturation 94°C 3 min 
Denaturation 94°C 30 sec 
Annealing  30 sec                  40-45 x 
Elongation 72°C 30 sec 
Final elongation 72°C 5 min 
Cooling 4°C ∞ 
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Table 17. Off-target primer 
Primer Sequence forward/reverse PCR product size 
Trpc4 5’ GTCAGCACCTAACGTGTC 3’ 
5’ CGTGGGGCTTAAGTCATAG 3’ 
707 bp 
Grm3 5’ CACTGTGACAGGAAGCTTC 3’ 
5’ GTGAGCCACACATCACAG 3’ 
587 bp 
Syngr1 5’ GGAACTCCTTTGGGGTATG 3’ 
5’ GTACCAGAAGAGCAAGTCTG 3’ 
666 bp 
Hprt “new” 5’ AATCCTCTGGGAGACGAC 3’ 
5’ GCCTGATCCTTCCTGAAG 3’ 
728 bp 
Kcne1 5’ TGCTGGAATTAGCCAATCAG 3’ 
5’ GGTGCCCCTACAATAAAGAC 3’ 
593 bp 
Hivep3 5’ CTCTACAAGCACAGGAAGTC 3’ 
5’ GATCTCACTGGTGTCCAC 3’ 
721 bp 
Table 18. CRISPR Off-target PCR annealing temperatures 
Primer Annealing temperature 
Trpc4 51 °C 
Grm3 59 °C 
Syngr1 59 °C 
Hprt “new” 54 °C 
Kcne1 54 °C 
Hivep3 54 °C 
 
After PCR amplification of the respective genomic DNA, an ExoSAP digest (USB® ExoSAP-IT® 
PCR Product Cleanup kit, affymetrix) was performed according to the manufacturer’s protocol 
to remove unused PCR primers and nucleotides for better sequencing results. In brief, 5 μL of 
the respective PCR product was mixed with 1 μL of ExoSAP reagent and incubated at 37 °C for 
30 minutes. Afterwards, the mixture was heated to 80 °C for 15 minutes in order to inactivate 
the ExoSAP reagent. For sequencing, 1 μL of the respective forward primer was added and sent 
for sequencing (EurofinsGenomics, Ebersberg, Germany). 
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2.3 Cell viability assays 
2.3.1 Cell morphology analysis 
Cell morphology for the analysis of cell death was assessed using a Leica DM6000 epi-
fluorescence microscope (Leica, Wetzlar, Germany) and light was collected through a 20 x 
objective. Images were acquired using phase contrast and were processed with ImageJ Software 
1.48v (Maryland, USA). Before imaging, cells were fixed with 4 % paraformaldehyde for 20 
minutes at room temperature and washed once with PBS.   
2.3.2 MTT assay 
Metabolic activity as a measure of cell death was determined using the MTT assay. Here, the 
reduction of a yellow salt, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, to 
an insoluble purple formazan (Figure 19) is exploited to determine activity of NAD(P)H-
dependent enzymes of the endoplasmic reticulum and mitochondria (Berridge, M.V., Tan, 
A.S., McCoy, K.D. & RUI WANG. BIOCHEMICA_96_4_p14-19) and thus metabolic activity 
or cell viability, respectively.  
 
Figure 19. MTT assay 
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Cells were seeded in 96-well plates and 24 hours later treated as indicated before. 20 μL MTT 
were added to the culture medium at a concentration of 2.5 mg/mL (in PBS; final 
concentration: 0.5 mg/mL). After incubation for 1 hour at 37 °C the medium was removed and 
plates were frozen at -80 °C for at least 1 hour.  The purple formazan was then dissolved in 
70 μL DMSO and incubated at 37 °C on a shaker for another hour before 570 nm absorbance 
was measured using FluoStar OPTIMA (BMG Labtech, Offenbach, Germany). Background 
signals at 630 nm were subtracted for background correction. Absorbance of control conditions 
was set as 100 % and metabolic activity was displayed relative to controls. 
2.3.3 XCELLigence system 
The xCELLigence system RTCA SP (Roche, Penzberg, Germany) is a real-time cell analysis tool 
employing non-invasive gold microelectrodes implanted in a multi-well plate. Here, electrical 
impedance is increasing upon proliferation of viable cells and drops with detachment of dying 
cells, and is utilized for real-time monitoring of cell proliferation, cell size/morphology, cell 
attachment quality, and cell invasion/migration upon specific stimuli. The changes in 
impedance are represented as cell index (CI) as a function of time by RTCA Software 1.2 (Roche 
Diagnostics, Penzberg, Germany). After background analysis with pure culture medium, cells 
were seeded into 96-well E-plates according to Diemert et al. [36]. Having reached a CI of ~ 
1.0, cells were treated with the indicated cell death inducers and/or inhibitors, respectively, and 
impedance was recorded for 14-24 hours. For subsequent presentation and comparability of 
the respective graphs, the cell index was normalized to 1.0 before treatment. After the 
experiment E-plates were re-used by removing the medium and washing with sterile bidest. 
H2O followed by incubation with trypsin for 15-30 min. After removal of trypsin the plate was 
washed three times with bidest. H2O and sterilized 30 minutes under UV light. 
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2.4 Glutathione assay 
The measurement of glutathione is based on the enzymatic recycling reaction of GSH 
converting Ellman’s reagent (5,5’-dithio-bis-(2-nitrobenzoic acid): DTNB) into the yellow 
colored 5-thio-2-nitrobenzoic acid (TNB). TNB production is directly proportional to the 
concentration of GSH and therefore provides an accurate estimation in the sample. The 
enzymatic reaction is as follows: 
Glucose-6-phosphate     NADP+  GSH + TNB  DTNB 
 
 
 
D-Glucono-1,5-   NADPH/H+      GSTNB   TNB 
lacton-6-phosphate  
 
Intracellular glutathione levels were determined according to the Glutathione Assay Kit 
(Cayman Chemical Company, Ann Arbor, US). Cells were seeded in 6-well plates at a density 
of 2 x105 or in 10 cm dishes at a density of 1 x106 and after 24 hours treated with cell death 
inducers and/or inhibitors. After the indicated amount of time, cells were scratched with a cell 
scraper and harvested by centrifugation at 1,000 rpm for 3 minutes. After washing the cell pellet 
once with PBS cells were centrifuged again and stored at -80 °C until the experiment.  
For the measurement of GSH levels, cell pellets were thawed on ice and assay reagents 
warmed up to room temperature. Cell pellets were re-suspended in 100 μL 1x MES-buffer 
(0.4 M 2-(N-morpholino) ethanesulphonic acid, 0.1 M phosphate, 2 mM EDTA, pH 6.0) and 
homogenized by sonication. Cell debris was removed by centrifugation at 10,000 g for 
15 minutes at 4 °C. 80 μL of the supernatants were transferred into another Eppendorf tube and 
deproteinated via addition of 80 μL of metaphosphoric acid (MPA, 1.25 M) and incubation for 
5 minutes at room temperature. The remaining supernatant was used for determination of 
protein amount using BCA assay (2.8.2). After deproteination the mixture was centrifuged 
again (17,000 g, 10 minutes, 4 °C). 100 μL of the supernatant was transferred into another tube 
and mixed with 5 μL of a 4 M triethanolamine solution to increase the pH.  
 
Figure 20. GSH assay 
Glucose-6-phosphat-
dehydrogenase 
Glutathione- 
reductase 
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For measuring a calibration curve, GSH standards were diluted as stated in the manufacturer’s 
protocol and 50 μL of each sample and GSH standard was pipetted into a 96-well plate and 
mixed with 150 μL of a freshly prepared assay cocktail containing 1x MES-buffer, co-factors 
(NADP+ and glucose-6-phosphate), enzymes (glutathione reductase and glucose-6-phosophate 
dehydrogenase) and Ellman’s reagent. Afterwards, the plate was incubated and shaken for 
20 minutes at room temperature protected from light and absorbance was measured at 405 nm 
using the ELX808 Ultra Microplate Reader (Bio-Tek Instruments, Bad Friedrichshall, 
Germany). Total GSH amount was calculated via the standard curve and normalized to protein 
content after BCA assay. Data are displayed as percent GSH of control, which was set to 100 %. 
2.5 Mitochondrial morphology and respiratory function 
2.5.1 Analysis of mitochondrial morphology 
In order to visualize mitochondria and analyze their morphology, mitochondria can be stained 
using MitoTracker® DeepRed FM (Invitrogen, Karlsruhe, Germany). MitoTracker is a cell-
permeant far red-fluorescent dye containing a mildly thiol-reactive chloromethyl moiety for 
labeling mitochondria and can be excited at ~644 nm under emission of ~665 nm light. 
MitoTracker was dissolved in DMSO to a stock concentration of 50 μM and stored at -20 °C in 
the dark.  
For counterstaining of nuclei the DNA-binding blue-fluorescent dye DAPI (4’, 6-
diamidin-2-phenylindol; Sigma Aldrich, Taufkirchen, Germany) was used (excitation at 
~358 nm, emission at ~461 nm). 
For the analysis of mitochondrial morphology, cells were seeded in 8-well ibidi-slides 
at a density of ~1.6 x105 and 24 hours later stained at 37 °C for 30 minutes with a working 
solution in normal growth medium of 200 nM (1:250) MitoTracker and 1 μg/mL DAPI, which 
was freshly prepared. After removing the medium, cells were treated with the indicated cell 
death inducers and/or inhibitors and fixed with 4 % paraformaldehyde for 20 minutes 
protected from light. After washing with PBS twice, ibidi slides were stored at 4 °C for further 
experiments.  
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Images were acquired using a Leica DM6000 epi-fluorescence microscope (Leica, Wetzlar, 
Germany) collecting light through a 63x or 100x objective. Images were acquired using band 
pass filters for 633 nm (MitoTracker) or 360 nm (DAPI) excitation and emission filters at 
640 nm (MitoTracker) and 470 nm (DAPI), respectively, and were processed with ImageJ 
Software 1.48v (Maryland, USA). 
2.5.1.1. Manual mitochondrial morphology classification system 
In order to examine changes in mitochondrial morphology during treatment with specific 
stimuli, ~500 MitoTracker-stained cells of each condition were counted blinded to treatment 
and categorized in three different classes according to their mitochondrial morphology as 
previously described [72]. Briefly, healthy elongated mitochondria localized throughout the 
whole cell were assigned to category I, whereas highly fragmented mitochondria accumulating 
around the nucleus were classified as category III. Mitochondria which already underwent 
fission but were still evenly distributed in the cytoplasm were defined as category II.  
2.5.1.2. Automated mitochondrial morphology analysis by ImageJ 
Automated quantification of the average perimeter of mitochondria as a measure of 
mitochondrial fragmentation was performed employing a custom macro for NIH ImageJ 
software (version 1.48) as described previously by Ruben K. Dagda (University of Nevada 
School of Medicine) and Charleen Chu (University of Pittsburgh) [33]. 
2.5.2 ATP bioluminescent assay 
For the quantitative analysis of whole cell ATP as a measure of mitochondrial respiratory 
function, the bioluminescent ViaLightTM ATP Plus-Kit (Lonza, Verviers, Belgium) was used 
according to the manufacturer’s protocol. The bioluminescent method utilizes an enzymatic 
reaction, where luciferase catalyzes the formation of light from ATP and luciferin according to 
the following reaction: 
 
ATP + Luciferin + O2   Oxyluciferin + AMP + PPi + CO2 
 
Luciferase 
Mg2+ 
Figure 21. ATP assay 
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The emitted light is linearly proportional to the ATP content in the respective sample and was 
measured using the FluoStar OPTIMA (BMG Labtech, Offenbach, Germany). 
For the analysis of cellular ATP content, 6,000-8,000 cells were seeded in white 96-well 
plates and 24 hours later treated with the indicated substances. All reagents of the ViaLightTM 
ATP Plus-Kit were warmed to room temperature and ATP was extracted by application of 
50 μL Cell Lysis Reagent to the culture medium. After 10 minutes of incubation in the dark, 
100 μL of ATP monitoring reagent plus (AMR) were added to generate the luminescent signal. 
After 2 more minutes of incubation luminescence was measured using the FluoStar OPTIMA. 
Signals were corrected for background noise and depicted as percent of control which was set 
to 100 %. 
2.5.3 Seahorse measurements 
Understanding mitochondrial alterations and energy metabolism in oxidative cell death is key 
to develop new strategies to protect the cells. The Seahorse XF96 system (Agilent Technologies, 
Santa Clara, US) provides vital information on mitochondrial respiration and glycolytic activity 
in a real-time manner and is used to detect even small changes in bio-energetic profile during 
induction of cell death. 
2.5.3.1. Oxygen consumption rate (OCR) 
For measuring oxygen consumption rate (OCR) the Mito Stress Test (Agilent Technologies, 
Santa Clara, US) was utilized to detect respiratory parameters. The Mito Stress Test uses 
injection of different modulators of specific components of the electron transport chain (ETC). 
The compounds oligomycin, FCCP, and a mix of rotenone and antimycin A, and in some 
experiments also 2-desoxyglucose (2-DG), were serially injected to measure basal and ATP-
linked respiration, maximal respiration and non-mitochondrial respiration, respectively. 
Proton leak and spare respiratory capacity can be calculated using basal respiration and the 
above-mentioned parameters as shown in Figure 22: 
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The modulators of electron chain components show the following effects: 
 
Oligomycin inhibits ATP synthase (complex V) by blockage of the proton channel and thereby 
causes an increased proton gradient, loss of electron transport and drop in oxygen 
consumption. Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) acts as a 
mobile ion carrier and uncoupler of the mitochondrial respiratory chain by transporting 
hydrogen ions through the membrane before they can be used to provide energy for oxidative 
phosphorylation. Thereby, MMP breaks down and ATP synthesis is disrupted leading to an 
immediate increase in OCR. The final application of rotenone as an inhibitor of mitochondrial 
complex I and antimycin A as an inhibitor of complex III completely shuts down mitochondrial 
respiration indicated by rapid decline in OCR. 
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Figure 22. Representative OCR measurement 
Figure 23. Respiratory chain modulators 
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2.5.3.2. Extracellular acidification rate (ECAR) 
Measurement of extracellular acidification rate (ECAR) in parallel with OCR during the Mito 
Stress Test is an indicator of glycolysis as glycolysis-derived lactate is exported from the cell 
together with protons thus decreasing pH.  Acidification rate is used to calculate glycolytic 
capacity, glycolytic reserve and non-glycolytic acidification after serial injection of the above-
mentioned modulators: 
 
2-Desoxyglucose is used to shut down glycolysis as it lacks the 2-hydroxyl group and 
competitively inhibits production of glucose-6 phosphate from glucose: 
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Figure 24. Representative ECAR measurement 
Figure 25. Glycolysis modulator 2-desoxyglucose 
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For the measurement of CRISPR Bid KO cells 8,000 HT22 or HT22 Bid KO cells were seeded 
in 96-well XF-plates and kept at 37 °C for 24 hours. Cells were treated with glutamate (2 mM) 
or erastin (0.25 μM) over night (16 hours) and culture medium was washed once with 100 μL 
and then replaced with 180 μL of Seahorse assay medium (DMEM containing 4.5 g/L glucose, 
2 mM L-Alanyl-L-glutamine, 1 mM Na-pyruvate, pH 7.35) and kept at 37 °C -CO2 for 1 hour.  
The cartridge was prepared as follows: 
Table 19. Cartridge design CRISPR Bid KO 
Port Substance Volume Stock concentration Final concentration 
Port A Oligomycin 20 μL 30 μM 3 μM 
Port B FCCP 22.5 μL 5 μM 0.5 μM 
Port C Rot./AA 25 μL 1 μM/10 μM 0.1 μM/1 μM 
Port D -  - - 
 
After calibration of the cartridge three baseline OCR/ECAR measurements were recorded 
before successively injecting port A-C followed by three measurements after application of each 
substance (3 min mixing followed by 3 min measuring). 
For RSL3 seahorse measurements 12,000 HT22 cells per well were seeded in 96-well 
XF-plates and kept at 37 °C for 24 hours. Culture medium was washed once with 100 μL and 
then replaced with 175 μL of Seahorse assay medium (DMEM containing 4.5 g/L glucose, 
2 mM L-Alanyl-L-glutamine, 1 mM Na-pyruvate, pH 7.35) and kept at 37 °C -CO2 for 1 hour. 
25 μL of the EC modulators were pipetted into the cartridge as follows: 
Table 20. Cartridge design RSL3 
Port Substance Stock concentration Final concentration 
Port A RSL3 8 μM 1 μM 
Port B Oligomycin 27 μM 3 μM 
Port C FCCP 5 μM 0.5 μM 
Port D Rot./AA/2-DG 1.1 μM/11 μM/550 mM 0.1 μM/1 μM/50 mM 
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After calibration of the cartridge three baseline OCR/ECAR measurements were recorded 
before applying port A. OCR/ECAR were measured for 6 hours before port B-D was injected 
successively followed by three measurements after application of each substance (3 min mixing 
followed by 3 min measurement).  
2.6 Flow cytometric measurements (FACS) 
Fluorescence-activated cell sorting (FACS) provides an objective and quantitative method for 
analyzing a heterogeneous mixture of cells based upon their individual light scattering and 
fluorescent characteristics. For FACS measurements the microcapillary Guava Easy Cyte 6-2 L 
system (Merck Millipore, Darmstadt, Germany) was used. Cells were seeded in a 24-well format 
at a density of 35,000-70,000 cells and were kept at 37 °C until further treatment. After 8 to 16 
hours of treatment cells were analyzed for specific parameters and data collected from at least 
4,000 cells per sample. For quantitative analysis the GuavaSoft Software package was used. 
2.6.1 BODIPY staining: Lipid peroxidation 
BODIPY 581/591 C11 (Figure 26) (Invitrogen, Karlsruhe, Germany) is a fluorescent lipid 
peroxidation sensor for FACS analysis.  
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Figure 26. BODIPY 581/591 C11 
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BODIPY was used to detect reactive lipid species in cells and membranes as oxidation of the 
polyunsaturated butadienyl portion of the dye results in a shift of the fluorescence emission 
peak from red (~590 nm) to green (~510 nm). For BODIPY FACS analysis fluorescence was 
excited with a 488 nm laser (blue) and emission recorded with a 525/30 nm filter (green) and a 
690/50 nm filter (red). For FACS analysis, after the indicated treatment, cells were stained with 
0.5 μL/well of BODIPY solution (final concentration 2 μM) for 30 minutes at 37°C and 
harvested with trypsin after washing once with PBS. The cell pellet was re-suspended in 130-
200 μL of PBS and was put on ice for the measurement. 
2.6.2 DCF staining: Soluble ROS 
CM-H2DCF (Figure 27) (Invitrogen, Karlsruhe, Germany) is a fluorescent soluble ROS 
indicator used in FACS experiments. 
DCF passively diffuses into the cytoplasm, where its acetate group is cleaved by intracellular 
esterases and its thiol-reactive chloromethyl group reacts with intracellular glutathione and 
other thiols. The oxidation-derived fluorescent adduct is now trapped inside the cell and 
facilitates long-term analysis. Oxidation of DCF results in an increase in emission at ~517–
527 nm. For DCF FACS analysis fluorescence was excited with a 488 nm laser (blue) and 
emission recorded with a 525/30 nm filter (green). For FACS analysis, after the indicated 
treatment, medium was exchanged by serum-free medium to avoid deacetylation and cells were 
stained with DCF solution (final concentration 2.5 μM) for 30 minutes at 37°C. Afterwards, 
cells were incubated another 30 minutes in serum-containing medium without DCF and 
harvested with trypsin after washing once with PBS. The cell pellet was re-suspended in 130-
200 μL of PBS and was put on ice for the measurement. 
Figure 27. CM-H2DCF 
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2.6.3 TMRE staining: Mitochondrial membrane potential 
Tetramethylrhodamin ethyl ester (TMRE) (Figure 28) (Immuno Chemistry Technologies, 
Bloomington, USA) is a lipophilic fluorescent FACS dye (orange, ~574 nm) accumulating in 
negatively charged mitochondria due to a delocalized positive charge. Upon collapse of the 
mitochondrial membrane potential, TMRE is dispersed throughout the cytosol thus 
fluorescence levels of the measured cells instantly drop. Detection of the loss of fluorescence of 
TMRE stained cells is a reliable method to quantify loss of mitochondrial membrane potential 
during mitochondrial damage. 
 
 TMRE was utilized to differentiate between those cells with healthy mitochondria and others 
with an acute loss of mitochondrial membrane potential upon mitochondrial damage. For 
TMRE FACS analysis fluorescence was excited with a 488 nm laser (blue) and emission 
recorded with a 690/50 nm filter (red). 
For FACS analysis, after the indicated treatment, cells were stained with 1 μL/well of 
TMRE solution (final concentration 400 nM) for 30 minutes at 37°C and harvested with trypsin 
after washing once with PBS. The cell pellet was re-suspended in 130-200 μL of PBS and was 
put on ice for the measurement. 
  
Figure 28. TMRE 
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2.6.4 MitoSOX staining: Mitochondrial ROS 
MitoSOX (Figure 29) (Invitrogen, Karlsruhe, Germany) is a live-cell permeant fluorescent 
mitochondrial ROS sensor for FACS analysis. 
 
MitoSOX was used for detection of reactive oxygen species in mitochondria. MitoSOX 
selectively localizes to the mitochondria and upon oxidation by superoxide shows increased 
light emission of ~580 nm wavelength. For MitoSOX FACS analysis fluorescence was excited 
with a 488 nm laser (blue) and emission recorded with a 690/50 nm filter (red). 
For FACS analysis, after the indicated treatment, cells were stained with 0.5 μL/well of 
MitoSOX solution (final concentration 2.5 μM) for 30 minutes at 37°C and harvested with 
trypsin after washing once with PBS. The cell pellet was re-suspended in 130-200 μL of PBS and 
was put on ice for the measurement. 
2.6.5 Annexin V and PI staining: Apoptosis and necrosis 
In order to detect early apoptosis and late necrosis as a measure of cell death Annexin V FITC 
and PI (propidium iodide) staining and subsequent FACS analysis were used. In early apoptotic 
cells, phosphatidyl serine (PS) is exposed to the extracellular space by translocation to the outer 
leaflet of the plasma membrane thereby facilitating calcium-dependent binding of Annexin V 
FITC as illustrated in Figure 30. PI is used for the detection of late necrotic cells, which became 
permeable upon membrane disruption and allow PI to pass through and bind to nucleic acids.  
N
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Figure 29. MitoSOX 
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Annexin V FITC/PI staining was utilized to detect cell death and fluorescence was excited with 
a 488 nm laser (blue) and emission recorded with a 525/30 nm filter (green) and a 690/50 nm 
filter (red). 
For FACS analysis, after the indicated treatment, cells were harvested with trypsin and 
washed once with PBS. The cell pellet was re-suspended in 130-200 μL of Annexin V FITC/PI-
binding puffer containing 0.5-1 μL Annexin V FITC and 0.5-1 μL PI per well and was incubated 
in the dark for 5 minutes at room temperature and afterwards put on ice for the measurement. 
2.7 Microscopy 
2.7.1 Epifluorescence microscopy 
For the analysis of cellular morphology, cells were seeded in 8-well ibidi slides, incubated at 
37 °C for 24 hours and treated with the indicated substances. After the indicated time-points 
cells were either instantly imaged at 37 °C or fixed with 4 % PFA for 20 minutes protected from 
light and washed with PBS twice. Ibidi slides were then stored at 4 °C for further experiments. 
Images were acquired at a Leica DM6000 epi-fluorescence microscope (Leica, Wetzlar, 
Germany) collecting light through a 20x objective using bright field illumination and were 
processed with ImageJ Software 1.48v (Maryland, USA). 
Figure 30. Annexin V/PI staining 
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2.7.2 Confocal laser scanning microscopy (CLSM) 
Confocal microscopy was performed on living cells using an LSM800 inverted microscope 
(Zeiss, Jena, Germany) equipped with an incubation chamber for temperature and CO2 control 
and coupled with ZEN blue software(2.3, Zeiss, Jena, Germany). For imaging, cells were seeded 
in 6-well plates at a density of 200,000 cells and for 24 hours transfected with 0.5 ng Life-Act-
GFP plasmid using Attractene transfection reagent (Qiagen, Hilden, Germany) and OptiMEM 
I medium (Invitrogen, Karlsruhe, Germany). Afterwards, cells were re-seeded in 8-well ibidi 
slides at a density of 14,000 cells/well and incubated for another 24 hours. After 30 minutes of 
MitoTracker staining as stated in 2.5.1, cells were treated with the indicated cell death inducers 
and inhibitors. After 5 hours of treatment, cells were put into the incubation chamber and 
imaged immediately.  
488 nm and 640 nm laser lines were used to excite LifeAct-GFP and MitoTracker Deep 
Red FM, respectively, and light was collected through a 63x1.4 NA oil immersion objective. Full 
confocal z-stacks with a section depth of 0.23 μm were acquired and processed with IMARIS 
(8.3.1, Bitplane, Zurich, Switzerland) by Matthias Plessner. 15x15x5 μm regions were cropped 
and smoothened by a Gaussian filter (filter size of 0.0673 μm) to reconstruct mitochondrial 
surfaces using automated settings. 
2.8 Protein analysis 
2.8.1 Protein sample preparation 
For protein analysis, cells were seeded in a 6-well format at a density of 100,000-200,000 cells. 
After ~24 hours cells were treated for the indicated amount of time and harvested by scratching 
and centrifugation for 5 minutes at 1,000-2,000 rpm at 4 °C. Cells were washed once with ice-
cold PBS and re-suspended in an appropriate volume of cold Western blot lysis buffer (Table 
21) (70-500 μL). 
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Table 21. Western blot lysis buffer, pH 7.8 
D-Mannitol 0.25 M 
Tris 0.05 M 
EDTA 1 mM 
EGTA 1 mM 
DTT 100 mM 1:100 
Triton® X-100 1:100 
PhosSTOP  1 tablet 
Complete Mini Protease Inhibitor Cocktail 1 tablet 
Bidest. H2O ad 10 mL 
 
Complete Mini Protease Inhibitor Cocktail and PhosSTOP were obtained from Roche 
(Penzberg, Germany). After mixing, the Western blot lysis buffer was stored at 4 °C until usage.  
After re-suspension of the cell pellet, the lysate was put into liquid nitrogen to disrupt 
cell membranes and either stored at -80 °C or directly thawed on ice and centrifuged for 15 
minutes at 10,000 rpm at 4 °C to eliminate cell debris. The supernatant was transferred into a 
fresh tube and kept on ice for the determination of protein content by BCA assay and 
subsequent Western blot analysis. 
2.8.2 BCA assay: Determination of protein content 
For the analysis of protein amount in cell lysates, the bicinchoninic acid assay (BCA) (Pierce® 
BCA Protein Assay Ki; Perbio Science, Bonn, Germany) was used. The BCA assay is a 
colorimetric method to quantitatively determine protein content exploiting purple Cu+-
bichinoninic acid complex formation. Cu2+ is reduced to Cu+ by peptide bonds of proteins in a 
temperature-dependent ratiometric manner and forms a chelate with two molecules of 
bicinchoninic acid assessed as a color change from green to purple by measuring absorbance at 
562 nm with FluoStar OPTIMA. For the BCA reaction, 2.5 μL of the respective protein sample 
was mixed with 100 μL of BCA mix (1:50 reagent A: reagent B) and shaken at 60 °C for 30 
minutes. After transferring the purple-colored mix to a 96-well plate, absorbance was measured 
and protein amount calculated using a protein standard curve of 0-190 μg/100 μL bovine serum 
albumin (Perbio Science, Bonn, Germany). 
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2.8.3 Polyacrylamide gel electrophoresis (PAGE) 
Protein electrophoresis, described as the movement of proteins in an electric field, is used to 
separate proteins for the purpose of analysis and purification. In an electric field proteins move 
to the electrode of the opposite charge depending on a variety of biophysical determinants, for 
instance pH, temperature, ion size, shape/charge of the protein. Electrophoresis performed in 
polyacrylamide gels is used to separate proteins depending on their size.  The gel structure and 
pore size allows smaller proteins to move faster than larger proteins and thereby provides a 
technique to separate proteins according to their molecular mass. Sodium dodecyl sulfate (SDS) 
is used to turn proteins into a state, where only its length and mass-to-charge ratio determines 
mobility. SDS is negatively charged and binds to proteins in a set ratio so that all proteins get a 
uniform charge-to-mass ratio independently of their original differences in charged amino 
acids. Through binding of SDS proteins also lose their spatial structure and will be fractionized 
in an electric field only by their molecular mass. Gels were prepared in a Bio-Rad gel caster 
(Munich, Germany) with a concentration of bisacrylamide of 3.5 % in the stacking gel (Table 
26) and 12.5 % in the running gel (Table 27) and. The materials and buffers used for gel 
preparation, electrophoresis and Western blot are provided in Table 22 – Table 34.  
Table 22. 1.5 M Tris pH 8.8 
Tris-HCl 23.6  g 
HCl q.s. for pH adjustment 
Bidest. H2O ad 100 mL 
Table 23. 0.5 M Tris pH 6.8 
Tris-HCl 7.88  g 
HCl q.s. for pH adjustment 
Bidest. H2O ad 100 mL 
Table 24. 10 % Sodium dodecyl sulfate (SDS) 
SDS 1 g 
Bidest. H2O ad 10 mL 
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Table 25. 10 % Ammonium persulfate (APS) 
APS 1 g 
Bidest. H2O ad 10 mL 
Table 26. Stacking gel 3.5 % 
Acrylamide/bisacrylamide (37.5:1) 30 % 0.58 mL 
Sodium dodecyl sulfate solution 10 % 0.05 mL 
0.5 M Tris-HCl buffer pH 6.8 1.2 mL 
Ammonium persulfate solution 10 % 0.03 mL 
Tetramethylethylenediamine (TEMED) 0.008 mL 
Phenol red q.s. 
Bidest. H2O  ad 5 mL 
Table 27. Running gel 12.5 % 
Acrylamide/bisacrylamide (37.5:1) 30 % 4.17 mL 
Sodium dodecyl sulfate solution 10 % 0.1 mL 
1.5 M Tris-HCl buffer pH 8.8 2.5 mL 
Ammonium persulfate solution 10 % 0.0625 mL 
Tetramethylethylenediamine (TEMED) 0.0125 mL 
Bidest. H2O  ad 10 mL 
Table 28. 5x SDS-sample buffer 
1.5 M Tris-HCl pH 6.8 2 mL 
Glycerol 5 mL 
SDS 1 g 
β-Mercaptoethanol 2.5 mL 
1 % Bromophenol blue 0.5 mL 
Table 29. 10x SDS-PAGE buffer 
Tris base 30 g 
SDS 10 g 
Glycine 144 g 
Bidest. H2O ad 1 L 
 
For SDS-PAGE 10x buffer was diluted 1:10 with bidest. H2O. 
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Table 30. 10x Western blot transfer buffer 
Tris base 30 g 
Glycine 144 g 
HCl q.s. for pH adjustment 
Bidest. H2O ad 1 L 
 
For Western blot 10x buffer was diluted 1:10 with bidest. H2O and 20 % methanol. 
Table 31. 10x TBS pH 7.5 
NaCl 292 g 
Tris base 24.2 g 
HCl q.s. for pH adjustment 
Bidest. H2O ad 1 L 
Table 32. 1x TBST 
10x TBS 100 mL 
Tween® 20 0.5 mL 
Bidest. H2O ad 1 L 
Table 33. 5 % Blocking milk 
Skim milk powder 5 g 
Bidest. H2O ad 100 mL 
Table 34. 0.2 %  I-Block blocking solution 
I-BlockTM 100 mg 
TBS 50 mL 
Tween® 20 50 μL 
 
I-Block was dissolved in TBS under heating to ~55 °C and afterwards cooled down to RT prior 
to Tween® 20 addition. 
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For SDS-PAGE samples were prepared as follows: 50-80 μg of protein were mixed with an 
appropriate volume of 5x SDS-sample buffer and heated up to 95 °C for 2 minutes while 
shaking at 600 rpm. After cooling, samples and protein standard (PageRulerTM Prestained 
Ladder, ThermoFisher Scientific, Schwerte, Germany, Figure 31) were loaded onto an SDS-gel 
and electrophoresis performed at 60 V until the samples reached the separation gel. Voltage 
was then switched to 100-120 V until separation was achieved appropriately.  
 
2.8.4 Western blot 
Western blotting is defined as the transfer of proteins to a solid-phase membrane followed by 
immuno-detection. After protein separation by SDS-PAGE, proteins can be bound to 
membranes where they are accessible for immunological or biochemical analysis, quantitative 
staining or identification of protein-protein interaction.  
Following protein separation by SDS-PAGE, proteins were blotted onto a 
polyvinylidene fluoride membrane (PVDF, Bio-Rad, Munich, Germany), which was activated 
by incubation in methanol for 2 minutes and in 1x Western blot transfer buffer for at least 10 
minutes. Western blot was performed according to the wet-blot Bio-Rad protocol in a Mini-
Trans-Blot Cell tank (Bio-Rad, Munich, Germany) for 75-120 minutes at 300-350 mA 
submerged with ice-cold 1x Western blot transfer buffer.  
Figure 31. PageRuler™ Prestained Protein Ladder, 10 to 180 kDa [129] 
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After protein transfer, the membrane was blocked for 1 hour with either 5 % blocking milk 
(Table 33) or I-Block (Table 34) at RT. Thereafter, the membrane was incubated over night at 
4 °C with the primary antibody in 5 % milk or I-Block while shaking. On the next day, the 
membrane was put on RT and incubated with the primary antibody (Table 35) for another 
hour, before washing three times with TBST (Table 32) for 15 minutes each. After this, the 
membrane was incubated with the corresponding secondary HRP-antibody (Table 37) for 1 
hour at RT and again washed three times with TBST for 15 minutes each. Subsequently, the 
membrane was put for 1-2 minutes in 1:1 HRP-Juice (PJK GmbH, Kleinblittersdorf, Germany) 
as a chemi-luminescent substrate for HRP and Western blot signals were detected with semi-
automated Chemidoc-XRS Imaging system and Quantity One software package(Bio-Rad, 
Munich, Germany).  
Equal protein loading was controlled for by washing the membrane once in TBST for 
10 minutes and re-probing with an appropriate antibody against a house-keeping protein 
(Table 36) and its corresponding secondary HRP-antibody. 
2.8.5 Antibodies 
2.8.5.1. Primary antibodies 
All primary antibodies used were diluted in either 5% blocking milk (Table 33) or I-Block 
(Table 34). For Western blot analysis the antibodies were purchased and diluted as given in 
Table 35: 
Table 35. Primary antibodies 
Antibody Company Diluted in Dilution Host 
12-LOX Biorbyt Milk 1:500 rabbit 
AIF D20 Santa Cruz Milk 1:1000 goat 
Bid Cell signaling Milk 1:1,000 rabbit 
GFP Rockland I-Block 1:500 goat 
GPX4 Abcam I-Block  1:500-1:750 rabbit 
xCT (mono) Abcam Milk 1:1000 rabbit 
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Table 36. Primary antibodies for house-keeping proteins 
Antibody Company Diluted in Dilution Host 
Actin C4 MP Biomedicals Milk 1:1,000-1:10,000 mouse 
Tubulin Cell signaling Milk 1:2,000 mouse 
Vinculin Sigma Aldrich Milk 1:20,000 mouse 
2.8.5.2. Secondary antibodies 
All secondary antibodies were purchased from Vector Labs (Burlingame, US) if not stated 
otherwise. Horse radish peroxidase (HRP) labeled anti-mouse IgG (H+L), anti-goat IgG (H+L) 
and anti-rabbit IgG (H+L) secondary antibodies were utilized for Western blot analysis as 
illustrated in Table 37. 
Table 37. Secondary antibodies 
Antibody Solvent Dilution 
HRP-anti-mouse 5% blocking milk 1:2,500-1,3000 
HRP-anti-rabbit 5% blocking milk 1:2,500-1,3000 
HRP-anti-goat 5% blocking milk 1:2,500-1,3000 
2.8.6 Coomassie protein staining 
For the purpose of visualizing purity or recombinant proteins (2.10.3), SDS-PAGE was 
followed by Coomassie Blue R-250 staining. Coomassie Brilliant Blue R-250 (ThermoFisher 
Scientific, Schwerte, Germany) binds to proteins in an unspecific manner via electrostatic, non-
covalent complex formation exhibiting blue color and thus providing a reliable method to 
optically analyze proteins in SDS gels. 
For Coomassie staining, gels were heated in Coomassie solution (Table 38) for 10-20 
minutes in the microwave. Thereafter, gels were discolored in acidic methanol solution (Table 
39) overnight at room temperature and images taken using white transmission light at the 
Chemidoc-XRS System (Bio-Rad, Munich, Germany). 
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Table 38. Coomassie Brilliant Blue R-250 solution 
Coomassie Blue R-250 1 g 
Methanol  450 mL 
100 % Acetic acid 100 mL 
Bidest. H2O ad 1 L 
Table 39. Coomassie staining solution 
Methanol  300 mL 
100 % Acetic acid 100 mL 
Bidest. H2O ad 1 L 
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2.9 DNA/RNA analysis 
2.9.1 PCR primer 
For PCR and RT-PCR all primers were synthesized by EurofinsGenomics (Ebersberg, 
Germany). Primer sequences were used as listed in Table 40: 
Table 40. Primers for PCR/RT-PCR 
Primer Sequence Length of gene product 
Bid fwd 5´-GGGAACTGCCTGTGCAAGCTTAC-3´ 1250 bp 
Bid rev 5´-CAGTGAGGCCTTGTCTCTGAA-3´  
GAPDH fwd 5′-CGTCTTCACCACCATGGAGAAGGC-3′ 399 bp 
GAPDH rev 5′-AAGGCCATGCCAGTGAGCTTCCC-3′  
Bid1028 fwd 5′-AGCCCTGAACGGAAACATGG-3′ 1028 bp 
Bid1028 rev 5′-CAGGCGGATCTCTGAGTTCG-3′  
Trpc4 fwd 5′-GTCAGCACCTAACGTGTC-3′ 707 bp 
Trpc4 rev 5′-CGTGGGGCTTAAGTCATAG-3′  
Grm3 fwd 5′-CACTGTGACAGGAAGCTTC-3′ 587 bp 
Grm3 rev 5′-GTGAGCCACACATCACAG-3′  
Syngr1 fwd 5′-GGAACTCCTTTGGGGTATG-3′ 666 bp 
Syngr1 rev 5′-GTACCAGAAGAGCAAGTCTG-3′  
Hprt fwd “new” 5′-AATCCTCTGGGAGACGAC-3′  
Hprt rev 5′-GCCTGATCCTTCCTGAAG-3′ 728 bp 
Hprt rev “new” 5′-TTCTAGAGGTGTTCCCTGG-3′ 809 bp 
Kcne1 fwd 5′-TGCTGGAATTAGCCAATCAG-3′ 593 bp 
Kcne1 rev 5′-GGTGCCCCTACAATAAAGAC-3′  
Hivep3 fwd 5′-CTCTACAAGCACAGGAAGTC-3′ 721 bp 
Hivep3 rev 5′-GATCTCACTGGTGTCCAC-3′  
2.9.2 RNA sample preparation 
RNA from frozen cell pellets (-80 °C) was isolated using the InviTrap® Spin Universal RNA 
Mini Kit (Stratec Molecular GmbH, Berlin, Germany) according to the manufacturer’s 
protocol.  
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Briefly, cells were thawed on ice and lysed with 350-700 μL Lysis Solution TR containing 
1 % β-mercaptoethanol. The lysate was transferred immediately onto a DNA-Binding Spin 
Filter and incubated for at least 1 minute at RT to allow contaminating DNA to bind to the 
filter. Afterwards, the sample was centrifuged for 1 minute at 11,000 rpm. The DNA-Binding 
Spin Filter was discarded and 350-700 μL 70 % ethanol added to the flow-through to adjust 
RNA-binding conditions. The sample was then transferred on the RNA-RTA Spin filter, 
incubated for at least 1 minute to facilitate RNA binding to the filter and centrifuged for 2 
minutes at 11,000 rpm. The flow-through was discarded. The RNA-RTA Spin filter was now 
washed with 600 μL Wash Buffer R1 and 700 μL Wash Buffer R2 with subsequent centrifugation 
at 11,000 rpm for 1 minute each to remove residual contaminants. In order to eliminate any 
traces of ethanol, the filter was centrifuged with an open lid for 4 minutes at maximum speed. 
After transferal of the filter into an RNAse free Elution Tube, 25-40 μL of Elution Buffer R was 
pipetted onto the membrane, incubated for at least 2 minutes to resolve purified RNA and 
centrifuged for 1 minute at 11,000 rpm. Eluted RNA was placed on ice and stored at -80 °C for 
further experiments. 
2.9.3 NanoDrop: Photometric determination of DNA/RNA amount 
For quantitative determination of RNA/DNA amounts absorbance at 260 nm was measured 
using the NanoPhotometerTM (Implen, Munich, Germany). To analyze contamination 
absorbance at 230 nm and 280 nm was measured simultaneously and the ratio of 260/230 nm 
and 260/280 nm calculated. A 260/280 ratio of ~2.0 was accepted as sufficiently pure RNA, for 
DNA the 260/280 ratio should be greater than 1.8 and the 260/230 ratio between 2.0 and 2.2. 
2.9.4 (Reverse transcriptase) polymerase chain reaction: (RT)-PCR 
For the amplification of DNA, the polymerase chain reaction (PCR) was exploited. In the case 
of RNA samples, first RNA had to be transcribed into complimentary DNA (cDNA) using 
reverse transcriptase and subsequent amplification via PCR. 
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For DNA amplification, REDTaq® ReadyMixTM PCR Reaction Mix (Sigma Aldrich, 
Taufkirchen, Germany) and for RT-PCR of RNA samples the SuperScript III One Step RT-
PCR System with Platinum® Taq (Invitrogen, Karlsruhe, Germany) were used. Primer were 
obtained from Eurofins (EurofinsGenomics, Ebersberg, Germany) and listed in Table 40.  
Table 41. RT-PCR 
2x reaction buffer 12.5 μL 
RNA sample 100-300 ng 
Fwd primer  1 μL 
Rev primer 1 μL 
SuperScript III enzyme 0.5 μL 
Nuclease free water ad 25 μL 
 
2.9.5 Agarose gel electrophoresis 
After PCR amplification, according to section 2.9.4, the PCR samples were mixed with an 
appropriate amount of 10x loading dye and loaded onto a 1 % agarose gel stained with ethidium 
bromide. For comparative analysis of product size 5 μL of GeneRuler 100 bp Plus DNA ladder 
(ThermoFisher Scientific, Schwerte, Germany) or 1 kb Plus DNA ladder (NEB, Frankfurt, 
Germany) was placed next to the samples on the gel.  Electrophoresis was performed at 80 V 
for 30-45 minutes and UV light with Chemidoc-XRS Imaging system (Bio-Rad, Munich, 
Germany) was used for visualization of the respective PCR products.  
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2.10 Protein X-ray crystallography 
2.10.1 Materials for recombinant protein expression 
Commercially available equipment used for the recombinant expression, purification and 
concentration of proteins are provided in Table 42. Materials for crystallographic methods are 
listed in Table 43. 
Table 42. Materials for protein expression, purification and concentration 
Materials Company 
0.22 μm Whatman PuradiscTM sterile filter Whatman, Dassel, Germany 
10 cm dishes for agar plates Greiner, Frickenhausen, Germany 
3 kDa Amicon® Ultra Centrifugal Filter Units, 15 mL Millipore, Schwalbach, Germany 
Collection tubes 14 mL, 105 x 16.8 mm, Polystyrene Sarstedt, Nümbrecht, Germany 
Cryo vials 2 mL Sarstedt, Nümbrecht, Germany 
Glutathione HiCap Column, 20 mL/10 mL Qiagen, Düsseldorf, Germany 
HiLoad 16/1600 Superdex 75 prep grade GE Healthcare Freiburg, Germany 
HisTrapTM FF, 5 mL GE Healthcare Freiburg, Germany 
HiTrap Q HP, 5 mL GE Healthcare Freiburg, Germany 
trUViewTM; single-use cuvettes Bio-Rad, Munich, Germany 
Ultra-centrifugation tubes Beckmann, Krefeld, Germany 
ZebaTM Desalt Spin Columns ThermoFisher Scientific, Schwerte, Germany 
Table 43. Equipment for protein crystallization 
Materials Company 
MRC2 2-drop-chamber 96-well crystallization plate JenaBioscience, Jena, Germany 
96-deep-well plate Masterblock Greiner, Frickenhausen, Germany 
ViewSealTM Greiner, Frickenhausen, Germany 
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2.10.2 Bid vectors and construct cloning 
In order to crystallize BID several constructs were used as described in Table 44. From the NMR 
structure of BID it became evident that the mobile N-terminus and loop would hinder 
crystallization, for which reason in construct Bid 1 and Bid 3 the loop and N-terminus was 
removed. To prevent covalent GSH binding to the protein during purification both thiol-
containing cysteines were replaced with serines (CCSS). 
Table 44. Bid vectors for crystallization 
Construct Tag Resistance Source Molecular weight (g/mol) 
pET15b-Bid-p22 His6 Amp Addgene plasmid 8784 21,951.7 
pET15b-Bid-p22 
CCSS 
His6 Amp Site-directed mutagenesis by 
Cornelius Krasel 
21,919.6 
pGEX Δ12-Y47 (Bid 
1) 
GST Amp As described in [132] 17,626.2 
pGEX Δ13-Y47 (Bid 
3) 
GST Amp As described in [132] 17,569.2 
pGEX Δ13-Y47 CCSS  
(Bid 3 CCSS) 
GST Amp Site-directed mutagenesis by 
Cornelius Krasel 
17,537.0 
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2.10.3 Recombinant protein expression 
2.10.3.1. Bacteria for protein expression 
For protein expression the vectors were transformed in Escherichia coli Rosetta2 (DE3) 
SingelsTM Competent Cells (Novagen/Merck, Darmstadt Germany) carrying chloramphenicol 
resistance gene. Rosetta2 (DE3) host strains are BL21 derivatives with high transformation 
efficiency suitable for expression of eukaryotic proteins that contain codons rarely used in 
Escherichia coli. Rosetta2 provide tRNAs for 7 rare codons (AGA, AGG, AUA, CUA, GGA, 
CCC, and CGG) on a compatible chloramphenicol-resistant plasmid and the tRNA genes are 
driven by their native promoters. T7 expression strains are lysogens of bacteriophage (λ) DE3, 
as indicated by the (DE3). These hosts carry a chromosomal copy of the T7 RNA polymerase 
gene under control of the lacUV5 promoter. Such strains are suitable for production of protein 
from target genes cloned in appropriate T7 expression vectors using Isopropyl β-D-1-
thiogalactopyranoside (IPTG) as an inducer. 
2.10.3.2. Transformation for recombinant protein expression 
Transformation of Rosetta2 (DE3) was performed according to the protocol recommended by 
Novagen. In brief, for transformation bacteria and plasmids were thawed on ice for 2-
5 minutes. Afterwards, 20-50 μL of Rosetta2 (DE3) were mixed with 1 μg of purified plasmid 
DNA and gently stirred. The tubes were incubated on ice for 5 minutes and heated for 
30 seconds to 42 °C without shaking to allow transformation. Thereafter, the tubes were put on 
ice for another 2 minutes before adding 250 μL of autoclaved LB (Table 45) or SOC medium 
(provided with Rosetta2) to each tube. The mixtures were shaken at 37 °C for 30 min in a 
thermocycler and then plated on LB-Amp agar plates (Table 46), which were treated with 50 μL 
of chloramphenicol (30 mg/mL in ethanol) beforehand. Then the transformation mix was 
spread on the LB agar plates. The agar plates were incubated at 37°C overnight until bacterial 
colonies were grown and visible as single dots. 
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Table 45. Autoclaved LB medium 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 5 g 
Bidest. H2O ad 1 L 
Table 46. Autoclaved agar plate mixture 
LB medium 500 mL 
Ampicillin 100mg/mL in H2O 0.5 mL 
Agar powder 7.5 g 
2.10.3.3. Protein expression and long-term cryo-conservation 
Single clones were picked for protein expression in liquid culture and an overnight culture of 
2.5-20 mL LB supplemented with 1:1000 ampicillin (100 mg/mL in H2O) and chloramphenicol 
(30 mg/mL in ethanol) was inoculated.  
After overnight incubation at 37 °C a cryo-stock for long-term-storage was prepare. To 
do so, 930 μL of the overnight culture were mixed with 70 μL DMSO as cryo-protectant and 
transferred to cryo-vials for storage at -80 °C. 
For expression of recombinant proteins 4x 300 mL LB medium (with 1:1000 ampicillin and 
chloramphenicol) were inoculated with the overnight culture of single clones or from cryo-
stocks, respectively. Cultures were shaken at 37 °C for 4 to 5 hours until an optical density of 
OD600 ~0.6 determined using single use cuvettes with the Bio-Rad SmartSpecTM Plus 
spectrophotometer (Bio-Rad laboratories, Munich, Germany). Prior to that, the 
spectrophotometer was blanked with sterile LB medium. At OD600 of ~0.6 1:1000 IPTG (1 M in 
H2O) was added to each culture to induce protein expression. IPTG mimics allolactose, a 
lactose metabolite, which triggers transcription of the lac operon through binding to the lac 
repressor and releasing it from the lac operator. After IPTG addition, protein expression was 
induced for 5 hours and bacteria harvested by centrifugation for 15 minutes at 5000 rpm and 
4 °C. All 4 pellets were pooled in 20 mL GSH binding buffer (Table 52) in case of GST-tagged 
proteins or HisTrap FF binding buffer (Table 48) in case of His6-tagged full-length BID each 
supplemented with 2 tablets of Complete Mini Protease Inhibitor Cocktail and stored at -80 °C.  
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2.10.3.4. Protein expression as heavy atom derivatives 
Having obtained diffracting protein crystals, the bottleneck in protein-structure determination 
is to solve the phase problem, which occurs as the x-ray detector can only record amplitudes 
but not phases of the electromagnetic waves. Molecular replacement (MR) is the method of 
choice to attain the phases but requires a protein structure with high sequence similarity to be 
available. If there is no such structure, other methods are used, for example introduction of 
heavy atom diffraction labels into the crystal (multiple isomorphous replacement, MIR) 
combined with multi-wavelength anomalous dispersion (MAD) method. Heavy atoms act as 
anomalous scatterers and multiple data sets of one single crystal can be collected using different 
wavelengths. Their variation in measured intensities at the different wavelengths can be used 
to extract the anomalous scatterer’s substructure to solve the phase problem.  
Selenium (Se) atoms act as anomalous scatterers and can be incorporated into proteins 
by replacement of methionines with selenomethionine (SeMet) during protein expression in 
bacteria to aid the structure elucidation. Ideally, the structure of the SeMet-substituted crystal 
is isomorphous to the native protein crystals, so that the native data can be included into data 
processing. 
To replace methionine with selenomethionine in Bid 3 CCSS the SelenoMet DreamTM 
Media Kit was utilized providing minimal growth medium for selenomethionine 
incorporation. The SelenoMet Dream Nutrient Mix is formulated for lactose-based or IPTG 
induction of the target protein. When E.coli is cultured in the presence of two carbon sources 
(glucose and lactose), the bacterium first utilizes glucose and then lactose. Thus, expression of 
proteins of target gene under control of a lac operon will be induced only when glucose as a 
carbon source is exhausted and the bacterium starts to consume lactose or when IPTG is added. 
The SelenoMet Dream Nutrient Mix lacks methionine as an amino acid and suppresses 
methionine biosynthesis in bacteria while providing selenomethionine instead. 
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Table 47. SelenoMet growth medium 
SelenoMet Dream Base 4 sachets 
SelenoMet Dream Nutrient Mix 4 sachets 
Bidest. H2O ad 4 L 
Glycerol 2 % (w/v) (optional) 
Ampicillin 100 mg/mL /Chloramphenicol  30 mg/mL 4 mL each (1:1000) 
SelenoMet Solution 10 mg/mL 16 mL 
 
SelenoMet Dream Base and Nutrient Mix were solved in bidest. water and autoclaved. Glycerol 
(optional), antibiotics and SelenoMet solution were added freshly before protein expression. 
Small-scale expression was done in order to determine optimal bacterial growth and 
protein expression conditions. For this reason, supplementation with 2 % glycerol and 
induction with or without IPTG were tested. 200 μL of an overnight culture in standard LB 
medium were used to inoculate 10 mL of SelenoMet growth medium (± 2 % glycerol, ± IPTG 
1mM) and harvested after 22 hours by centrifugation for 15 minutes at 5,000 rpm and 4 °C. 
Pellets were re-suspended in 50 μL of 2.5x Western blot sample buffer (Table 28), lysed by 
sonication and run on a 12.5 % SDS-gel. After electrophoresis proteins were stained using 
Coomassie staining according to 2.8.6. 
For large-scale Bid 3 CCSS SeMet expression, 100 mL of SelenoMet growth medium (Table 47) 
was inoculated with Bid 3 CCSS cryo-stock bacteria and incubated at 37 °C as an overnight 
culture. Further protein expression was carried out in 4 L SelenoMet growth medium according 
to 2.10.3.3.  
2.10.4 Protein purification 
2.10.4.1. Buffers for protein purification 
All buffers for protein purification were made according to Table 48-Table 54, sterile-filtered 
through a 0.22 μm filter and degassed under vacuum for at least 2 hours at RT. Sodium azide 
was added to avoid bacterial growth. 
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Table 48. Nickel affinity binding buffer for HisTrapTM FF column 5 mL, pH 7.5 
20 mM Tris base 2.42 g 
250 mM NaCl 14.6 g 
10 mM β-Mercaptoethanol 0.78 g (~ 22 drops) 
20 mM Imidazole 1.36 g 
Bidest. H2O ad 1 L 
HCl q.s. for pH adjustment 
0.03 % Na-azide 1 mL (30% aqueous solution) 
Table 49. Nickel affinity elution buffer for HisTrapTM FF column 5 mL, pH 7.5 
20 mM Tris base 2.42 g 
20 mM NaCl 1.17 g 
10 mM β-Mercaptoethanol 0.78 g (~ 22 drops) 
400 mM Imidazole 27.24 g 
Bidest. H2O ad 1 L 
HCl q.s. for pH adjustment 
0.03 % Na-azide 1 mL (30% aqueous solution) 
Table 50. Ion exchange binding buffer for HiTrap Q HP column 5 mL, pH 8.0 
20 mM Tris base 2.42 g 
10 mM β-Mercaptoethanol 0.78 g (~ 22 drops) 
Bidest. H2O ad 1 L 
HCl q.s. for pH adjustment 
0.03 % Na-azide 1 mL (30% aqueous solution) 
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Table 51. Ion exchange elution buffer for HiTrap Q HP column 5 mL, pH 8.0 
20 mM Tris base 2.42 g 
500 mM NaCl 29.22 g 
10 mM β-Mercaptoethanol 0.78 g (~ 22 drops) 
Bidest. H2O ad 1 L 
HCl q.s. for pH adjustment 
0.03 % Na-azide 1 mL (30% aqueous solution) 
Table 52. GSH binding buffer for GSH HiCap column 20 mL, pH 7.6 
20 mM Tris base 2.42 g 
100 mM NaCl 5.84 g 
1 mM EDTA 0.29 g 
1 mM DTT 1 mL (1 M stock) 
Bidest. H2O ad 1 L 
HCl q.s. for pH adjustment 
0.03 % Na-azide 1 mL (30% aqueous solution) 
Table 53. GSH elution buffer for GSH HiCap column 20 mL, pH 8.0 
50 mM Tris base 6.06 g 
10 mM Reduced L-glutathione 3.07 g 
1 mM EDTA 0.29 g 
1 mM DTT 1 mL (1 M stock) 
Bidest. H2O ad 1 L 
HCl q.s. for pH adjustment 
0.03 % Na-azide 1 mL (30% aqueous solution) 
Table 54. Gel filtration buffer for HiLoadTM 16/600 Superdex 75 pg gel filtration column 120 mL, pH 7.4 
20 mM Tris base 2.42 g 
50 mM NaCl 2.92 g 
TCEP 1 g (optional) 
Bidest. H2O ad 1 L 
HCl q.s. for pH adjustment 
0.03 % Na-azide 1 mL (30% aqueous solution) 
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2.10.4.2. ÄKTA prime plus 
ÄKTA prime plus (GE Healthcare, Freiburg, Germany) is a small-scale liquid chromatography 
system for simple protein purification and includes a system pump, fraction collector, valves 
for buffer selection, sample injection, gradient formation and flow diversion, and monitors for 
UV, conductivity and pH. Methods were programmed, results monitored and results presented 
using PrimeView 5.0 software (GE Healthcare, Freiburg, Germany). 
Before each protein purification, the system was pre-equilibrated to remove 20 % 
ethanol, in which the system was stored. All components were purged three times with degassed 
bidest. water using system wash and the columns were rinsed with 2 volumes water of the 
respective column by manual run (flow rate 0.5-1.5 mL/min). Afterwards, the system was 
prepared for the respective purification method by purging it with 2 column volumes of the 
required binding buffer by manual run and system wash. At the end of each purification, the 
system was again purged with water as described above and stored in 20 % ethanol. The 
maximum pressure was fixed to 0.3-0.5 MPa for all purification columns. 
Purification was monitored for protein content by UV/Vis detection using PrimeView 
5.0 software. Elution fractions were always analyzed for purity by SDS-gel electrophoresis and 
subsequent Coomassie staining in order to decide which fractions to pool for further 
purification steps. 
2.10.4.3. Lysis of bacterial cells 
Bacterial protein lysates produced according to 2.10.3 were lysed prior to purification with 
ÄKTA prime plus liquid chromatography. For this, the 20 mL lysate was sonicated on ice using 
the Branson Sonifier Cell Disrupter S-450D (Branson Ultrasonics, Dietzenbach, Germany) 
with a macro-tip at 20 % maximum power. To prevent overheating, sonication was performed 
with an interval of 1 second followed by 1 second without sonication for a total duration of 
20 minutes. Afterwards, the lysate was centrifuged in ultra-centrifugation tubes for 60 minutes 
at 35,000 rpm and 4 °C (Beckman Optima XE-90, Ti70.1 rotor, Beckman Coulter, Krefeld, 
Germany). The supernatant was kept on ice and sterile-filtered through a 0.22 μm filter to avoid 
particles clogging the chromatography system. 
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2.10.4.4. Purification of His6-tagged full-length BID 
Purification of His6-tagged BID and BID CCSS was performed using three subsequent 
chromatography steps including nickel-affinity chromatography, ion exchange 
chromatography and size-exclusion gel chromatography. 
For nickel affinity chromatography two connected HisTrapTM FF columns 5 mL (GE 
Healthcare, Freiburg, Germany) containing Ni sepharose were used. Immobilized metal ion 
affinity chromatography (IMAC) is exploited to bind histidine-tagged proteins to metal ions 
and retain them in a column. Elution of the desired protein is achieved by competitive binding 
of excess imidazole. 
For purification two HisTrapTM FF columns were connected to the ÄKTA prime plus 
system and pre-equilibrated with nickel affinity binding buffer (Table 48) as described above. 
The sterile-filtered protein lysate of recombinant full-length BID (CCSS) with an N-terminal 
hexa-histidine tag was purified using the following automated program with a pressure limit of 
0.5 MPa: 
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Table 55. Method #9 for Ni-affinity chromatography 
 Break-
point 
Volume 
(mL) 
Concentration 
Buffer B (%) 
Flow rate 
(mL/min) 
Fraction 
size (mL) 
Inject valve 
position 
Equilibration 1 0 0 1 0 Load 
Sample injection 1 2 5 0 1 8 Inject 
Wash Buffer A 3 13 0 1 0 Load 
Sample injection 2 4 15 0 1 8 Inject 
Wash Buffer A 5 23 0 1 0 Load 
Sample injection 3 6 25 0 1 8 Inject 
Wash Buffer A 7 33 0 1 0 Load 
Sample injection 4 8 35 0 1 8 Inject 
Wash Buffer A 9 43 0 1 0 Load 
Sample injection 5 10 55 0 1 8 Inject 
Wash Buffer A 11 63 0 1 5 Load 
Start Elution 12 83 5 1 1 Load 
Elution 13 103 75 1 1 Load 
Elution 14 123 75 1 5 Load 
Elution 15 128 100 1 5 Load 
Elution wash out 16 133 100 1 0 Load 
Re-equilibration 17 143 0 1 0 Waste 
 
Protein samples were loaded by repeated injections (4-5 times) in a 5 mL sample injection loop 
while collecting flow-through in 8 mL volume fractions. Elution of histidine-tagged proteins 
was performed using an imidazole gradient with nickel affinity elution buffer (Table 49) and 1-
5 mL elution fractions were collected and stored at 4 °C until further use.  
After the first purification by Nickel-affinity chromatography, the histidine-tag had to 
be removed. Therefore, the protein was cleaved using thrombin as described in 2.10.4.6. After 
cleavage the protein samples had to be de-salted to be suitable for ion exchange 
chromatography by efficient ionic binding. Therefore, either 5 mL ZebaTM Desalt Spin 
Columns (ThermoFisher Scientific, Schwerte, Germany) were used according to the 
manufacturer’s protocol or the protein samples were concentrated using 3 kDa cut-off Amicon 
filters at 4,000 rpm and 4 °C (Merck Millipore, Darmstadt, Germany) and subsequently diluted 
in ion exchange binding buffer (Table 50). 
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Ion exchange chromatography (IEX) was accordingly performed using an anionic HiTrap Q 
HP column 5 mL (GE Healthcare, Freiburg, Germany) with cross-linked agarose beads with 
quaternary ammonium (Q) anions. Anionic IEX is commonly used to separate molecules based 
on their net positive surface charge in buffers with a pH above their isoelectric point and is 
applicable for protein purification. Positive charged proteins will competitively bind to the 
anionic column in ion exchange binding buffer (Table 50) and can be eluted with ion exchange 
elution buffer (Table 51) containing a high amount of positive charged sodium ions. The 
program with a pressure limit of 0.5 MPa used with ÄKTA prime plus is as follows: 
Table 56. Method #10 for ion exchange chromatography 
 Break-
point 
Volume 
(mL) 
Concentration 
Buffer B (%) 
Flow rate 
(mL/min) 
Fraction 
size (mL) 
Inject valve 
position 
Equilibration 1 0 0 5 0 Load 
Sample injection 1 2 25 0 5 5 Inject 
Wash Buffer A 3 32 0 5 2 Load 
Sample injection 2 4 39 0 5 5 Inject 
Wash Buffer A 5 46 0 5 2 Load 
Sample injection 3 6 53 0 5 5 Inject 
Wash Buffer A 7 58 0 5 5 Load 
Start Elution  8 85 0 5 2.5 Load 
Elution 9 185 100 5 2.5 Load 
Elution wash out 10 205 100 5 2.5 Load 
Re-equilibration 11 210 0 5 0 Load 
End method 12 235 0 5 0 Load 
 
Protein samples were loaded by repeated injections (2-3 times) in a 5 mL sample injection loop 
while collecting flow-through in 2-5 mL volume fractions. Elution of proteins was performed 
using a sodium ion gradient with ion exchange elution buffer (Table 51) and 2.5 mL elution 
fractions were collected and stored at 4 °C until further use.  
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As a final purification step, size-exclusion chromatography (gel filtration) was performed using 
a HiLoadTM 16/600 Superdex 75 pg gel filtration column 120 mL (GE Healthcare, Freiburg, 
Germany). Therefore, the desired protein sample is given onto a column with dextran 
covalently bound to highly cross-linked agarose. Dextran determines the separation properties 
as it traps small molecules and lets bigger molecules pass by depending on its pore size. The 
column used allowed for separation of molecules in a range of 3-70 kDa. 
In order to reduce the sample size to 5 mL so that the whole sample can be injected into 
the sample loop at once and separation efficiency is thus maximized, the protein sample was 
washed with gel filtration buffer (Table 54), concentrated using 3 kDa cut-off Amicon filters at 
4000 rpm and 4 °C and subsequently sterile-filtered through a 0.22 μm filter. For purification 
the following method was used with a pressure limit of 0.3 MPa:  
Table 57. Method #14 for gel filtration 
 Break-
point 
Volume 
(mL) 
Concentration 
Buffer B (%) 
Flow rate 
(mL/min) 
Fraction 
size (mL) 
Inject valve 
position 
Equilibration 1 0 0 0.8 0 Load 
Sample injection  2 10 0 0.8 0 Inject 
Elution Start 3 16 0 0.8 5 Load 
Elution 4 20 0 0.8 2 Load 
Elution  5 45 0 0.8 2 Load 
Elution Wash-Out 6 160 0 0.8 2 Load 
 
Protein samples were loaded by one injection in a 5 mL sample injection loop. Elution of 
proteins was performed using gel filtration buffer (Table 54) and 2-5 mL elution fractions were 
collected and stored at 4 °C until further use.  
For crystallization, the pooled fractions containing pure BID (CCSS) were concentrated 
to ~5-14 mg/mL using 3 kDa cut-off Amicon filters at 4000 rpm and 4 °C, subsequently sterile-
filtered through a 0.22 μm filter and kept at 4 °C until crystallization. 
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2.10.4.5. Purification of GST-tagged BID proteins 
GST-tags are commonly used for protein purification as they support protein solubility, 
expression efficiency and UV/Vis protein detection especially in case of small proteins, which 
can be purified in a two-step chromatography of successive glutathione affinity and size-
exclusion chromatography.  
In order to purify GST-tagged proteins glutathione affinity chromatography using a 
GSH HiCap column 20 mL (Qiagen, Düsseldorf, Germany) with glutathione sepharose was 
utilized.  Glutathione-S-transferase (GST) binds with high affinity to immobilized glutathione 
in the column, thus retaining N-terminal GST-tagged BID protein constructs. Elution of the 
desired protein is achieved by competitive binding of excess reduced L-glutathione. 
For purification a GSH HiCap column 20 mL was connected to the ÄKTA prime plus system 
and pre-equilibrated with glutathione binding buffer (Table 52) as described above. The sterile-
filtered protein lysate of recombinant BID constructs with an N-terminal GST-tag was purified 
using the following automated program with a pressure limit of 0.1 MPa:  
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Table 58. Method #27 GSH affinity chromatography 
 Break-
point 
Volume 
(mL) 
Concentration 
Buffer B (%) 
Flow rate 
(mL/min) 
Fraction 
size (mL) 
Inject valve 
position 
Pre-equilibration 1 0 0 1 0 Load 
Equilibration 2 10 0 1 0 Load 
Sample injection 1 3 12 0 1 5 Inject 
Wash Buffer A 4 17 0 1 2 Load 
Sample injection 2 5 19 0 1 5 Inject 
Wash Buffer A 6 24 0 1 2 Load 
Sample injection 3 7 26 0 1 5 Inject 
Wash Buffer A 8 31 0 1 2 Load 
Sample injection 4 9 33 0 1 5 Inject 
Wash Buffer A 10 38 0 1 2 Load 
Sample injection 5 11 40 0 1 5 Inject 
Wash Buffer A 12 45 0 1 2 Load 
Sample injection 6 13 47 0 1 5 Inject 
Wash Buffer A 14 52 0 1 2 Load 
Start Elution 15 132 0 1 2 Load 
Elution 16 134 100 1 2 Load 
Elution 17 174 100 1 2 Load 
Elution wash out 18 180 0 1 2 Load 
Re-equilibration 19 190 0 1 0 Load 
 
Protein samples were loaded by repeated injections (5-6 times) in a 5 mL sample injection loop 
while collecting flow-through in 2-5 mL volume fractions. Elution of proteins was performed 
using a reduced glutathione gradient with glutathione elution buffer (Table 53) and 2 mL 
elution fractions were collected and stored at 4 °C until further use. Fractions containing the 
respective GST-tagged BID construct were pooled and subjected to thrombin cleavage 
according to 2.10.4.6.  
In order to reduce the sample size to 5 mL, the protein sample was washed with gel 
filtration buffer (Table 54), concentrated using 3 kDa cut-off Amicon filters at 4000 rpm and 
4 °C and subsequently sterile-filtered through a 0.22 μm filter. Subsequent gel filtration was 
performed as described in 2.10.4.4.  
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For crystallization the pooled fractions containing pure BID constructs (CCSS) were 
concentrated to ~5-13 mg/mL using 3 kDa cut-off Amicon filters at 4000 rpm and 4 °C 
subsequently sterile-filtered through a 0.22 μm filter and kept at 4 °C until crystallization. 
2.10.4.6. Quantification of protein content  
The concentration of protein content during the purification process was determined by either 
Bradford assay or using the NanoPhotometerTM (Implen, Munich, Germany). 
Bradford assay was performed according to the manufacturer’s protocol (AppliChem, 
Darmstadt, Germany) to estimate tagged protein constructs prior to thrombin cleavage. Similar 
to 2.8.6 Coomassie Brilliant Blue G-250 is binding to proteins in an unspecific manner while 
showing a deep blue color. In particular, the absorbance maximum is shifted from 465 nm to 
595 nm and can be quantitatively determined using a spectrophotometer (Bio-Rad, Munich, 
Germany), which was blanked to zero using protein buffer. A standard curve was calculated by 
means of serial BSA stock (10 mg/ml) dilution with the respective protein buffer to 
concentrations of 0-10 μg/mL BSA. 100 μL of the respective sample (diluted at least 1:10 in 
protein buffer) were mixed with 1 mL of Bradford reagent and transferred to single-use cuvettes 
(trUViewTM, Bio-Rad, Munich, Germany) to measure absorbance at 595 nm wavelength. 
Amino acids containing aromatic rings, such as tyrosine, tryptophan and 
phenylalanine, have an absorption maximum at ~280 nm, so that protein content can be 
quantified measuring absorbance at 280 nm wavelength. As the absorption greatly depends on 
the relative content of these amino acids in a specific protein, extinction coefficients (molecular 
weight/molar extinction coefficient) for each protein construct had to be calculated from the 
amino acid sequence data according to [65].  
Table 59. Molar extinction coefficients and A280 factors 
Protein Molecular weight 
(g/mol) 
Molar extinction coefficient 
(mol/L·cm-1) 
A280 factor 
Full-length His6-Bid (CCSS) 24,115 (24,147) 8250 2.923 
Bid1 17,626 2560 6.885 
Bid3 (CCSS) 17,569 (17,601) 2560 6.863 
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For determination of protein content with the NanoPhotometerTM the system was blanked with 
pure protein buffer and 4 μL of the respective protein sample were quantified at 280 nm 
absorbance corrected with A280 factor. 
2.10.4.7. Thrombin-cleavage of His6- and GST-fusion proteins 
For the purpose of cleaving the His6- or GST-tag from the protein to avoid disturbing protein 
crystallization, the protease thrombin (Novagen/Merck, Darmstadt, Germany) was used. The 
protein expression vectors pET15b and pGEX include the thrombin recognition sequence 
LVPR/GS to enable site-specific cleavage to remove tags from the respective recombinant 
protein. 
His6-tags from full-length Bid constructs were removed after Nickel-affinity 
chromatography and GST-tag after GSH affinity chromatography, respectively. In order to 
calculate the appropriate amount of thrombin for cleavage, the protein amount was estimated 
using the Bradford assay (2.10.4.6). For cleavage, 1 unit thrombin was used for 1 mg of protein 
in the presence of 12 mM CaCl2 to enhance cutting efficiency. The thrombin solution was 
incubated at 37 °C for 16-18 hours and stopped by the addition of 1 mM PMSF 
phenylmethylsulfonyl fluoride. Cleavage was controlled for by SDS-PAGE and Coomassie 
staining.  
2.10.4.8. Mass spectrometry  
Mass spectrometry was exploited to analyze identity and purity of the purified proteins. 
Therefore, Jörg Kahnt (Max-Planck-Institute of Terrestrical Microbiology, Marburg, 
Germany) kindly performed MALDI-TOF analysis and checked for protein mass and potential 
contamination with cleavage byproducts or remaining purification chemicals. 
2.10.5 Protein crystallization 
For the structural analysis and deeper understanding of molecular BID function and interaction 
in cell death cascades, purified full-length BID and various constructs were crystallized and 
analyzed by means of X-ray crystallography to obtain electron density data for structure 
calculation.  
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All crystallization attempts were performed at the MarXtal crystallization lab (SYNMICRO, 
University of Marburg, Germany) using high-throughput crystallization robotics (Digilab 
Honeybee 963TM, Cartesian MicrosysTM SQ 4000; Formulatrix Rock ImagerTM documentation) 
with the kind support of Dr. Vasundara Srinivasan and Ralf Pöschke. 
2.10.5.1. Crystallization techniques 
The most common crystallization technique is vapor diffusion as sitting or in fewer cases 
hanging drops. Vapor diffusion utilizes a dynamic equilibration process to dehydrate a drop of 
protein, buffer and precipitant, thus driving it gently into a state of oversaturation. The protein 
drop is sealed air-tight in a chamber with a reservoir solution of higher precipitant 
concentration forcing water to evaporate towards the reservoir solution. As the drop and the 
reservoir solution equilibrate, precipitant and protein concentration constantly increase and 
allow for protein crystallization in case an appropriate concentration ratio is reached. However, 
identification of optimal crystallization conditions needs extensive testing. 
Vapor diffusion can be performed as hanging or sitting drops. Hanging drops are 
placed on an inverted cover slip suspended above the reservoir, whereas sitting drops are placed 
on a pedestal separate from the reservoir (Figure 32). 
For extensive screening, 96-well plates with micro-chambers and two-drop wells were used 
with volumes of 100-500 nL/drop. Protein-precipitant solutions were automatically pipetted 
using MarXtal robots, incubated and imaged at 4 °C in Formulatrix Rock ImagerTM and 
screened for crystal growth by eye using RockImager Web Interface. Imaging was performed 
using normal visible light and in addition with polarized light to distinguish between salt 
crystals (no color) and protein crystals (colors due to anisotropic double refraction). 
Figure 32. Vapor diffusion techniques 
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The following ready-to-use screens were available at MarXtal crystallization lab to screen a huge 
variety of crystallization conditions, such as precipitant concentration, pH, buffer composition, 
presence of salt anions and additives. Each screen provides 96 different buffers to ensure 
maximum diversity with limited effort. 
Table 60. MarXtal crystallization screens 
1 JCSG Core I Qiagen GmbH, Düsseldorf, Germany 
2 JCSG Core II Qiagen GmbH, Düsseldorf, Germany 
3 JCSG Core III Qiagen GmbH, Düsseldorf, Germany 
4 JCSG Core IV Qiagen GmbH, Düsseldorf, Germany 
5 JCSG+ Qiagen GmbH, Düsseldorf, Germany 
6 PACT Qiagen GmbH, Düsseldorf, Germany 
7 Classics Qiagen GmbH, Düsseldorf, Germany 
8 Classics Lite Qiagen GmbH, Düsseldorf, Germany 
9 Cryo Suite Qiagen GmbH, Düsseldorf, Germany 
10 AmSO4 Qiagen GmbH, Düsseldorf, Germany 
11 Anions Qiagen GmbH, Düsseldorf, Germany 
12 JB Penta JenaBioscience, Jena, Germany 
13 Morpheus  Molecular Dimensions, Suffolk UK 
14 Morpheus II Molecular Dimensions, Suffolk UK 
15 MBC I-II Qiagen GmbH, Düsseldorf, Germany 
16 MEMGold Molecular Dimensions, Suffolk UK 
17 MEMStart/Sys Molecular Dimensions, Suffolk UK 
a Additive Screen HT Hampton Research, Aliso Viejo, USA 
Opti  Morpheus A5/8 Opti Self-made 
OptiSeed Morpheus A5/8 Opti + 
Seeding crystals BID3 CCSS 
Self-made 
A5 Morpheus A5 Self-made 
A8 Morpheus A8 Self-made 
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Screens were automatically filled in 2.2 mL 96-deep-well plates (Greiner,  Frickenhausen, 
Germany) with Lissy-system (Zinsser Analytic GmbH, Frankfurt, Germany), and 80 μL 
transferred to the reservoirs of an MRC2 2-drop-chamber 96-well crystallization plates 
(JenaBioscience, Jena, Germany). Using the robot system 300 nL of protein and reservoir 
solution, respectively, were transferred in the wells as a sitting drop and sealed with ViewSealTM 
(Greiner Bio-one, Frickenhausen, Germany). 
Optimization of promising original crystallization screens, addition of additives, nanoparticles 
and seeding with small splitters of crystals (no nucleation energy required) were performed to 
increase crystal size/quality and resolution of diffraction data. 
Morpheus A5/8 Opti Screen was designed as shown in Figure 33 and manually 
prepared with stock solutions according to Table 61-Table 64 in order to vary salt and 
precipitant concentration. 1 mL of each reservoir solution was filled in a 96-deep-well plate. 
 
Table 61. Salt stock solution for Opti Screen 
0.25 M CaCl2 · 2 H2O 11.03 g 
0.25 M MgCl2 · 6 H2O 15.25 g 
Bidest. H2O ad 300 mL 
Precipitant 20 %                 42 %
Precipitant 30 % 46.5 %
Salt   0.04 M
0.1 M
Salt   0.04 M
0.1 M
Morpheus A5 original conditions
Precipitant 20%/10% (1/2):  40 % v/v PEG500*MME, 20 % w/v PEG 20,000
Buffer 0.1 M (1/10): 1 M Na‐HEPES titrated to pH 7.5 with 1 M MOPS
Salt 0.06 M (1/10): 0.3 M MgCl2 ∙ 6 H2O + 0.3 M CaCl2 ∙ 2 H2O
Morpheus A8 original conditions
Precipitant
12.5%/12.5%/12.5%  (1/2):  25 % v/v MPD, 25 % w/v PEG 1,000, 25 % w/v 3350
Buffer 0.1 M (1/10): 1 M Na‐HEPES titrated to pH 7.5 with 1 M MOPS
Salt 0.06 M (1/10): 0.3 M MgCl2 ∙ 6 H2O + 0.3 M CaCl2 ∙ 2 H2O
Figure 33. Morpheus A5/8 Opti Screen 
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Table 62. Buffer stock solution for pH 7.5 
1 M Na-HEPES 7.8 g in 30 mL 
1 M MOPS 31.39 g in 150 mL 
Titrate to pH 7.5 with 1 M MOPS  
Table 63. A5 Precipitant stock solution for Opti Screen 
40 % PEG500*MME 20 mL 
20 % PEG 20,000  10 g 
Bidest. H2O ad 50 mL (solve in 37 °C water bath)  
Table 64. A8 Precipitant stock solution for Opti Screen 
25 % MPD 12.5 mL 
25 % PEG 1,000  12.5 g 
25 % PEG 3,350 12.5 g 
Bidest. H2O ad 50 mL (solve in 37 °C water bath) 
 
Morpheus A5 and Morpheus A8 screens were mixed manually using original stock solutions 
(Molecular Dimensions, Suffolk, UK) as shown in and 0.5 mL transferred into a 96-deep-well 
plate. 
Additives were used in this thesis to optimize crystal growth of promising “hit-
conditions” Morpheus A5 and A8. A pre-defined commercially available screen (Additive 
Screen HTTM) from Hampton Research was used (Table 60) including multivalent cations, salts, 
amino acids, dissociating agents,  linker, polyamines, chaotropes, co-factors, reducing agents, 
chelators, polymers, carbohydrates, polyols, detergents, non-detergents, amphiphiles, 
osmolytes and organics. In case of an additive screen, 90 μL of reservoir solution were mixed 
with 10 μL additive solution in the reservoir wells of the respective crystallization plate and 
additionally used for protein drop preparation (0.3 μL protein + 0.3 μL reservoir solution 
containing 1:10 additives). 
An overview of all purified protein constructs and crystallization screens tested in this 
thesis is depicted in Table 65: 
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Table 65. Crystallization screens 
Screen # 1 2 3 4 5 6 7 8 9 10 
Protein 
construct 
Bid 3 Bid 1 Bid 3 
CCSS 
Bid 3 
CCSS  
Bid 3 
CCSS 
Bid 22 Bid 22 
CCSS 
Bid 3 
CCSS 
Bid 3 
CCSS 
SeMet 
Bid 3 
CCSS 
SeMet 
Drop 1  + 2 % 
NP 
10.7 +BI283
19 27 
mM 
+BI283
19 1 
mM 
 +BI283
19 0.07 
mM 
+BI283
19  
  
Drop2   5.3   +BI283
19 0.8 
mM 
  + 
BI6c9 
0.25 
mM 
+ 
BI6c9 
0.25 
mM 
Conc. 
(mg/mL) 
9.5 12.7 
+TCEP 
10.7 5.3 12.3 4.75 14 12.3 13.2 13.2 
Buffer 20 mM Tris. 50 mM NaCl, 0.03 % Na-Azid (Gel filtration buffer) 
Temp. 18 °C 18 °C 18 °C 18 °C 18 °C 18 °C 18 °C 4 °C 
18 °C 
18 °C 18 °C 
Screens 
(Table 60) 
1-3,13 5,9,13 1-
11,13,1
5 
10,13,1
6,17 
Opti, 
Opti 
w/o 
reservo
ir 
Opti 1-
13,15-
17 
A5a, 
A8a, 
OptiSe
ed 
13,Opti
, A5a, 
A8a 
A5a, 
A5aD3 
2.11 X-ray crystallography 
High energy x-ray beams are used to obtain diffraction patterns caused by crystalline atoms. By 
computational analysis of angles and intensities of diffracted beams a three-dimensional 
picture of electron densities within a protein crystal can be calculated and ideally converted in 
a 3D protein structure in case of sufficient resolution.  Protein crystals are regularly shaped bio-
macromolecules with a set of flat faces comprising constant angles and they are built from a 
unit cell of protein molecules symmetrically arranged in a three-dimensionally periodic 
manner. In total, 65 space groups are described for chiral molecules, such as for instance 
orthorhombic with the space group P222 (α = β = γ = 90°): 
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X-rays are produced when a high-energy electron beam accelerated through a voltage in 
vacuum hits a target. Mostly, a rotating copper anode is used in x-ray sources and produces 
synchrotron radiation when electrons are kept under the influence of magnetic fields and travel 
in a pseudocircular trajectory. Synchrotron radiation is then focused by reflectors before the 
beam is directed onto a mounted shock-frozen crystal, which is rotated around its center. X-
ray diffraction is registered using a detector. Crystals are isolated from the crystallization drop 
using a cryo-loop and stored in cryo-protectant containing mother liquor in liquid nitrogen 
until measured at a beam-line.  
Many macromolecular crystals suffer from radiation damage upon high energy x-ray 
exposure. For this reason, crystals are mostly cooled to low temperatures allowing for example 
collection of several data sets from one crystal as the lifetime is dramatically increased. After 
collecting a complete data set, data have to be processed: Therefore, raw data are visualized and 
diffraction patterns indexed. Crystal and detector parameters are refined and diffraction spots 
subsequently integrated. Afterwards, the relative scale factors have to be identified and crystal 
parameters have to be refined precisely using the whole data set and measurements related by 
space-group symmetry are merged and analyzed.  
Figure 34. Orthorhombic space group P222 
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X-ray data in this thesis were collected at a microfocus beamline in Grenoble (ESRF Grenoble, 
France) using cryo-crystallography to avoid radiation damage during data collection. 
Therefore, crystals were picked with a cryo-loop (Hampton Research, Aliso Viejo, USA), flash-
frozen and stored in mother liquor containing cryo-protectant until the day of measurement. 
Crystal preparation, data collection and processing was kindly performed by Dr. Vasundara 
Srinivasan (Core facility Structural Biology, MarXtal Crystallization Lab, LOEWE-Center, 
SYNMIKRO, Marburg, Germany). 
2.12 Statistical analysis 
2.12.1 Data presentation and tests of statistical significance 
All data are presented as mean + or ± standard deviation (SD). Statistical analysis of treatment 
groups was performed using analysis of variance (ANOVA) followed by Scheffé’s post-hoc test 
to correct for multiple comparison. Calculations were done using Winstat standard statistical 
software (R. Fitch Software, Germany). 
2.12.2 Concentration-response curves and EC50 values 
Half-maximal effect concentrations (EC50 values) were calculated from normalized (stretched 
to 0-100 %) dose-response curves of at least three independent MTT assays using GraphPad 
Prism Software 6.05 (GraphPad Software Inc., La Jolla, USA) as non-linear fit (log(inhibitor) 
vs. response, variable slope) following the equation:  
ܻ ൌ ܤ݋ݐݐ݋݉ ൅ ሺܶ݋݌ െ ܤ݋ݐݐ݋݉ሻ1 ൅ 10ሺ୪୭୥ ூ஼ହ଴ି௑ሻ∙ு௜௟௟ௌ௟௢௣௘ 
2.12.3 Quantification of RNA/Western blot bands 
To quantify and compare intensity of RNA or Western blot bands, Image Lab 4.0.1 Software 
(Bio-Rad, Munich, Germany) was used. Using rectangles, bands were selected and intensity 
(with background subtraction) calculated as percent of the intensity of the respective band of a 
housekeeping gene/protein. 
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3 Results 
3.1 Oxidative cell death in HT22 and MEF cells 
3.1.1 Glutamate-induced cell death in HT22 cells is circumvented by BI-6c9 
Spindle-shaped mouse hippocampal HT22cells respond to ~2-10 mM glutamate by 
competitive system Xc- blockage resulting in detrimental oxidative stress and injured 
mitochondria [185]. In the following, rapid cell death becomes visible through rounding up 
and detaching from the plate’s bottom.  
In HT22 cells treated with different concentrations of glutamate, this oxidative form of 
cell death occurred in a concentration-dependent manner starting at 2-3 mM glutamate 
assessed by loss of metabolic activity with the MTT assay (Figure 35a). Notably, also the amount 
of seeded cells per well determined sensitivity towards glutamate as conditions with less cells 
responded to even 1 mM glutamate (Figure 35b). 
 
Figure 35. Glutamate-induced cell death in HT22 cells 
a, b: MTT assay in HT22 cells reveals dose- and cell number-dependent glutamate sensitivity (a: 8K cells/well seeded, 
b:  4K/well; n=16/treatment condition, 16 hours treatment). Data are shown as mean + SD. *p<0.05, ***p<0.001 compared
to untreated control (ANOVA, Scheffé’s test). 
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The pro-apoptotic protein BID was shown to mediate fatal mitochondrial demise upon oxytosis 
induction in HT22 cells which is commonly referred to as the point of no return in cells 
undergoing regulated cell death [103]. The influence of diverse insults on mitochondrial 
function can be assessed as alterations in the oxygen consumption rate (OCR) using Seahorse 
XF96 extracellular flux measurements, where oxygen consumption indicates the rate of 
mitochondrial respiration. The subsequent application of ATP-synthase inhibitor oligomycin, 
respiratory chain uncoupling agent FCCP and complex I/III inhibitors antimycin A/rotenone, 
allows for assessing parameters of basal respiration, spare respiratory capacity, ATP production 
and maximum respiration.  
The analysis of OCR in HT22 cells treated with glutamate revealed a time-dependent 
loss of mitochondrial respiration and respiratory capacity starting approximately 8 hours after 
the glutamate challenge (Figure 36a). Consequently, the well-established BID inhibitor BI-6c9 
protected metabolic activity of HT22 cells until at least 8 hours post-treatment of glutamate 
exposure (Figure 36b) suggesting mitochondrial damage as the critical step in the cell’s 
commitment to die. In xCELLigence real-time impedance analyses, BI-6c9 prevented the loss 
of cell index until 6 hours after glutamate exposure (Figure 36c) owing to higher glutamate 
concentrations (10 mM) compared to the MTT assay (6 mM) which shifted detrimental 
mitochondrial demise to earlier time-points. 
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3.1.2 Comprehensive analysis of erastin-induced cell death in HT22 and MEF cells 
Erastin-induced ferroptosis has been generally described in non-neuronal cells [38]. In these 
cells, similar to glutamate, erastin inhibits Xc- [39] thereby provoking depletion of glutathione, 
impaired GPX4 function, and thus, strong lipid peroxidation. However, the detailed 
biochemical mechanism in neurons and cell death execution downstream of lipid peroxidation 
remain to be clarified.  
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Figure 36. Glutamate induces mitochondrial damage attenuated by BID inhibitor BI-6c9 
a: Seahorse OCR measurement (oligomycin: 3 μM, FCCP 0.5 μM, antimycin A 1 μM, rotenone 100 nM) demonstrates 
time-dependent loss of mitochondrial respiration upon glutamate challenge (6 mM) in HT22 cells (n=4-5/treatment 
condition). b: MTT assay of HT22 cells treated with glutamate (6 mM) ± BI-6c9 (10 μM, 0-8 hours post-treatment) 
(n=8/treatment condition) reveals protection until 8 hours after glutamate exposure. c: xCELLigence impedance 
measurement shows time-dependent protection of HT22 cells treated with glutamate (10 mM, 24 hours) ± BI-6c9 (10 μM, 
0-8 hours post-treatment) until 6-8 hours after treatment (n=5-8/treatment condition). Data are shown as mean + or ±
SD. ***p<0.001 compared to untreated control, ###p<0.001 compared to treated control (ANOVA, Scheffé’s test). 
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Due to apparent mechanistic similarity of cell death induction by glutamate and erastin 
through Xc- inhibition, erastin-induced cell death was evaluated according to commonly known 
features in oxytosis. As ferroptosis was investigated mostly in non-neuronal cells so far, here, 
erastin-induced cell death in neuronal HT22 cells was compared to MEF cells to control for cell 
type specific effects.  
In MTT assays erastin induced dose-dependent loss of metabolic activity in low 
micromolar concentrations (Figure 37a) which was prevented by BI-6c9 with an EC50 value of 
1.4 μM (Figure 37b). In post-treatment experiments BI-6c9 was able to rescue HT22 cells until 
4 hours after erastin challenge demonstrated in MTT (Figure 37c) and in xCELLigence 
impedance measurements (Figure 37d) indicating that erastin-induced direct Xc- inhibition is 
accelerated compared to glutamate. 
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Figure 37. Erastin-induced cell death is circumvented by BI-6c9 
a: Increasing erastin-concentrations indicate dose-dependent loss of metabolic activity in HT22 cells (MTT,
n=16/treatment condition, 16 hours treatment). b: EC50 calculation of MTT experiments reveals protection of BI-6c9 
against erastin-induced cell death (1.5 μM) in HT22 cells with an EC50 value of 1.4 μM (n=28/treatment condition,
16 hours treatment). c: MTT assay of HT22 cells treated with erastin (2 μM) ± BI-6c9 (10 μM, 0-8 hours post-treatment) 
(n=8/treatment condition) shows protection until 4 hours after erastin exposure. d: xCELLigence impedance 
measurement depicts time-dependent protection of HT22 cells treated with erastin (1 μM, 24 hours) ± BI-6c9 (10 μM, 0-
8 hours post-treatment) until 4 hours after treatment (n=5-8/treatment condition). Data are shown as mean + or ± SD.
**p<0.01, ***p<0.001 compared to untreated control, ###p<0.001 compared to treated control (ANOVA, Scheffé’s test). 
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To investigate the chronology of erastin-mediated events, time-course experiments of 
successive lipid peroxidation, mitochondrial ROS formation, loss of membrane potential and 
cell death were carried out in HT22 and MEF cells using FACS analyses. In both cell lines, 
significant lipid peroxidation started at 6 hours (Figure 38a, b) followed by mitochondrial ROS 
formation (Figure 38c, d) and cell death at 8 hours (Figure 38e, f) after onset of erastin exposure. 
In HT22 cells loss of mitochondrial membrane potential assessed by TMRE FACS analysis 
started already 4 hours after erastin treatment (Figure 38g) presumably owing to early lipid 
peroxidation at the mitochondrial membrane and disruption of membrane morphology. 
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Figure 38. Time-course analysis of erastin-induced cell death 
a, b: BODIPY FACS analyses show time-dependent increase in lipid peroxidation starting 6 hours after erastin treatment 
(1 μM) in HT22 (a) and MEF cells (b) (n=3/treatment condition). c, d: MitoSOX FACS analyses reveal time-dependent 
mitochondrial ROS formation after 8 hours of erastin treatment (1 μM) in HT22 (c) and MEF cells (d) (n=3/treatment 
condition). e, f: FACS analyses for Annexin V/PI stained cells demonstrate cell death after 8 hours of erastin challenge (1
μM) in HT22 (e) and MEF cells (f) (n=3/treatment condition). g: TMRE staining and subsequent FACS analysis indicates
loss of membrane potential after 4 hours of erastin treatment (1 μM) in HT22 cells (positive control: FCCP, 5 min 50 μM)
(n=3/treatment condition). Data are shown as mean + SD.***p<0.001 compared to untreated control (ANOVA, Scheffé’s 
test). 
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For the purpose of investigating the specific impact of erastin on mitochondrial morphology 
and function in HT22 and MEF cells, cellular ATP levels were assessed by luminescence 
measurements, OCR with Seahorse XF96 and mitochondrial morphology by staining with 
MitoTracker DeepRed and subsequent optical analysis using fluorescence microscopy. As 
previously described [72], cells were categorized into three subclasses according to their 
mitochondrial morphology. In brief, cells with elongated mitochondria, organized in a long 
tubular network represent category I. Cells with predominantly large dotted mitochondria 
equally distributed in the cytosol were assigned to category II, whereas cells with completely 
fragmented mitochondria accumulating around the nucleus were classified as category III. In 
order to re-validate this classification system, the results were compared using ImageJ software-
based automated quantification. Quantification of the average perimeter of mitochondria was 
performed using a custom macro for NIH ImageJ software in order to measure mitochondrial 
fragmentation as described previously by R. K. Dagda and C. Chu [33].  
Measurements of ATP revealed a significant loss of cellular ATP levels 6 hours after 
erastin treatment in HT22 cells which was well in line with the significantly reduced OCR and 
impaired maximal respiration after 6 hours of erastin challenge detected in the Seahorse 
experiments (Figure 39).  
The detrimental loss of mitochondrial function occurred at time-points of 
mitochondrial ROS formation and loss of mitochondrial membrane potential as an additional 
hallmark of mitochondrial damage and, interestingly, succeeded loss of morphological 
integrity, which was already apparent 2 hours after erastin exposure in epifluorescence 
microscopy (Figure 40) indicating morphological damage to be a prerequisite to mitochondrial 
dysfunction. 
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Figure 39. Erastin impairs mitochondrial function 
a: ATP luminescence assay reveals loss of cellular ATP levels 6 hours after erastin treatment (1 μM) (n=6/treatment 
condition). b: Time-course analysis of oxygen consumption rate (oligomycin 3 μM, FCCP 0.5 μM, antimycin A 1 μM,
rotenone 100 nM) of erastin-treated (1 μM) HT22 cells shows time-dependent decrease of oxygen consumption and
maximum respiration (n=3-5/treatment condition). Data are shown as mean + or ± SD. ***p<0.001 compared to 
untreated control (ANOVA, Scheffé’s test). 
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Figure 40. Erastin impairs mitochondrial morphology 
a: Representative epifluorescence pictures (63x objective) of Mitotracker-stained (200 nM) HT22 cells depict time-
dependent mitochondrial fragmentation and accumulation around the nucleus upon erastin treatment (1 μM). Scale bar
50 μm. b: Quantification of mitochondrial morphology categories of at least 500 cells/condition counted blind to 
treatment demonstrates early occurrence of fragmented mitochondria upon erastin treatment (1 μM) (n=3/treatment
condition). c: Automated calculation of average mitochondrial perimeter with ImageJ macro of Mitotracker-stained (200 
nM) HT22 cells confirms mitochondrial fragmentation starting 2 hours after erastin exposure (1 μM) (n=10
cells/treatment condition). Data are shown as mean + SD. ***p<0.001 compared to untreated control (ANOVA, Scheffé’s 
test). 
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3.1.3 AIF depletion abrogates glutamate- and erastin-induced cell death 
Based on the assumption that oxytosis and ferroptosis share common mechanistic hallmarks, 
such as AIF translocation, which is critical for cell death in oxytosis [133], was anticipated to 
be required in also ferroptosis. To test this hypothesis, AIF was depleted in HT22 cells by siRNA 
(siAIF) and cell viability evaluated by real-time impedance measurements. Here, siAIF was 
found to protect against glutamate- and erastin-induced cell death compared to control siRNA 
indicating a common cell death execution mechanism (Figure 41). 
3.1.4 H2O2-induced oxidative death 
To ensure that commonly used oxytosis and ferroptosis inhibitors BI-6c9 and ferrostatin-1, 
respectively, are not protective due to mere antioxidant capacity, the metabolic activity of HT22 
cells was assessed upon oxidative stress induction by H2O2. MTT assay revealed that neither BI-
6c9 nor ferrostatin could protect cells from H2O2-induced oxidative injury (Figure 42). 
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Figure 41. AIF depletion by siRNA prevents glutamate and erastin toxicity  
XCELLigence real-time impedance measurement demonstrates protection of cell viability by AIF siRNA (20 nM,
48 hours) against glutamate- (5.5 mM) or erastin-induced toxicity (0.5 μM) in HT22 cells compared to control siRNA
(n=5-8/treatment condition). Data are shown as mean ± SD. 
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3.2 BID links ferroptosis to mitochondrial cell death pathways 
In order to address the role of BID in oxidative stress induced cell death, BID was depleted by 
either siRNA approach or CRISPR/Cas9 knockout to assess alterations in mitochondrial 
parameters and cell death after glutamate- or erastin exposure. 
3.2.1 BID deletion by siRNA knockdown 
In order to specifically deplete the protein levels of BID, two different siRNAs targeting Bid 
mRNA were used. Protein analysis on Western blot confirmed significant knockdown of BID 
protein with siRNA#1 and #2 48 hours after transfection compared to control siRNA (Figure 
43a, b). On a functional level, Bid siRNA #2 but not #1 significantly reduced the glutamate-
induced loss of metabolic activity (Figure 43c) and slightly attenuated cell death assessed by 
Annexin V/PI FACS analysis (Figure 43d) indicating a critical role for BID in mediating 
mitochondrial damage and cell death in oxidative stress induced cell death. However, as siRNA 
#1 and #2 gave differing results and the siRNAs did not lead to a complete knockdown of BID 
protein, full knockout of the protein was desirable. 
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Figure 42. BI-6c9 and ferrostatin do not prevent H2O2-induced toxicity 
MTT assay of HT22 cells treated with H2O2 (1 mM, 16 hours) ± BI-6c9 (10 μM) or ± ferrostatin-1 (10 μM) shows no 
protection of the oxytosis and ferroptosis inhibitors against oxidative stress challenge. Data are shown as mean + SD. 
***p<0.001 compared to untreated control (ANOVA, Scheffé’s test). 
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Figure 43. BID siRNA knockdown partly protects against glutamate toxicity 
a, b: Western blot (a) and subsequent quantification (b, normalized to actin protein levels) of HT22 cells transfected with
two different siRNAs (40 nM, 48 hours) against Bid mRNA demonstrates strong reduction of BID protein levels compared
to control siRNA conditions. c: MTT assay in Bid siRNA transfected (40 nM, 48 hours) HT22 cell reveals protection
against glutamate (6 mM, 16 hours) by siRNA #2 compared to control siRNA (n=3/treatment condition). d: Annexin 
V/PI FACS analysis in Bid siRNA transfected (40 nM, 48 hours) HT22 cell depicts a trend towards protection for Bid
siRNA #2 against glutamate treatment (6 mM, 16 hours) (n=3/treatment condition). Data are shown as mean + SD.
***p<0.001 compared to untreated vehicle control, ##p<0.01, ###p<0.001 compared to treated vehicle control (ANOVA, 
Scheffé’s test). 
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3.2.2 CRISPR/Cas9 Bid knockout in HT22 cells  
3.2.2.1. Generation of HT22 Bid knockout cells 
With the aim of achieving a full knockout of BID protein, the emerging CRISPR/Cas9 
technique was utilized to create HT22 Bid knockout cells. CRISPR/Cas9 induces targeted DNA 
double-strand breaks leading to error-prone genetic repair and, by this, to insertion/deletion 
or frameshift mutations that ideally cause a functional protein knockout. In this study, a pre-
designed ready-to-use CRISPR Bid plasmid from Sigma Aldrich (Taufkirchen, Germany) was 
transfected in HT22 cells and the cells were screened for Bid knockout. The plasmid contained 
the genetic material for the Cas9 endonuclease enzyme, a tracrRNA guiding the enzyme to the 
target site, and a guideRNA (gRNA) specifically designed to recognize the mouse Bid gene 
(Figure 44a, b). In addition, Cas9 was coupled to GFP (green-fluorescent protein) to facilitate 
sorting of successfully transfected cells (Figure 44b).  
Figure 44. CRISPR/Cas9 plasmid design 
a: CRISPR/Cas9 targeting Bid at genomic DNA level (modified from [137]). b: Commercially available ready-to-use Bid 
CRISPR/Cas9 plasmid from Sigma Aldrich (Taufkirchen, Germany) with Bid guideRNA, tracrRNA and GFP-labelled 
Cas9 endonuclease. 
a b 
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In order to test whether the correct plasmid was obtained from the company, a restriction digest 
with XbaI enzyme was performed to check for the plasmid size, which was 8.3 kb as expected 
(Figure 45a). After 48 hours of transfection, HT22 cells were sorted by FACS to enrich GFP-
positive cells indicating successful transfection with the CRISPR plasmid. Fluorescence 
microscopy revealed a sufficient transfection efficiency of about 10-20 % (Figure 45b). 
Subsequently, cells were seeded in 96-well plates with either 1 cell, 2 cells or 5 cells per well and 
were constantly screened for colony growth. Each individual colony was subjected to Western 
blot and genetic sequence analysis to screen for Bid knockout. In addition to Western blot 
analysis, the resulting clonal colonies were sequenced to detect mutations in the CRISPR target 
region using site-specific primer sequences. A PCR protocol was established to amplify the 
genomic DNA around the CRISPR Bid target site resulting in a 1028 bp PCR product (Figure 
45c). 
 
a c 
b 
Figure 45. CRISPR/Cas9 establishment  
a: Agarose gel (1 % with EtBr) of XbaI digest (1.5 hours, 37 °C) for testing the correct CRISPR/Cas9 plasmid size reveals
a correct size of ~ 8 kb and nicked and supercoiled DNA in the undigested sample. b: Fluorescence light microscopy 
pictures (20x objective) depict ~10-20 % transfection efficiency of GFP-labelled CRISPR/Cas9 in HT22 cells (48 hours, 5 
μg plasmid DNA). Scale bar 50 μm. c: Agarose gel (1 % with EtBr) of PCR amplification of a 1028 bp region around the
CRISPR Bid target site. 
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Following the CRISPR/Cas9 knockout procedure, a total of 38 colonies were obtained. Western 
blot analysis of the obtained colonies #3-#38 and subsequent quantification (Figure 46) revealed 
most efficient knockout of Bid in colonies #4, #14, #15 and #25 suggesting a full knockout on 
both alleles in a homogenous population of HT22 cells. 
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Figure 46. CRISPR Western blot analysis 
a, b: Western blot analysis (a) and quantification (b) of HT22 CRISPR Bid colonies depicts efficient knockdown of BID
protein in colonies #4, #14, #15 and #25 (normalized to actin as housekeeping protein) (a: 80 μg protein, 12.5 % SDS gel, 
b: pooled data from 4 individual Western blots). 
a 
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In order to detect mutations on the genetic level, the genomic DNA of colonies #4, #14, #15 
and #25 was isolated, the CRISPR Bid region amplified by PCR and visualized on an EtBr 
agarose gel (Figure 47). The amplified PCR products were purified and sequenced. Sequencing 
results demonstrated no mutation in colony #14 and partial mutations and/or deletion in 
colonies #4, #15 and #25 indicated as multiple peaks in the sequencing plots (Figure 48). Since 
colony #4 was the most promising knockout colony with a deletion mutation, this colony was 
chosen for functional experiments and in the following is referred to as HT22 Bid KO. 
Colony
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CRISPR target region
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no mutation detected
#25
#15
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partial mutation
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Figure 48. CRISPR sequencing results 
Sequencing of genomic CRISPR Bid DNA sites in HT22 cells reveals partial mutations and/or deletion in colonies #4, #15
and #25 and no mutation in colony #14 compared to the WT mouse genomic DNA sequence. 
Figure 47. CRISPR target site amplification by PCR 
Agarose gel (1 % with EtBr) of CRISPR Bid target site amplification by PCR (200 ng DNA template) visualizes 1028 bp 
PCR product. 
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The CRISPR/Cas9 technique is prone to off-targeting as guideRNAs (gRNAs) are limited to 19-
24 nucleotides length. In consequence, gRNAs may target resembling DNA sequences in the 
genome by mistake depending on the order and number of similar nucleotides. In order to 
reduce off-target probability, gRNAs should be carefully designed by specific web-based design 
tools using various algorithms to avoid similarity to unspecific genomic DNA sites [179,225]. 
In this study, these tools were exploited to calculate the most probable off-target sites 
to sequence the genomic DNA at these specific spots in order to rule out off-target-based 
functional effects. According to the web-based tools Trpc4, Grm3, Syngr1, Hivep3, Hprt and 
Kcne1 could be identified as potential off-targets sites. Hence, in HT22 Bid KO cells these DNA 
sites were amplified by PCR and the sequences were analyzed. As depicted in Figure 49, no off-
target mutation was found in Trpc4, Grm3, Syngr1, Hivep3 and Hprt compared to mouse 
genomic WT DNA, however, Kcne1 contained one mutation, which was also found in HT22 
WT DNA, for which reason this mutation was not attributed to the CRISPR/Cas9 knockout 
procedure. 
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Figure 49 CRISPR off-target sequencing 
Sequencing of potential CRISPR off-target sites depicts no mutation in Trpc4, Grm3, Syngr1, Hivep3 or Hprt compared 
to the respective mouse genomic WT DNA sequence. Kcne1 contained one mutation which was also found in HT22 WT
DNA. 
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In addition to sequencing of potential off-targets in HT22 Bid KO cells, Western blot was used 
to rule out alterations in 12-LOX and xCT protein levels, which would interfere with the cell 
death process upon glutamate or erastin treatment. The analysis revealed that the according 
protein levels were comparable to HT22 WT protein levels (Figure 50). 
3.2.2.2. Functional analysis of HT22 Bid knockout cells 
As a first hint on the influence of CRISPR/Cas9 Bid knockout on glutamate-induced oxidative 
cell death, pooled CRISPR plasmid transfected HT22 cells (referred to as HT22 CRISPR Bid 
stock) were subjected to gentle glutamate treatment and subsequent MTT assay to check for 
cell viability. Here, the HT22 CRISPR Bid stock cells showed protected metabolic activity 
compared to HT22 WT cells (Figure 51) implying a crucial role for BID in the execution of cell 
death. 
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Figure 50. Western blot off-target analysis 
Western blot analysis of 12-LOX and xCT protein in HT22 Bid KO cells depicts no downregulation compared to HT22
WT protein lysates (12-LOX: 40 μg protein, xCT, Bid: 80 μg protein, 12.5 % SDS gel). 
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Having identified CRISPR colony #4 as a favorable Bid knockout cell line, these cells were 
analyzed for their ability to undergo cell death upon erastin challenge in order to elucidate the 
role of BID in ferroptotic cell death. The obtained results were compared to HT22 WT cells and 
to glutamate-induced oxytosis, where BID could be already identified as a key protein in 
mediating mitochondrial damage and cell death. 
 
Therefore, HT22 WT and Bid KO cells were exposed to glutamate or erastin, respectively, and 
cell death was assessed using MTT assay for metabolic activity, Annexin V/PI FACS analysis to 
estimate cell death induction and xCELLigence measurements for real-time monitoring of cell 
viability. Remarkably, Bid KO led to a full and permanent protection of HT22 cells against 
glutamate or erastin insults comparable to BI-6c9 mediated rescue (Figure 52). 
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Figure 51. MTT assay in CRISPR Bid stock cells 
MTT assay of HT22 CRISPR Bid stock cells upon gentle glutamate treatment (4.5 mM, 17 hours) demonstrates protection
compared to HT22 WT cells (n=3/treatment condition). Data are shown as mean + SD. *p<0.05 compared to untreated
HT22 WT control, #p<0.05 compared to treated HT22 WT control (ANOVA, Scheffé’s test). 
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BID is known to mediate mitochondrial dysfunction downstream of GSH depletion in the 
model system of oxytosis. Thus, investigations on cellular GSH levels in HT22 Bid KO cells 
upon glutamate or erastin exposure still showed GSH depletion in a time-dependent manner 
(Figure 53a, b). Fluorescent BODIPY or DCF staining and subsequent FACS analyses were used 
to evaluate the formation of lipid peroxides and soluble ROS after GSH depletion and 
successive activation of 12/15-LOX. Increasing levels of lipid peroxides (Figure 53c, d) and ROS 
(Figure 53e, f) were measured in HT22 WT cells, whereas BID deletion significantly prevented 
lipid peroxide and ROS formation upon glutamate or erastin treatment indicating a critical role 
of BID in lipid and soluble ROS formation. 
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Figure 52. Bid KO protects against glutamate- and erastin-induced cell death 
a, b: MTT assay (a) and Annexin/PI FACS measurement (b) demonstrate Bid KO to completely prevent cell death induced
by glutamate (a: 7 mM, 16 hours; b: 8 mM, 17 hours) or erastin (1 μM, a: 16 hours, b: 17 hours). Protection was 
comparable to BI-6c9 (10 μM) mediated rescue (a: n=8/treatment condition, b: n=4/treatment condition). c: xCELLigence 
real-time impedance measurement confirms full protection against glutamate (7 mM) or erastin (1 μM) challenge by Bid
KO and underlines permanence of cell death prevention (n=5-14/treatment condition). Data are shown as mean + or ± 
SD. ***p<0.001 compared to untreated HT22 WT control, ###p<0.001 compared to treated HT22 WT control (ANOVA, 
Scheffé’s test). 
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Figure 53. Bid KO does not inhibit GSH depletion but prevents ROS formation 
a, b: Measurement of cellular glutathione levels depicts rapid decrease of GSH after glutamate (8 mM, a) or erastin (1 μM, 
b) exposure which was not restored by Bid KO (n=4-8/treatment condition). c, d: Cells were stained with BODIPY 
581/591 and changes of fluorescence were detected by FACS analysis after 10 hours of glutamate (7.5 mM) or erastin 
(1 μM) treatment. Quantification (c) and FACS plots (d) show that Bid KO fully prevents the formation of lipid peroxides 
compared to WT control cells (n=4/treatment condition). e, f: DCF FACS analysis depicts massive accumulation of
soluble ROS upon glutamate (7 mM, 17 hours) and erastin (1 μM, 17 hours) challenge in HT22 WT cells, whereas HT22
Bid KO cells show constant ROS levels comparable to those in control cells according to quantification (e) and 
representative FACS plots (f) (n=4/treatment condition). Data are shown as mean + SD. **p<0.01, ***p<0.001 compared
to untreated HT22 WT control, #p<0.05, ###p<0.001 compared to respective treated HT22 WT control (ANOVA, Scheffé’s 
test). 
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Mitochondrial ROS formation and loss of mitochondrial membrane potential succeeding lipid 
peroxidation were analyzed by FACS of MitoSOX and TMRE red fluorescence in HT22 Bid KO 
cells upon glutamate and erastin exposure. Notably, Bid KO completely abrogated 
mitochondrial ROS formation (Figure 54a, b) as well as loss of mitochondrial membrane 
potential (Figure 54c, d) compared to massive ROS and disruption of the mitochondrial 
membrane potential in WT cells suggesting a key role for BID in mediating mitochondrial 
damage in both paradigms of oxytosis and ferroptosis. 
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Figure 54. Bid KO prevents mitochondrial damage 
a, b: MitoSOX staining and subsequent FACS analysis depicts reduced formation of mitochondrial ROS in HT22 Bid KO 
cells compared to HT22 WT cells after erastin (1 μM, 16 hours) or glutamate (7 mM, 16 hours) challenge according to
quantification (a) and representative FACS plots (b) (n=4/treatment condition). c, d: TMRE FACS measurements for 
assessment of the loss of mitochondrial membrane potential upon erastin (1.2 μM, 16 hours) or glutamate (8 mM,
16 hours) exposure demonstrates rescue by Bid KO compared to HT22 WT cells in the quantification (c) and 
representative FACS plots (d) (n=4/treatment condition). Data are shown as mean + SD. ***p<0.001 compared to
untreated HT22 WT control, ###p<0.001 compared to respective treated HT22 WT control (ANOVA, Scheffé’s test). 
  3 Results 
 
111 
 
Furthermore, erastin as well as glutamate treatment led to a significant loss of cellular ATP 
levels which was circumvented by Bid KO (Figure 55a) suggesting that mitochondria of HT22 
Bid KO cells were also protected at a functional level. In order to further investigate 
mitochondrial respiration, both HT22 WT and Bid KO cells were treated with glutamate 
(Figure 55b) or erastin (Figure 55c), respectively, and analyzed for OCR in Seahorse XF96 flux 
analyzer. Interestingly, oxygen consumption of HT22 Bid KO cells was completely preserved 
compared to pronounced reduction in treated HT22 WT cells. Morphological analysis by 
evaluation of MitoTracker DeepRed stained cells resulted in substantial loss of healthy 
mitochondria (category I) in HT22 WT cells after 16 hours of glutamate or erastin exposure, 
respectively, whereas HT22 Bid KO cells displayed unchanged mitochondrial morphology with 
almost no cells of category II or III mitochondria (Figure 55e, f). 
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Figure 55. Bid KO preserves mitochondrial morphology 
a: After 17 hours of treatment with glutamate (7 mM) or erastin (1 μM) ATP levels are measured. Bid KO prevents ATP 
depletion compared to HT22 WT controls (n=8/treatment condition). b, c: Measurement of the oxygen consumption
rate (OCR) reveals restored basal and maximal respiration in Bid KO cells compared to WT controls after 15 hours
glutamate (2 mM; b) or erastin (0.25 μM; c) exposure (n=6/treatment condition).e, f: Representative microscopy pictures
(e) and mitochondrial classification (f) of Mitotracker (200 nM) stained HT22 WT and Bid KO cells which were treated 
with glutamate (5 mM, 17 hours) or erastin (0.5 μM, 17  hours), respectively. Mitochondrial morphology is massively
disturbed with erastin and glutamate in HT22 WT cells, whereas Bid KO cells do not show alterations in the morphology
(n=3/treatment condition). Scale bar 50 μm. Data are shown as mean + SD. ***p<0.001 compared to untreated HT22 WT 
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3.2.2.3. TBID overexpression abrogates protection by Bid KO  
Since Bid knockout was shown to protect against cell death and to preserve mitochondrial 
morphology and function, overexpression of full-length BID or tBID should circumvent the 
experimental protective effects thereby confirming that the observed outcome specifically 
resulted from Bid knockout. In order to restore BID expression, pcDNA3 Bid p22 was 
transfected in HT22 Bid KO cells which, subsequently, were exposed to glutamate. Cell death 
was assessed by metabolic activity in MTT assay and compared to the effects of pcDNA3 control 
vector and HT22 WT cells. HT22 Bid KO cells were protected upon transfection with the 
control vector but regained sensitivity to glutamate when full-length BID was expressed (Figure 
56a). Similarly, upon expression of active tBID, HT22 Bid KO cells showed reduced cell viability 
comparable to tBID-expressing HT22 WT cells analyzed by xCELLigence real-time 
measurements (Figure 56b). Furthermore, tBID expression was able to restore lipid 
peroxidation in HT22 Bid KO cells (Figure 56c).  
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Figure 56. TBID and BID expression reverse protection mediated by Bid knockout 
a: MTT assay demonstrates rescue of BID-mediated cell death with glutamate (7 mM, 16 hours) upon transfection of full-
length BID (pcDNA3 Bid p22, 48 hours transfection, 200 ng DNA/well) in HT22 Bid KO cells compared to HT22 WT 
cells and control vector (pcDNA3) (n=4/treatment condition). b: Real-time analysis of HT22 Bid KO cells expressing 
active tBID (pcDNA3 p15, 0.75 μg DNA/well) reveals cell death induction comparable to HT22 WT cells (n=3-
8/treatment condition). c: BODIPY FACS analysis in HT22 Bid KO cells reveals restoration of lipid peroxidation upon
tBID expression (2 μg DNA/well, 10 hours) compared to control vector (pcDNA3) (n=3/treatment condition). Data are 
shown as mean + or ± SD. ***p<0.001 compared to respective untreated HT22 WT control, ###p<0.001 compared to 
treated HT22 WT control, +++p<0.001 compared to treated HT22 Bid KO control (ANOVA, Scheffé’s test). 
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3.2.2.4. Staurosporine-induced cell death in HT22 Bid KO cells 
Staurosporine is a natural alkaloid isolated from Streptomyces staurosporeus and is used to 
induce cell death by ATP-competitive binding to protein kinases. The mechanism of cell death 
induction by staurosporine is still under debate and differs between various cell lines, however, 
caspase-3 activation is a generally accepted hallmark [20] and BID independence is discussed. 
In order to control that HT22 Bid KO cells still respond to cell death induction apart from 
oxidative stress by glutamate or erastin, these cells were subjected to staurosporine treatment. 
Cell death assessed by MTT assay (Figure 57a) and Annexin V/PI FACS analysis (Figure 57b) 
was comparable to cell death in HT22 WT cells suggesting a BID-independent pathway of 
staurosporine induced cell death and underlining that HT22 Bid KO cells are still sensitive to 
other forms of cell death. 
3.2.3 Liproxstatin-1 protects against oxytosis and ferroptosis 
In order to check for protective effects of ferroptosis inhibition in the paradigm of oxytosis, the 
recently described ferroptosis inhibitor liproxstatin-1 [53,227] was applied in the present model 
systems of erastin-induced ferroptosis and glutamate-induced oxytosis in HT22 WT cells. In 
both paradigms of oxidative death, liproxstatin prevented cell death in a concentration-
dependent manner shown by calculated EC50 values of 0.02 μM for glutamate and 0.03 μM for 
erastin challenge, respectively (Figure 58a, b).  
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Figure 57. Bid KO does not prevent staurosporine-induced cell death 
a, b: MTT assay (a) and Annexin V/PI staining and subsequent FACS analysis (b) reveals staurosporine sensitivity to be
comparable in HT22 WT and Bid KO cells (a: 17 hours treatment, n=8/treatment condition, b: 7 hours treatment, 
n=3/treatment condition). Data are shown as mean + SD. ***p<0.001 compared to untreated HT22 WT control (ANOVA, 
Scheffé’s test). 
  3 Results 
 
115 
 
In post-treatment MTT measurements, liproxstatin was able to attenuate loss of metabolic 
activity up to 4 hours after glutamate or erastin treatment (Figure 58c, d). Similar results were 
obtained by real-time xCELLigence measurements where liproxstatin preserved cell viability 
up to 6 hours after glutamate and erastin exposure (Figure 58e, f). 
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Figure 58. Liproxstatin attenuates glutamate- and erastin-induced toxicity 
a, b: Concentration-response curves of liproxstatin upon glutamate (5 mM, 16-17 hours, a) and erastin (1 μM, b) 
treatment. Cell viability data were fitted from 0 for glutamate-treated control to 100 for highest protection at 1 μM Lip-1 
(n=3/treatment condition). c, d: MTT assay reveals protection of liproxstatin (Lip, 150 nM) against glutamate (6 mM, 24 
hours, c) or erastin (1 μM, d) toxicity until 4 hours post-treatment (n=8/treatment condition). e, f: Real-time impedance 
measurements confirm protection of liproxstatin (150 nM) against glutamate (6 mM, e) or erastin (1 μM, f) toxicity until 
6 to 8 hours post-treatment (n=4-8/treatment condition). Data are shown as mean + or ± SD. ***p<0.001 compared to 
untreated control, ###p<0.001 compared to treated control (ANOVA, Scheffé’s test). 
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In addition, liproxstatin rescued associated hallmarks of glutamate- and erastin-induced 
mitochondrial damage such as lipid peroxidation (Figure 59c, d), mitochondrial ROS 
formation (Figure 59e, f), loss of mitochondrial membrane potential (Figure 59g, h) and 
mitochondrial morphology (Figure 60a-c) in a concentration-dependent and GSH depletion-
independent (Figure 59a, b) manner. In conclusion, these results strongly underline the 
assumption of shared pathways of oxytosis and ferroptosis including BID-mediated 
mitochondrial damage.  
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Figure 59. Liproxstatin preserves mitochondrial parameters 
a, b: GSH analysis depicts rapid decrease after glutamate (6 mM, a) or erastin (1 μM, b) which could not be restored upon 
liproxstatin (150 nM) co-treatment (n=5-6/treatment condition). c, d: Glutamate (8 mM, 8 hours, c) or erastin (1 μM, d) 
treatment increase lipid peroxide production which is blocked by liproxstatin in a concentration-dependent manner 
(n=3/treatment condition). e, f: Glutamate (7 mM, 16 hours, e) or erastin (1 μM, f) treatment increases mitochondrial 
ROS production, which is blocked by co-treatment with liproxstatin in a concentration dependent-manner 
(n=3/treatment condition). g, h: TMRE FACS analysis shows concentration-dependent MMP restoration by liproxstatin
after glutamate (8 mM, 16 hours, g) or erastin (1 μM, h) exposure (n=3/treatment condition). Data are shown as mean + 
SD. *p<0.05, **p<0.01, ***p<0.001 compared to untreated control, #p<0.05, ##p<0.01, ###p<0.001 compared to treated 
control (ANOVA, Scheffé’s test). 
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3.3 Characterization of RSL3-induced oxidative death in HT22 and MEF 
cells 
3.3.1 Cell death induction by various isomeric RSL3 forms 
Ferroptosis as an oxidative form of regulated necrotic cell death features GSH depletion, 
disrupted GPX4 redox defense and detrimental lipid ROS formation [38,41,90]. The actual 
findings so far identified mitochondrial damage in both models of oxidative glutamate toxicity 
and ferroptosis. Despite knowledge on the signaling pathways of ferroptosis is currently 
increasing, the particular role of mitochondrial damage requires more in-depth investigation 
in order to achieve effective treatment options targeting mitochondria. Therefore, in this study, 
the direct GPX4 inhibitor RSL3 (Figure 61) and its isomers were applied to induce ferroptosis 
in neuronal HT22 cells and MEFs.  
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Figure 60. Liproxstatin protects mitochondrial morphology 
a: Representative images (63x objective) show mitochondrial morphology with glutamate (4 mM, 16 hours, j) or erastin 
(0.5 μM, k) ± liproxstatin (150 nM). b, c: Classification of 500 cells (n=3) reveals liproxstatin-dependent reduction of 
glutamate- or erastin-induced mitochondrial fission. Scale bar 50 μm. Data are shown as mean + SD. *p<0.05, **p<0.01, 
***p<0.001 compared to untreated control, #p<0.05, ##p<0.01, ###p<0.001 compared to treated control (ANOVA, Scheffé’s 
test). 
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For investigating cell toxicity of the different RSL3 isomers all four compounds were 
synthesized according to Yang et al. [211] (Figure 13) and their potency to induce cell death 
was evaluated by MTT assay and EC50 calculation. Yang and co-workers demonstrated that in 
BJ cells (human foreskin fibroblasts) expressing HRAS the 1S, 3R-RSL3 isomer was significantly 
more active than the other isomers lacking selectivity for GPX4 [211].  
In line with these previously published results, the EC50 values of 0.004 μM for 1S, 3R-
RSL3 and ~ 5-7 μM for the other three isomers were calculated indicating that the 1S, 3R-RSL3 
was at least 1000-fold more potent in HT22 WT cells than the structural isomers (Figure 62a-
d). Apart from HT22 cells, 1S, 3R-RSL3 was slightly less active in MEF cells and in primary 
mouse and rat cortical neurons with EC50 values of 0.2 μM, 1.5 μM and 7.2 μM, respectively 
(Figure 62i-k). Since BID was already identified as a key mediator of oxidative mitochondrial 
damage and subsequent cell death, the RSL3 isomers were tested in HT22 Bid KO cells. In these 
cells, 1S, 3R-RSL3 was less potent to induce cell death and unspecific toxicity of the remaining 
isomers was observed within a similar concentration range as in HT22 WT cells (Figure 62e-
h). 
  
Figure 61. 1S, 3R-RSL3 
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Figure 62. Dose-response curves of RSL3 isomers 
a-d: Concentration-response curves in HT22 WT cells derived from MTT experiments depict strong cell death induction 
of 1S, 3R-RSL3 and less toxic effects of the isomeric forms of RSL3 (16 hours treatment, n=3-5). e-g: Dose-response curves 
in HT22 Bid KO cells show reduced toxicity of 1S, 3R-RSL3 and unspecific toxicity of the isomers in a similar range as in 
HT22 WT cells (16 hours treatment, n=3-5). i, j, k: Concentration-response curves of 1S, 3R-RSL3 in primary mouse (i) 
and rat (j) cortical neurons and in MEF cells (k) (16 hours treatment, n=3-4). Data are shown as mean ± SD. and are fitted 
to 0-100 %. 
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As 1S, 3R-RSL3 was described to directly inactivate GPX4 through covalent binding at its 
electrophilic chloroacetamide position [212], the effects of the corresponding des-chloro-
derivative 1S, 3R-RSL3-Cl were investigated. In line with the suggested mechanism comprising 
chlorine as an indispensable chemical feature of RSL3, the inactive 1S, 3R-RSL3-Cl isoform did 
not affect cell viability assessed by FACS Annexin/PI and xCELLigence measurement in HT22 
WT or MEF cells even when applied at high micromolar concentrations (Figure 63). 
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Figure 63. RSL3 -Cl does not induce cell death 
a, b: Annexin/PI staining and subsequent FACS analysis reveals no cell death induction by 1S, 3R-RSL3 –Cl (18 hours
treatment) in HT22 (a) and MEF cells (b) (n=3/treatment condition) compared to 1S, 3R-RSL3 (1 μM). c, d: xCELLigence
measurements confirm that 1S, 3R-RSL3 –Cl is non-toxic in HT22 (c) and MEF cells (d) (n=5-8/treatment condition).
Data are shown as mean + or ± SD. ***p<0.001 compared to untreated control, ###p<0.001 compared to 1S, 3R-RSL3
treated control (ANOVA, Scheffé’s test). 
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3.3.2 RSL3 induces disruption of the cell’s redox defense 
To evaluate the effects of 1S, 3R-RSL3 on GPX4 and the cell’s redox defense, intracellular GSH 
levels were evaluated in HT22 cells after treatment with 1S, 3R-RSL3 and in co-treatment 
together with ferrostatin (Figure 64a, b). Neither 1S, 3R-RSL3 nor 1S, 3R-RSL3 combined with 
ferrostatin affected GSH levels 2 to 8 hours after the respective treatment. Interestingly, a 
significant reduction of GPX4 protein levels was observed after 10 hours of 1S, 3R-RSL3 
exposure in HT22 and MEF cells but not with the inactive des-chloro-derivative (Figure 64c, 
d). In line with previous findings [90], these results indicate that RSL3 caused rapid proteolysis 
of inactive GPX4. 
1S, 3R-RSL3 provokes sustained lipid peroxidation [212] as a result of GPX4 inhibition, 
autoxidation and subsequently increased 12/15-LOX activity [162,186,195]. Using BODIPY 
staining combined with time-course FACS analysis in 1S, 3R-RSL3-induced ferroptosis in 
HT22 WT and MEF cells, increased lipid peroxidation was detected early after RSL3 exposure 
in HT22 and in MEF cells (Figure 64e, f) and was prevented by application of the BID inhibitor 
BI-6c9 and the commonly used ferroptosis inhibitors liproxstatin, deferoxamine and 
ferrostatin (Figure 64g, h).  
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Figure 64. RSL3 impairs the cells’ redox homeostasis 
a, b: GSH measurements in HT22 cells reveal no alterations after 2-8 hours of RSL3 treatment (a, 1 μM) ± ferrostatin (b, 
10 μM) (n=3/treatment condition, normalized to protein content of the respective sample). c: Representative Western 
blot shows pronounced loss of GPX4 protein levels after 10 hours of 1S, 3R-RSL3 treatment (0.5 and 5.0 μM) in HT22
WT and MEF cells and sustained GPX4 levels after treatment with 5 μM 1S, 3R-RSL3 -Cl. d: Quantification of Western 
blot as optical density compared to tubulin as loading control confirms a strong decrease of GPX4 protein upon 1S, 3R-
RSL3 treatment and no significant alteration with 1S, 3R-RSL3 –Cl (n=3-4/treatment condition). e, f: BODIPY FACS 
analysis for measurement of lipid peroxide formation shows time-dependent increase in the fluorescence after 1S, 3R-
RSL3 (e: 100 nM, f: 1000 nM, 2-8 hours) exposure in HT22 WT (e) and MEF cells f) (n=4/treatment condition). g, h: 
BODIPY analysis reveals protection of BI-6c9 (10 μM) and ferroptosis inhibitors deferoxamine (10 μM), liproxstatin (200
nM) and ferrostatin (10 μM) upon 1S, 3R-RSL3 (g: 50 nM, h: 1000 nM, 8 h) treatment in HT22 WT (g) and MEF cells (h)
(n=4/treatment condition). All data are shown as mean + SD. ***p<0.001 compared to untreated control, ###p<0.001 
compared to treated control (ANOVA, Scheffé’s test). 
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3.3.3 BID inhibitor BI-6c9 and ferroptosis inhibitors abrogate 1S, 3R-RSL3 induced 
cell death in HT22 and MEF cells 
In order to further investigate 1S, 3R-RSL3 (in the following referred to as RSL3) induced cell 
death (Figure 65a, d), loss of cell viability was assessed by means of MTT, depicting cell death 
6 hours after RSL3 challenge in HT22 and MEF cells (Figure 65b, e). Real-time impedance 
measurements using the xCELLigence system demonstrated concentration-dependent 
induction of ferroptosis in both cell types (Figure 65c, f).  
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Figure 65. RSL3 toxicity is time- and concentration-dependent 
a, d: Representative microscopic pictures of RSL3-treated HT22 (a, 24 hours treatment, 500 nM) and MEF cells (d, 1000 
nM) ± BI-6c9, deferoxamine, ferrostatin (10 μM) or liproxstatin (200 nM). Scale bar 100 μm. b, e: MTT assays reveal 
time-dependent loss of metabolic activity of HT22 (b) and MEF cells (e) upon 1S, 3R-RSL3 treatment (b: 100 nM, e: 200 
nM, n=6-8/treatment condition). c, f: Real-time impedance measurements shows concentration-dependent toxicity of 
1S, 3R-RSL3 in HT22 (c) and MEF cells (f) (n=6-8/treatment condition). Data are shown as mean + or ± SD. ***p<0.001 
compared to untreated control (ANOVA, Scheffé’s test). 
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To evaluate the significance of BID activation in oxidative stress induced cell death in more 
detail, the well-established BID inhibitor BI-6c9 [13] was applied upon RSL3 treatment and its 
effect was compared to the commonly used ferroptosis inhibitors deferoxamine, liproxstatin 
and ferrostatin. XCELLigence experiments revealed that BI-6c9 preserved cell viability in HT22 
and in MEF cells (Figure 66c, f) comparable to the ferroptosis inhibitors in conditions of RSL3 
challenge. Most strikingly, BI-6c9 as well as liproxstatin, deferoxamine and ferrostatin rescued 
HT22 and MEF cells (Figure 66a, b, d, e) even when applied 4 to 6 hours after RSL3 treatment 
suggesting that the irreversible steps of cell death occurred downstream of early lipid ROS 
formation. 
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Figure 66. RSL3 toxicity is attenuated by BI-6c9 and ferroptosis inhibitors 
a, b, d, e: MTT assays reveal protection of BID inhibitor BI-6c9 (10 μM, a, d) and ferroptosis inhibitors deferoxamine (10
μM, b, e), liproxstatin (200 nM, a, d) and ferrostatin (10 μM, b, e) upon 1S, 3R-RSL3 (a, b: 100 nM, d, e: 200 nM, 24 h) 
challenge until 4 to 6 hours post-treatment in HT22 (a, b) and MEF cells (d, e) (n=6-8/treatment condition). c, f: Real-
time impedance measurements show protective effects of BID inhibitor BI-6c9 (10 μM) and ferroptosis inhibitors
deferoxamine (10 μM), liproxstatin (200 nM) and ferrostatin (10 μM) against 1S, 3R-RSL3 treatment (c: 50 nM, f: 1000 
nM) in HT22 (c) and MEF cells (f) (n=5-8/treatment condition). Data are shown as mean + or ± SD. ***p<0.001 compared
to untreated control, ###p<0.001 compared to treated control (ANOVA, Scheffé’s test).  
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3.3.4 RSL3 impairs mitochondrial morphology and function 
To shed more light on the specific order of events in the induction of RSL3-induced toxicity, 
FACS measurements were utilized to study mitochondrial ROS formation and loss of 
mitochondrial membrane potential in HT22 and MEF cells (Figure 67a-h). Using MitoSOX 
staining and FACS, mitochondrial ROS was evaluated which constantly rose starting at 2 hours 
after RSL3 exposure and was abolished with the applied inhibitors. Further mitochondrial 
damage, for instance loss of mitochondrial membrane potential, was assessed by TMRE 
staining indicating vanishing membrane potential with effect from 4 hours after RSL3 
challenge. Consistent with other experiments, the inhibitors were able to completely abolish 
RSL3-induced mitochondrial damage and to preserve the mitochondrial membrane potential. 
Functionally, RSL3 provoked strong deficiency in ATP production after 4 hours of treatment 
(Figure 67i, j). In conclusion, these data imply a chronological order of stepwise lipid 
peroxidation, mitochondrial ROS formation and succeeding dysfunction of ATP synthesis 
owing to the loss of mitochondrial membrane potential upon RSL3 treatment.  
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Figure 67. RSL3 induces mitochondrial impairment 
a-d: MitoSOX staining shows time-dependent ROS formation after RSL3 exposure (a: 100 nM, b: 1000nM) and protection 
of BI-6c9 (10 μM) and ferroptosis inhibitors deferoxamine (10 μM), liproxstatin (200 nM) and ferrostatin (10 μM) upon
RSL3 treatment (c: 50 nM, d: 1000 nM, 6 h) in HT22 (a, c) and MEF cells (b, d). e-h: TMRE staining for mitochondrial 
membrane potential shows time-dependent loss after RSL3 exposure (e: 100 nM, f: 1000 nM) and protection of BI-6c9 
and ferroptosis inhibitors upon RSL3 treatment (g: 50 nM, h: 1000 nM, 16 h) in HT22 (e, g) and MEF cells (f, h)
(n=4/treatment condition). i, j: ATP assay illustrates time-dependent loss of ATP levels in HT22 (i) and MEF (j) cells 
after RSL3 challenge (i: 100 nM, j: 500 nM) (n=8/treatment condition). Data are shown as mean + SD. ***p<0.001
compared to untreated, ###p<0.001 compared to treated control (ANOVA, Scheffé’s test). 
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3.3.5 AIF executes final cell death in RSL3-induced ferroptosis 
In order to investigate death signaling downstream of RSL3-induced mitochondrial damage, 
the potential involvement of AIF was addressed. Assuming that AIF mediates mitochondrial 
damage induced death signaling similar to previous findings in glutamate-induced oxytosis, 
AIF protein levels were depleted by siRNA and cell death measured by means of MTT and 
xCELLigence. Knockdown of AIF was confirmed using Western blot (Figure 68a, b). In line 
with earlier studies demonstrating a role for AIF in oxidative cell death by loss of GPX4 [162], 
considerable protection against RSL3-induced cell death was detected by AIF gene silencing 
using siRNA in the HT22 cells (Figure 68c, d). The results confirmed that silencing AIF 
provides protection against mitochondrial damage in this model of ferroptosis. The observed 
effect may be attributed to direct loss of death-mediating AIF or to enhanced mitochondrial 
stability through preconditioning effects by complex I degradation as demonstrated by Öxler 
et al. [23,24,133].  
Figure 68. AIF mediates mitochondrial damage induced cell death signals 
a: Representative Western blot (a) and quantification (b) confirm strong knockdown of AIF protein with siAIF (50 μg 
protein, 72 hours transfection, 20 nM siRNA) in HT22 cells compared to control siRNA. Vinculin was used as loading 
control. c: Real-time impedance measurements demonstrate long-term protection of cell viability of HT22 cells by siAIF 
(72 hours, 20 nM) against 1S, 3R-RSL3 challenge (200 nM, n=4-6/treatment condition) compared to control siRNA. d: 
MTT assay of siAIF transfected HT22 cells (72 hours, 20 nM) confirms strong protection against 1S, 3R-RSL3 treatment 
(200 nM, 5 hours, n=6/treatment condition) compared to control siRNA. Data are shown as mean + or ± SD. ***p<0.001 
compared to untreated control, ###p<0.001 compared to treated control (ANOVA, Scheffé’s test). 
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3.4 Mitochondrial antioxidant MitoQ abrogates GPX4-dependent 
ferroptosis 
3.4.1 MitoQ abrogates RSL3-toxicity 
Mitochondrial damage including the organelle’s deformation, loss of membrane integrity and 
extensive ROS formation is considered as the point of no return in oxidative stress induced cell 
death [126] which is essentially why reduction of ROS formation at the mitochondrial site 
should prevent oxidative cell death. For the purpose of explicitly blocking mitochondrial ROS 
formation, the potential protective effects of the mitochondria-targeted ubiquinone derivative 
MitoQ [94] were analyzed in this thesis. 
In order to analyze the effects of MitoQ on cell viability MTT, xCELLigence impedance 
and Annexin/PI FACS measurements were performed. MitoQ preserved cell viability in HT22 
and MEF cells in a dose-dependent manner; however, high concentrations of MitoQ alone 
induced a pronounced reduction in the cell’s metabolic activity (Figure 69a, b) and little but 
significant cell death (Figure 69e, f). Remarkably, protective effects were abolished when HT22 
or MEF cells were treated with MitoQ combined with the glycolytic inhibitor 2-desoxyglucose 
(2-DG) (Figure 69g, h) suggesting that a shift from mitochondrial oxidative phosphorylation 
towards glycolysis is needed for the observed protective effect. FACS analysis revealed that high 
doses of MitoQ completely eliminate lipid peroxidation (Figure 70a, b) as well as mitochondrial 
ROS formation (Figure 70c, d), and preserve the mitochondrial membrane potential (Figure 
70e, f) in HT22 and MEF cells exposed to RSL3. 
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Figure 69. MitoQ abrogates RSL3-induced cell death 
a, b: MTT assay reveals dose-dependent protection of MitoQ against RSL3 treatment (a: 200 nM, b:500 nM) in HT22 (a) 
and MEF cells (b) (16 hours treatment, n=8/treatment condition). c, d: xCELLigence real-time measurements illustrate 
concentration-dependent protection by MitoQ upon RSL3 challenge (c: 200 nM, d: 1000 nM, n=4-6/treatment condition) 
in HT22 (c) and MEF cells (d). e, f: Annexin/PI FACS analysis demonstrates strong inhibition of cell death by MitoQ 
upon RSL3 challenge (e: 400 nM, f: 800 nM, 16 hours treatment, n=3/treatment condition) in HT22 (e) and MEF cells 
(f). g, h: Annexin/PI FACS analysis reveals loss of protection by MitoQ (1 μM) upon 2-desoxyglucose (2-DG) co-
treatment (150 mM) against RSL3 challenge (g: 500 nM, h: 1000 nM, 16 hours treatment) in HT22 (g) and MEF cells (h)
(n=3/treatment condition). Data are shown as mean + or ± SD. **p<0.01 , ***p<0.001 compared to untreated control,
###p<0.001 compared to treated control, +++p<0.001 compared to MitoQ+RSL3 treated condition (ANOVA, Scheffé’s test).
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Figure 70. MitoQ abolishes RSL3 toxicity 
a, b: BODIPY 581/591 staining and subsequent FACS analysis for measurement of lipid peroxide formation shows 
protection by high MitoQ concentrations (HT22: 1.0 μM, MEF: 1.5 μM) after RSL3 exposure (a: 200 nM, b: 1500 nM, 6 
hours, n=3/treatment condition) in HT22 cells (a) and MEF cells (b). c, d: MitoSOX staining and subsequent FACS
analysis for mitochondrial ROS formation shows a reduction of the fluorescence with MitoQ (0.5 μM) after RSL3
treatment (c: 200 nM, d: 700 nM, 16 hours, n=3/treatment condition) in HT22 cells (c) and MEF cells (d). e, f: TMRE 
FACS analysis for mitochondrial membrane potential demonstrates that MitoQ (0.5 μM) preserves the MMP after RSL3 
(e: 200 nM, f: 700 nM, 16 hours, n=3/treatment condition) in HT22 cells (e) and MEF cells (f). Data are shown as mean 
+ or ± SD. *p<0.05, ***p<0.001 compared to untreated control, #p<0.05, ###p<0.001 compared to treated control (ANOVA,
Scheffé’s test). 
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3.4.2 MitoQ preserves mitochondrial morphology and function through a glycolytic 
shift 
In order to further address mitochondrial changes due to RSL3-induced oxidative stress, 
mitochondrial morphology of HT22 and MEF cells stained with LifeAct-GFP for actin and 
MitoTracker DeepRed for mitochondria was studied after RSL3 exposure (Figure 71). 
Mitochondrial fragmentation and accumulation around the nucleus was observable after 5 
hours in response to RSL3 treatment shown by quantification according to the recently 
established classification system [72,126]. Mitochondrial shape judged as 3D mitochondrial 
reconstructions of stacked confocal images after RSL3 challenge revealed a pronounced loss of 
category I healthy cells and an equivalent increase in category III cells after 5 hours (Figure 71). 
This is in line with the above-mentioned rise in mitochondrial ROS formation and loss of 
mitochondrial membrane potential as an additional indicator of mitochondrial damage. 
Remarkably, MitoQ alone induced mitochondrial fragmentation quantified as an increase in 
category II but did not harm the cells as judged by the cell shape and cell viability 
measurements. Conversely, in combination with RSL3 MitoQ reduced strong mitochondrial 
damage and prevented cell damage.  
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Figure 71. Mitochondrial morphology is preserved by MitoQ 
a, b: Representative confocal microscopy images (63x objective) and 3D mitochondrial reconstructions of HT22 (a) and 
MEF cells (b) stained with LifeAct-GFP and MitoTracker DeepRed (200 nM) with RSL3 (a: 250 nM, b: 500 nM, 5 h) ± 
MitoQ (1.0 μM, 5 h). Scale bars: 20 μm, zoom 1 μm. c, d: Quantification of 500 cells demonstrates time-dependent 
mitochondrial fission and translocation to the nucleus in HT22 (c) and MEF (d) cells after RSL3 exposure (n=3/treatment 
condition). MitoQ treatment reveals strong shift to category II when applied alone but rescues mitochondrial phenotype
after RSL3 treatment. Data are shown as mean + SD. ***p<0.001 compared to untreated control, ###p<0.001 compared to 
treated control (ANOVA, Scheffé’s test). 
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To characterize RSL3 and MitoQ treatment functionally, Seahorse XF96 measurements were 
performed and mitochondrial respiration (oxygen consumption rate, OCR) and glycolysis 
(extracellular acidification rate, ECAR) were assessed. In line with the detected mitochondrial 
damage upon RSL3 treatment, both OCR and ECAR were concomitantly reduced in HT22 cells 
over time (Figure 72). However, cells did not die completely as spare respiratory capacity was 
still present after injection of the uncoupling agent FCCP. Interestingly, MitoQ reduced 
mitochondrial respiration to such an extent that the cells no longer reacted to the uncoupling 
agent FCCP suggesting no spare respiratory capacity, however, cells shifted their energy 
metabolism towards ATP production through glycolysis to meet their energy demands. In 
sharp contrast, RSL3 treated cells could not increase the glycolytic activity suggesting their 
energy metabolism to be substantially harmed. In conclusion, RSL3 provokes a tremendous 
disruption of mitochondrial morphology and function, which can be reduced to a non-fatal 
state by MitoQ. 
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Figure 72. MitoQ protects against RSL3 by shift to glycolysis 
a, b: Normalized Seahorse measurements show inhibition of mitochondrial respiration (a, OCR) and no further decrease 
with oligomycin by RSL3 (1.5 μM) or MitoQ (1 μM) in HT22 cells compared to untreated control. After FCCP injection,
MitoQ treated cells do not exhibit a spare respiratory capacity compared to control or RSL3 treated cells. ECAR
measurements (b) as an indicator for glycolytic activity reveal glycolytic switch with MitoQ ± RSL3 in HT22 cells and
reduced glycolysis with RSL3 alone. Data are shown as mean ± SD. 
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3.4.3 MitoQ does not prevent tBID-induced toxicity 
In order to further define the scope of protection by MitoQ, tBID toxicity was investigated, 
which directly mediates mitochondrial membrane disruption and release of death-promoting 
factors such as Cytc and AIF. For this purpose, active tBID was overexpressed in HT22 cells 
and cell viability monitored by xCELLigence measurement (Figure 73). Here, tBID induced a 
significant reduction in cell viability, and MitoQ co-treatment could not prevent tBID toxicity. 
In fact, MitoQ increased the toxic effects of tBID expression. These findings suggested that 
upon tBID challenge mitochondrial ROS formation is not the major cause of cell death and that 
MitoQ acts upstream of BID-mediated mitochondrial release of pro-apoptotic factors. In 
contrast, the BID inhibitor BI-6c9 was shown to prevent tBID-induced cell death 
[103]suggesting that it was able to bind to tBID and prevent cell death at advanced stages of 
death signaling, where mitochondrial antioxidants are not effective anymore. 
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Figure 73. MitoQ does not prevent tBID toxicity 
XCELLigence measurement demonstrates significant reduction of cell viability after tBID overexpression (pIRES-EGFP-
tBid: 0.3 μg DNA/well) in HT22 cells, which cannot be circumvented by MitoQ co-treatment (n=5-8/treatment 
condition). Data are shown as mean ± SD. 
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3.5 Elucidating the structure of BID by crystallization: towards structure-
based design of BID inhibitors  
Programmed cell death is associated with different human pathologies, such as 
neurodegenerative diseases (AD or PD) and ischemic brain damage. If brain tissue is 
degenerating, this ultimately results in cognitive impairment and physical disabilities. As 
demonstrated in the first part of this thesis, neuronal cell death is tightly connected to BID 
transactivation and, therefore, impeding BID function should be an auspicious chance to 
protect brain tissue in neurodegenerative processes.  
Functional BID studies and the development of novel small molecule BID inhibitors to 
provide therapeutic perspectives could be facilitated by structure-guided ligand design 
requiring high-resolution protein structures. So far, two solution NMR structures for BID have 
been identified [26,120], however, high-resolution X-ray data are still desirable for precise in 
silico modeling. In previous attempts [132], the expression and purification of a variety of 
recombinant Bid constructs was established and first crystallization conditions were identified 
providing the starting point for further optimization. In this work, several modified Bid 
constructs (Table 44) were cloned with either GST- or His6-tag, purified and subjected to vapor 
diffusion crystallization in order to obtain crystals for x-ray structural analysis. As the 
previously published NMR structures of BID suggested 8 core α-helices and additional mobile 
regions, such as the flexible intramolecular loop and a flittering N-terminus, in constructs Bid 1 
and Bid 3 these regions were removed (Figure 74) to potentially facilitate crystallization. 
Further constructs contained CCSS mutations to reduce the chance of GSH binding to the 
thiol-containing cysteines during the purification process. 
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3.5.1 Initial Bid 1 and Bid 3 purification 
Initially, Bid 1 and Bid 3 GST-tagged constructs were transformed and expressed in Escherichia 
coli strain Rosetta2 (DE3) until a suitable optical density was achieved. Subsequently, IPTG was 
added to induce protein expression for 5 hours before harvesting bacteria. The expression of 
high amounts of the respective protein construct was verified by SDS-PAGE and Coomassie 
staining of the total bacterial lysate (TL). Purification of GST-tagged proteins was performed 
in a two-step chromatography process using the ÄKTA prime plus system. In the first step, 
proteins were pre-cleaned by GSH affinity chromatography once or twice depending on the 
amount of total bacterial lysate followed by SDS-PAGE and Coomassie staining to evaluate the 
resulting protein purity. In addition, the flow-through (FT) was investigated to estimate loss of 
recombinant BID protein owing to limited column binding capacity. Thereafter, GST-tags were 
cleaved using thrombin and controlled by SDS-PAGE. In a second step, gel size exclusion 
chromatography was performed in order to remove cleaved GST-tags and to obtain 
homogenous protein solutions. Finally, the protein was concentrated on 3 kDa cut-off Amicon 
filters to a desired concentration of 5-15 mg/mL and sterile-filtered to prevent microbial growth 
during crystallization. To further investigate the purified proteins, the final protein solution 
was subjected to MALDI-TOF analysis. 
Figure 74. Mouse Bid NMR structure (1DDB) and alignment of constructs for crystallization  
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Bid3-GST was purified in two fractions by GSH-affinity chromatography (Figure 76a-d). 
Chromatograms and corresponding SDS-PAGE analysis revealed adequate protein content in 
the total lysate (TL), a sufficient initial enrichment of protein in the elution fractions 37-41 and 
33-37, respectively, and only a slight loss of protein in the flow-through (FT) due to limited 
binding capacity of the column. The elution fractions 37-41 and 33-37 were pooled and 
subjected to thrombin-cleavage (TC) with a cleavage rate of ~ 60-70 %. After concentration 
with 3 kDa Amicon cut-off filters and subsequent size exclusion gel chromatography (Figure 
76a, b) elution fractions 34-39 were pooled as they showed pure Bid3 protein after SDS-gel 
electrophoresis. Fractions 24-29 containing uncleaved Bid3-GST and GST were discarded. The 
protein solution was again concentrated to a final concentration of 9.5 mg/mL and sterile-
filtered. MALDI-TOF analysis (Figure 76c) revealed multiple and sub-divided split peaks which 
may be due to partial protein degradation (~ 13-14 kDa, Figure 76d) and GSH disulfide adducts 
to the proteins’ cysteine residues (Δ 307 Da). To prevent these covalent GSH binding, the 
reducing agent TCEP (tris [2-carboxyethyl] phosphine) was added to the buffers for GSH-
affinity chromatography of following Bid1-GST purification and novel constructs were cloned 
containing serines instead of cysteines (CCSS mutation).  
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Figure 75. Bid3 purification for screen #1 I 
GSH affinity chromatography: Chromatograms of two runs (a, b) on Glutathione HiCap 10 mL column and
corresponding Coomassie-stained SDS-gels (c, d). Total-lysate (TL, c, d) depicts sufficient recombinant protein
expression. In both runs, UV absorption shows a clear peak for Bid3-GST (~ 44 kDa) (a, b: fractions 37-41 and 33-37, 
respectively) which was confirmed by SDS-PAGE (c, d). Flow-through (FT) analysis reveals limited binding capacity
inside the column leading to a slight loss of Bid3-GST protein (c, d). A sample after thrombin-cleavage (TC, c) reveals 
that a large amount of Bid3-GST was cleaved into GST (~ 26 kDa) and Bid3 (17.5 kDa, missing on gel). 
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After purification Bid3 was subjected to extensive crystallization screening (Table 65) at the 
MarXtal crystallization lab (SYNMICRO, University of Marburg, Germany) using high-
throughput crystallization robotics. Within 1 week, in the Morpheus screen (well A8-1) a very 
small crystal was obtained (Figure 77) providing the basis for the further optimization of 
crystallization conditions comprising Na-HEPES/MOPS pH7.5 buffer and MPD, PEG1,000 
and PEG3,350 as precipitants as well as MgCl2 and CaCl2 as divalent cation salt additives. 
Figure 76. Bid3 purification for screen #1 II 
Size exclusion gel chromatography: Chromatogram of a HiLoad 16/1600 Superdex 75 run depicts pronounced UV 
absorption peaks for GST and Bid3-GST in the beginning (a) confirmed by SDS-PAGE (b) and a smaller peak for Bid3 
in fractions 34-39 (a) due to lower amount of aromatic amino acids. Elution fractions after gel chromatography 
demonstrate successful purification of Bid3 (b). MALDI-TOF analysis after 6 weeks (c) reveals multiple peaks for Bid3 
presumably due to GSH covalent binding and protein degradation which was further confirmed by SDS-PAGE (d). 
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Next, Bid1-GST was purified by GSH-affinity chromatography (Figure 78a, b) in the presence 
of TCEP to prevent covalent GSH binding to cysteine residues. Chromatograms and SDS-
PAGE demonstrated sufficient protein amount in the total lysate (TL), a clean initial 
enrichment of protein in the elution fractions 68-98 and very little loss of protein in the flow-
through (FT) as this time a larger column with 20 mL GSH matrix instead of 10 mL was used. 
The elution fractions 68-98 were pooled and cleaved by thrombin (TC). After protein 
concentration with 3 kDa Amicon cut-off filters and size exclusion gel chromatography (Figure 
78c, d) elution fractions 36-40 were pooled as they displayed the Bid1 protein with the highest 
purity as confirmed by SDS-gel electrophoresis. The protein solution was further concentrated 
to a final concentration of 12.7 mg/mL and sterile-filtered. MALDI-TOF analysis (Figure 78e) 
depicted single peaks indicating pure protein and no GSH disulfide adducts or degradation. 
With the obtained protein solution several screens were performed according to Table 65 with 
the addition of 2 % nanoparticles in drop 1 to facilitate nucleation for crystallization. After 
several weeks very fine protein needles were obtained (Figure 78f) in Morpheus A8-1 and in 
A9-1 (Tris/BICINE buffer pH 8.5, PEG500 MME and PEG20,000 as precipitants and MgCl2 
and CaCl2 as salt additives) suggesting that divalent cations and PEGs (polyethylene glycols) 
may assist BID crystal growth.  
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Figure 77. Bid3 crystal 
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Figure 78. Bid1 purification for screen #2 
GSH affinity chromatography: Chromatogram (a) of a Glutathione HiCap 20 mL column run and corresponding 
Coomassie-stained SDS-gel (b). Total-lysate (TL, b) depicts high recombinant protein expression. UV absorption shows
a clear peak for Bid1-GST (~ 44 kDa) (a: fractions 68-98) which was confirmed by SDS-PAGE (b). Flow-through (FT) 
analysis reveals very little loss of Bid1-GST protein (b). A sample after thrombin-cleavage (TC, d) reveals complete 
cleavage into GST (~ 26 kDa) and Bid1 (17.5 kDa) protein. Size exclusion gel chromatography: Chromatogram of a 
HiLoad 16/1600 Superdex 75 run depicts pronounced UV absorption peaks for GST in the beginning (e) confirmed by 
SDS-PAGE (d) and a smaller peak for Bid1 in fractions 36-40 (c) due to lower amount of aromatic amino acids. Elution 
fractions after gel chromatography demonstrate very successful purification of Bid1 (d). MALDI-TOF analysis directly 
after purification (e) reveals single peaks for Bid1 indicating no GSH covalent binding or protein degradation.
Representative Bid1 crystals (f). 
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3.5.2 Bid 3 construct optimization by CCSS mutation 
As a second strategy to circumvent undesirable GSH binding to the BID protein, both cysteines 
of Bid3 were mutated to serines (Bid3 CCSS) using site-directed mutagenesis. The protein was 
again expressed and purified according to section 3.5.1. In a first step of GSH affinity 
chromatography (Figure 79a, b, d) remarkably high amounts of Bid3-GST CCSS protein were 
obtained in fractions 68-78, while very little protein was lost with the flow-through (FT). After 
thrombin-cleavage (TC) of pooled fractions 68-78, which was almost complete, size exclusion 
gel chromatography was successful so that excessive Bid3 CCSS protein was obtained according 
to SDS-PAGE analysis. Notably, in gel fractions 31-37 a small quantity of residual GST was 
detected which was hardly found in MALDI-TOF analysis. Elution fractions 31-37 were pooled 
as they displayed the highest Bid3 CCSS protein content as confirmed by SDS-gel 
electrophoresis. The protein solution was then concentrated to a final concentration of 
10.7 mg/mL and sterile-filtered.  
The protein solution was subjected to a great variety of crystallization screens (Table 
65) with 10.7 mg/mL and a 1:2 dilution to 5.3 mg/mL protein content (screen #3). In the 
Morpheus screen (well A5-1, and A8-1) as well as in the AmSO4 screen (well D1-1: NaCl and 
ammonium sulfate) larger crystals were obtained (Figure 80, upper panel). Red-marked crystals 
were analyzed at the synchrotron microfocus beamline in Grenoble (ESRF Grenoble, France) 
using cryo-crystallography. 
Remaining Bid3 CCSS was used for additional screens (#4) with 5.3 mg/mL 
concentration protein either alone or supplemented with a novel water-soluble BID inhibitor 
(BI-28319, 27 mM) in an attempt to obtain co-crystals (Table 65). Again, in Morpheus (well 
A8-1) and also in MemGold (well A4-1: NaCl, Na3PO4 buffer pH 7.0, PEG4,000, NaN3) small 
crystals were obtained (Figure 80 lower panel).  
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Figure 79. Bid3 CCSS purification for screen #3 and #4 
GSH affinity chromatography: Chromatogram (a) of a Glutathione HiCap column run and corresponding Coomassie-
stained SDS-gels (b, d). Total-lysate (TL, b, d) depicts high recombinant protein expression. UV absorption shows a clear
peak for Bid3 CCSS-GST (~ 44 kDa) (a: fractions 68-78), which was confirmed by SDS-PAGE (b, d). Flow-through (FT) 
analysis reveals very little loss of Bid3 CCSS-GST protein (b, d). A sample after thrombin-cleavage (TC, d) reveals almost 
complete cleavage into GST (~ 26 kDa) and Bid3 CCSS (17.5 kDa) protein. Size exclusion gel chromatography:
Chromatogram of a HiLoad 16/1600 Superdex 75 run depicts pronounced UV absorption peaks for GST in the beginning 
(c) and a smaller peak for Bid3 CCSS in fractions 31-37 (c). Elution fractions after gel chromatography demonstrate
purification of Bid3 CCSS (f), however, a faint band at the size of GST is still observable. MALDI-TOF analysis directly 
after purification (e) reveals single peaks for Bid3 CCSS indicating no GSH covalent binding. 
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Figure 80. Bid3 CCSS crystals of screen #3 and #4 
Bid3 CCSS crystals obtained in screen #3 (upper panel) and #4 (lower panel). 
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In order to further optimize the most promising Morpheus conditions, additional Bid3 CCSS 
protein was required, for what reason a second purification was performed (Figure 81). In GSH 
affinity chromatography again high amounts of relatively pure Bid3-GST CCSS protein were 
obtained in fractions 71-77, while very little protein was lost with the flow-through (FT). After 
thrombin-cleavage (TC) of pooled fractions 71-77, which was almost complete, size exclusion 
gel chromatography was successful so that pure Bid3 CCSS protein was obtained according to 
SDS-PAGE analysis. Elution fractions 32-36 were pooled as they displayed the highest amount 
of Bid3 CCSS protein. The protein solution was then concentrated to a final concentration of 
12.3 mg/mL and sterile-filtered.  
Subsequently, the protein solution was subjected to a variety of optimization screens 
with conditions similar to Morpheus A5 and A8 and the protein was again supplemented with 
BI-28319 (1 mM) to allow co-crystal growth (screen #5). Remaining protein was used for a 
seeding screen, where old crystals were smashed and used as seeding crystals, and an additive 
screen, where several chemical substances so-called additives were tested whether they may 
improve crystal growth (screen #8). A large crystal was obtained in the Opti screen well C9-1 
(similar conditions as Morpheus A5) (Figure 81e), in the additive screen with Morpheus A5 
conditions (well B4-1 with CoCl2 * 6 H2O and B5-1 with LiCl) and in the additive screen with 
Morpheus A8 conditions (well B4-1 with CoCl2 * 6 H2O and C6-1 with 6-Aminohexanoic acid). 
In conclusion, these conditions further underline a better crystal growth in the presence of 
divalent cations such as magnesium, calcium and cobalt. 
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Figure 81. Bid3 CCSS purification for screen #5 and #8 
GSH affinity chromatography: Chromatogram (a) of a Glutathione HiCap column run and corresponding Coomassie-
stained SDS-gel (b). Total-lysate (TL, b) depicts high recombinant protein expression. UV absorption shows a clear peak
for Bid3 CCSS-GST (~ 44 kDa) (a: fractions 71-77), which was confirmed by SDS-PAGE (b). Flow-through (FT) analysis 
reveals very little loss of Bid3 CCSS-GST protein (b). A sample after thrombin-cleavage (TC, d) reveals complete cleavage 
into GST (~ 26 kDa) and Bid3 CCSS (17.5 kDa) protein. Size exclusion gel chromatography: Chromatogram of a HiLoad 
16/1600 Superdex 75 run depicts pronounced UV absorption peaks for GST in the beginning (c) and a smaller peak for 
Bid3 CCSS in fractions 32-36 (c). Elution fractions after gel chromatography demonstrate purification of Bid3 CCSS (d). 
Representative Bid3 CCSS crystals (e) of screen #5 (upper left) and screen #8 (remaining pictures). 
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3.5.3 Selenomethionine heavy atom exchange in Bid 3 CCSS 
Having obtained diffracting protein crystals, the major difficulty of elucidating protein 
structures is to solve the phase problem which occurs as x-ray detection only records 
amplitudes but not the phases of electromagnetic waves. Besides molecular replacement (MR), 
introduction of heavy atom diffraction labels into the crystal (multiple isomorphous 
replacement, MIR) combined with multi-wavelength anomalous dispersion (MAD) is used. 
Heavy atoms like selenium (Se) can act as anomalous scatterers and multiple data sets of one 
single crystal can be collected using different wavelengths. Their variation in recorded 
intensities at the different wavelengths can be used to extract the anomalous substructure of the 
scatterer to solve the phase problem.  
In light of this, to aid structure elucidation, selenium was incorporated into Bid3 CCSS 
protein by replacement of methionines with selenomethionine (SeMet) during recombinant 
protein expression according to section 2.10.3.4. A preliminary small scale expression test was 
performed to check whether selenomethionine exchanged protein expression principally works 
and to decide whether the selenomethionine expression media should be supplemented with 
glycerol as the manufacturer’s protocol suggested. For this reason, supplementation with 2 % 
glycerol was tested compared to normal protein expression in IPTG-induced LB medium and 
samples run on an SDS-gel with subsequent Coomassie staining for visualization (Figure 82). 
Since expression worked best in conditions without glycerol (Figure 82) further large-scale 
SeMet Bid3 CCSS expression was performed without the supplement. 
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SeMet Bid3 CCSS was purified similarly to regular Bid3 CCSS recombinant protein using GSH 
affinity and size exclusion chromatography. In GSH affinity chromatography excessive 
amounts of highly purified SeMet Bid3-GST CCSS protein were obtained in fractions 67-84, 
while little protein was lost with the flow-through (FT) (Figure 83a, b). After thrombin-cleavage 
(TC, Figure 83c) of pooled fractions 67-84 size exclusion gel chromatography was effective so 
that pure SeMet Bid3 CCSS protein was obtained according to SDS-PAGE analysis (Figure 83d, 
e). Elution fractions 31-37 were pooled as they displayed pure SeMet Bid3 CCSS protein. The 
protein solution was then concentrated to a final concentration of 13.2 mg/mL and sterile-
filtered.  
 
 
 
 
 
 
 
 
 
MarkerkDa
25
15
35
40
55
Bid3CCSS-GST SeMet
LB-
IPT
G
SeM
et SeM
et +
Gly
cero
l
Figure 82. Small-scale SeMet Bid3 CCSS expression test on SDS-gel 
Coomassie-stained SDS-gel of preliminary small-scale protein expression test reveals best Bid3 CCSS-GST SeMet 
expression in SeMet media without addition of 2 % glycerol. 
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Figure 83. Bid3 CCS SeMet purification for screen #9 and #10 
GSH affinity chromatography: Chromatogram (a) of a Glutathione HiCap column run and corresponding Coomassie-
stained SDS-gel (b). Total-lysate (TL, b) depicts sufficient recombinant protein expression. The UV absorption graph 
shows a clear peak for Bid3 CCSS SeMet-GST (~ 44 kDa) (a: fractions 67-84), which was confirmed by SDS-PAGE (b). 
Flow-through (FT) analysis reveals very little loss of Bid3 CCSS SeMet-GST protein (b). Samples after thrombin-cleavage 
(TC, c) reveal complete cleavage into GST (~ 26 kDa) and Bid3 CCSS SeMet (~18 kDa) protein. Size exclusion gel 
chromatography: Chromatogram of a HiLoad 16/1600 Superdex 75 run depicts pronounced UV absorption peaks for 
GST in the beginning (e) and a small peak for Bid3 CCSS SeMet in fractions 31-37 (f). Elution fractions after gel 
chromatography demonstrate successful purification of Bid3 CCSS SeMet (f). 
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MALDI-TOF analysis confirmed increased protein mass of Bid3 CCSS SeMet (Δ 282 Da) by 
selenium incorporation compared to Bid3 CCSS suggesting 6 sulfur atom exchanges by 
selenium (Δ 47 Da) per protein molecule on average (Figure 84a). After purification, the 
protein solution was subjected to Morpheus screen and various optimization screens with 
conditions similar to Morpheus A5 and A8 and the protein was supplemented with BI-6c9 (0.25 
mM) to allow co-crystal growth (screen #8). The remaining protein was used for another round 
of screening with optimization of Morpheus A5 and Morpheus A5 well D3 (screen #9). Several 
crystals were obtained including a large crystal in the Morpheus A5 Opti screen well D3-2 
(Figure 84b) which was analyzed by x-ray diffraction.  
 
Figure 84. MALDI-TOF analysis and crystals of Bid3 CCSS SeMet  
a: MALDI-TOF analysis directly after protein purification reveals single peaks for Bid3 CCSS SeMet indicating successful 
protein purification. A difference in protein mass of Δ 282 Dalton of Bid3 CCSS compared to Bid3 CCSS without selenium
incorporation indicates an average incorporation of 6 selenium atoms per protein molecule. b: Representative Bid3 CCSS 
SeMet crystals of screen #8 (upper left and middle) and screen #9 (remaining pictures). 
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3.5.4 Full-length Bid 22 purification and construct optimization by CCSS mutation 
Since the major aim was to identify the 3D protein structure of full-length BID, Bid 22 was 
recombinantly expressed, purified and subjected to crystallization screens which were already 
identified as potentially helpful regarding reproducible crystal growth. As the Bid 22 construct 
contains a His6-tag for purification instead of GST the protein purification process was 
modified accordingly (see section 2.10.4.4).  
Briefly, purification of His6-tagged BID was performed by three independent 
chromatography steps comprising nickel-affinity, ion exchange and size-exclusion gel 
chromatography. Importantly, after the nickel affinity chromatography step, the protein 
solution had to be desalted for ion exchange chromatography. As CCSS mutation already 
improved Bid construct purification also a full-length Bid construct with CCSS mutation was 
generated and purified similarly for crystallization screening. 
Bid22-His6 was expressed as stated in 2.10.3 and purified by Nickel affinity 
chromatography as a first step. According to the UV absorption spectrum (Figure 86a) and the 
Coomassie-stained SDS-gel (Figure 86b) fractions 33-48 contained relatively pure Bid22-His6 
protein (~ 23 kDa). These fractions were pooled and after the subsequent desalting procedure 
(see 2.10.4.4) the protein solution was applicable for ion exchange chromatography (Figure 
86c) to further purify the protein, which was successful according to SDS-gel analysis although 
two peaks were apparent in the UV absorption spectrum (Figure 86d).  
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Pooled fractions 41-53 were subjected to thrombin-cleavage (see 2.10.4.7) to remove the His6-
tag and finally loaded on a gel column for size exclusion chromatography to remove the cleaved 
protein parts. Interestingly, SDS-gel analysis revealed a second unexpected purification product 
of ~ 14-15 kDa in size which was not removed after gel chromatography (Figure 86a, b). The 
fragment likely was a Bid22 fragment due to unspecific thrombin cleavage which could not be 
removed by a second ion exchange chromatography step (Figure 86c) suggesting that the 
fragments are cleaved but do not separate from each other. Subsequent Western blot analysis 
showed that the Bid antibody recognized this fragment confirming that it indeed was an 
unspecific BID cleavage product (Figure 86d). MALDI-TOF analysis revealed full-length BID 
with 22.3 kDa and unspecific cleavage products of 14.9 and 7.5 kDa size (Figure 87). After 
purification the protein solution was concentrated to 4.75 mg/mL. Crystallization attempts 
with the Morpheus A5/A8 Opti Screen (screen #6) ± BI-28319 (0.8 mM) did not result in crystal 
growth presumably due to heterogeneous protein solution or due to low protein concentration. 
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Figure 85. Bid22 purification for screen #6 I 
Nickel affinity chromatography: Chromatogram (a) of a Nickel HisTrap FF column run and corresponding Coomassie-
stained SDS-gel (b). Total-lysate (TL, b) depicts sufficient recombinant protein expression. The UV absorption graph 
shows a clear peak for Bid22-His6 (~ 23 kDa) (a: fractions 33-48) which was confirmed by SDS-PAGE (b). Flow-through 
(FT) analysis reveals almost no loss of Bid22-His6 protein (b). Ion exchange chromatography: Chromatogram of a run 
on an ion exchange HiTrap Q HP column shows two elution peaks of Bid22-His6 (c) confirmed by SDS-gel analysis of 
fractions 41-53 (d). 
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Figure 86. Bid22 purification for screen #6 II 
A sample after thrombin-cleavage (TC, b) reveals an unspecific cleavage product of ~ 14 kDa size. Size exclusion gel 
chromatography: Chromatogram of a HiLoad 16/1600 Superdex 75 run depicts two UV absorption peaks for Bid22 in 
fractions 22-33 (a). Elution fractions after gel chromatography demonstrate purification of Bid22 and a smaller fragment
(b). Ion exchange chromatography: Second ion chromatography results in two peaks of fractions 48-59 (c) containing 
Bid22 and a Bid fragment which is confirmed by Western-blot demonstrating detection of both bands by Bid antibody
(d). 
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In addition, purification of Bid22 CCSS was performed similar to Bid22 purification. According 
to the UV absorption spectrum (Figure 88a) and the Coomassie-stained SDS-gel (Figure 88b) 
fractions 34-45 contained relatively pure Bid22 CCSS-His6 protein (~ 23 kDa). These fractions 
were pooled and the His6-tag cleaved by thrombin. However, again SDS-gel analysis revealed a 
second purification product of ~ 14-15 kDa size. After the subsequent desalting procedure (see 
2.10.4.4) the protein solution was applicable for ion exchange chromatography (Figure 88c) to 
further purify the protein. According to SDS-gel analysis much protein remained in the flow-
through (Figure 88d) which is why a second ion exchange chromatography step was performed 
with fractions 1-14 (Figure 88e). Elution fractions of both runs (first: 36-47, second: 42-47) were 
subsequently pooled and subjected to gel chromatography (Figure 88f). MALDI-TOF analysis 
of pooled fractions 27-33 revealed full-length BID with 22.2 kDa and unspecific cleavage 
products of 14.9 and 7.4 kDa in size (Figure 89). After the purification process the protein 
solution was concentrated to 14.0 mg/mL. Crystallization attempts with various conditions 
(screen #7) ± BI-28319 (0.07 mM) did not result in crystal growth presumably due to 
heterogeneous protein. 
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Figure 87. MALDI-TOF analysis of Bid22 purification product 
MALDI-TOF analysis shows full-length BID of 22.3 kDa and reveals unspecific thrombin cleavage products of 14.9 and 
7.5 kDa size. 
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Figure 88. Bid22 CCSS purification for screen #7  
Nickel affinity chromatography: Chromatogram (a) of a Nickel HisTrap FF column run and corresponding Coomassie-
stained SDS-gel (b). Total-lysate (TL, b) depicts sufficient recombinant protein expression. The UV absorption graph
shows a clear peak for Bid22 CCSS-His6 (~ 23 kDa) (a: fractions 31-51) which was confirmed by SDS-PAGE (b). Flow-
through (FT) analysis reveals almost no loss of Bid22-His6 protein (b). A sample after thrombin-cleavage (TC, d) reveals 
an unspecific cleavage product of ~ 14 kDa size. Ion exchange chromatography: Chromatogram of a run on an ion
exchange HiTrap Q HP column shows a peak of Bid22 CCSS-His6 (c) confirmed by SDS-gel analysis of fractions 31-51
(d), however, the flow-through (FT) still contains much protein. Chromatogram of a second ion exchange run of flow-
through fractions 1-14 (e). Size exclusion gel chromatography: Chromatogram of a HiLoad 16/1600 Superdex 75 run
depicts a clear UV absorption peak for Bid22 CCSS in fractions 27-33 (f).  
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 In conclusion, novel recombinant BID protein constructs were successfully expressed and 
optimized to improve the purity and to enhance the probability of crystal growth. For the first 
time, crystallization conditions for reproducible crystal growth were identified and optimized 
to obtain larger crystals. In order to solve the phase problem, selenomethionine protein 
expression resulting in reproducible crystal growth was established. Despite relatively large 
crystals, first x-ray analyses could not solve the 3D structure due to insufficient diffraction 
resolution but the improved protocols provide a promising basis for further crystallization 
attempts.  
 
  
Bid22CCSS60
80
100
20
40
0
3229 2472516127118277528
Mass (m/z)
Int
en
sit
y %
20426
Bid22CCSS fragment
Bid22CCSS/2
Bid22CCSS fragment
Figure 89. MALDI-TOF analysis of Bid22CCSS purification product 
MALDI-TOF analysis shows full-length BID CCSS of 22.2 kDa and reveals unspecific thrombin cleavage products of 14.9 
and 7.4 kDa size (g). 
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4 Discussion 
Disturbed cellular homeostasis and cell death owing to the accumulation of ROS and 
subsequent mitochondrial damage are well-established features of pathologic processes in the 
course of neurodegeneration. Despite some evidence for the involvement of the pro-apoptotic 
protein BID, the underlying mechanisms driving mitochondrial demise in the course of 
oxidative programmed neural cell death remain poorly defined. Therefore, the aim of the 
present thesis was to elucidate the role of BID in oxidative cell death pathways affecting 
mitochondrial integrity and function. In addition, effects of mitochondria-targeted 
antioxidants were evaluated according to the potential role in preserving mitochondrial 
function upon RSL3-induced cell death. Finally, the protein BID was recombinantly expressed 
and purified for X-ray crystal structure analysis and potential in silico modeling for the 
optimization of BID inhibitors. 
The first part of this thesis highlights a pivotal role for BID-induced mitochondrial 
damage in shared pathways of glutamate-induced oxytosis and erastin-induced ferroptosis, 
both of which were accompanied by BID transactivation to mitochondria and their subsequent 
fatal damage. In addition, CRISPR/Cas9 BID knockout in neuronal HT22 cells revealed 
sustained protection against glutamate- or erastin-induced cell death by protein deletion, 
thereby supporting a crucial involvement of BID in ROS-induced cell death. The protective 
effects mediated by the well-established BID and ferroptosis inhibitors in the respective other 
model system of oxytosis and ferroptosis, confirmed common mechanistic hallmarks of these 
two cell death modalities and highlighted the crucial involvement of mitochondrial pathways 
in these paradigms of cell death. 
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The second part of the actual study addressed the detailed mechanism of RSL3-induced 
ferroptosis and the chronological sequence of biochemical hallmarks. RSL3 induced ROS-
dependent cell death similar to glutamate and erastin, and involved BID-mediated loss of 
mitochondrial function and morphological alterations. The detailed analysis of RSL3 isomeric 
forms revealed a specific inhibitory effect on GPX4 only by 1S, 3R-RSL3 which was 
accompanied by GPX4 protein degradation and demonstrated that the chloroacetamide moiety 
of RSL3 was responsible for covalent GPX4 binding. Not only BI-6c9 and ferroptosis inhibitors 
prevented RSL3-induced cytotoxicity, but also the mitochondria-specific ROS scavenger 
MitoQ was identified as a potent inhibitor of ferroptotic mitochondrial damage and successive 
cell death by scavenging ROS and shifting energy metabolism towards glycolysis. These data 
suggest BID-mediated mitochondrial demise as the point of no return in the cell’s commitment 
to die while at the same time providing a novel therapeutic strategy to treat oxidative cell death-
related neurodegenerative diseases. 
Finally, recombinant BID constructs were optimized for X-ray protein crystallography 
and crystallization conditions for reproducible crystal growth were established. Despite 
considerable progress in the optimization of protein constructs and crystallization conditions, 
electron density data of crystals measured at the microfocus beamline did not have a sufficient 
resolution to finally elucidate the 3D structure but provided a promising basis for further 
optimization. 
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4.1 A key role for BID in glutamate- and erastin-induced oxidative cell 
death  
Oxytosis in HT22 cells is a well-established model system to study neuronal oxidative cell death 
[125,183–185] and was therefore used to confirm already established concepts on the 
involvement of BID and mitochondrial damage in ROS-induced cellular demise. In this thesis, 
these observations were significantly extended by time-course analyses of ROS-mediated 
mitochondrial dysfunction. Prior work has documented alterations in mitochondrial 
morphology and function to be implicated in a variety of ROS-dependent neuropathological 
processes in Alzheimer’s disease, Parkinson’s disease, and in brain injuries caused by ischemic 
stroke, trauma or hemorrhagic insults [109,152]. In the model system of oxytosis, glutamate 
application mimics these pathophysiological conditions by provoking 12/15-lipoxygenase-
mediated increases in soluble and lipid ROS [184,186], which were shown to provoke fatal 
mitochondrial damage mediated by BID transactivation to the outer mitochondrial membrane 
[72,103]. 
Consistent with earlier studies on glutamate-induced oxytosis [36,103,125,186], 
glutamate toxicity by inhibition of system Xc- was shown to depend on the cell density at the 
time of treatment and on the glutamate concentration applied to the cells. Variable sensitivity 
towards glutamate can be explained as a reason of differing extents of system Xc- blockage 
depending on how dense the cells are at the time of treatment.  
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Mitochondrial impairment or dysfunction has been observed in a variety of neuropathological 
conditions and was identified as a major hallmark of glutamate-induced oxytosis. To address 
the question of when exactly mitochondrial function is impaired in the course of oxidative cell 
death, mitochondrial respiration was assessed. By the subsequent application of the ATP-
synthase inhibitor oligomycin, uncoupler FCCP and complex I and III inhibitors rotenone and 
antimycin A, it became evident that mitochondrial respiration was compromised and the 
respiratory capacity was reduced after 8 hours of glutamate challenge in HT22 cells. Recent 
publications suggested mitochondrial damage to be mediated by the transactivation of BID to 
the mitochondria [103,186]. Consequently, inhibition of BID by the well-established BID 
inhibitor BI-6c9 [13,14] successfully rescued HT22 cells until 6 to 8 hours post-treatment after 
cell death induction. Taken together, these data imply mitochondrial damage as the point of no 
return in oxidative cell death given the fact that cells cannot be rescued once their mitochondria 
are no longer functional. 
The recently coined term ferroptosis describes a form of oxidative cell death very similar 
to the previously established models of glutamate-induced oxytosis. Common features 
established so far are the induction of oxidative death by Xc- inhibition with glutamate or erastin 
[42], GSH depletion, impaired GPX4 activity or direct inhibition by 1S, 3R-RSL3 [211] and 
subsequent burst of mainly lipid ROS [38,41,90,211]. The formation of lipid ROS, mostly 
involving oxidized arachidonic [20:4] and adrenic [22:4] phosphatidylethanolamines, is based 
on iron-dependent autoxidation processes [164] as well as enhanced 12/15-lipoxygenase 
activity [170,212]. However, common mechanisms downstream of lipid ROS occurrence 
leading to cell death, in particular mitochondrial and BID contribution, were not entirely clear 
in the context of ferroptosis and, therefore, remained to be further analyzed. Due to apparent 
mechanistic analogy, erastin-induced cell death in HT22 cells was investigated with respect to 
well-known biochemical hallmarks of oxytosis and compared to MEF cells to exclude cell-line 
specific effects.  
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Similar to glutamate-induced oxytosis, erastin-induced cell death in HT22 cells occurred in a 
concentration-dependent manner and could be rescued by BID inhibitor BI-6c9 application. 
Notably, BI-6c9 was not able to rescue H2O2-induced oxidative death excluding unspecific 
antioxidant effects of this compound. Combined XCELLigence measurements and BI-6c9 post-
treatment revealed that erastin-induced cell death required lower concentrations of the Xc- 
inhibiting compound and appeared about 2 hours earlier than glutamate-induced death. In 
addition, the fact that cell death could be rescued by BI-6c9 only until 4 hours post-treatment 
underlines the potency of erastin to induce rapid and strong cell death.  
In contrast to glutamate, erastin was described to mediate direct detrimental effects at 
the mitochondria apart from glutamate/cystine-antiporter inhibition. Yagoda et al. [208] 
suggested that erastin acts through mitochondrial voltage-dependent anion channels 2/3 
(VDAC 2/3), appearance of oxidative species and mitochondrial outer membrane 
permeabilization in tumor cells. Of note, Dixon and co-workers detected erastin-induced 
alterations of mitochondrial morphology, however, they could not observe BID-dependence or 
mitochondrial ROS while Yuan et al. described CDGSH iron sulfur domain 1 (CISD1)-
dependent mitochondrial lipid peroxidation [220]. Analyses of lipid peroxidation, 
mitochondrial ROS formation, mitochondrial membrane potential and cell death established a 
well-ordered erastin-induced cell death pathway in HT22 and MEF cells. While alterations in 
mitochondrial morphology, loss of mitochondrial membrane potential, lipid ROS and loss of 
mitochondrial function consecutively appeared 2 to 6 hours after erastin treatment, 
mitochondrial ROS and cell death were detected rising after 8 to 10 hours post-treatment 
implying harmed mitochondria as the source of ROS production being responsible for 
succeeding cell death applying to both neuronal and non-neuronal cells. 
In conclusion, these data indeed confirm shared mitochondrial cell death pathways of 
oxytosis and ferroptosis in neuronal HT22 cells. Hence, ferroptosis was supposed to involve 
apoptosis inducing factor (AIF) being an essential player in oxytosis [103,162]. Similar to 
oxytosis AIF knockdown provided protection against glutamate or erastin-induced cell death 
by either direct effects of AIF as a pro-death factor or by indirect preconditioning effects 
[23,24,133].  
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To address the role of the pro-apoptotic protein BID in these mutual oxidative cell death 
paradigms, the protein was depleted by two different siRNA sequences and CRISPR/Cas9 to 
achieve full knockout. Transfection of BID siRNAs for 48 hours resulted in 80-90 % reduction 
of BID protein levels. Despite this efficient knockdown, functional effects on cell death were 
hardly detectable and were only found for BID siRNA #2 significantly reducing cell death 
assessed by MTT assay and showing a trend towards protection in Annexin V/PI FACS 
measurements. Thus, these data did not completely match the results of robust protection by 
BID siRNA shown by Landshamer et al. [103] and imply strong contribution of residual BID 
after knockdown for what reason a complete knockout of the protein was desirable. Therefore, 
a pre-designed CRISPR/Cas9 plasmid targeting Bid was transfected in HT22 cells and 
subsequently screened for knockout colonies. On protein level, several colonies were identified 
as potential knockout colonies (#4, #15, #25) as the Bid antibody detected almost no protein. 
However, lacking a protein band on Western-blot level may also result from protein mutations 
at the antibody recognition site. Therefore, genomic DNA sequencing additionally confirmed 
mutations in the CRISPR Bid target region of colonies #15 and #25, while colony #4 additionally 
displayed a nucleotide deletion, hence being the most promising candidate for successful BID 
protein knockout. As the CRISPR guideRNAs are limited to 19-24 nucleotides in length, 
CRISPR targeting is prone to off-target mutations due to unspecific DNA binding. As control, 
the most probable off-target sites were identified using web-based algorithms [179,225] and 
subsequently analyzed by sequencing of colony #4 genomic DNA. In addition, 12/15-LOX and 
xCT protein levels were determined to exclude alterations in these proteins as they are 
essentially involved in oxidative death signaling. Having excluded off-target effects, CRISPR 
BID colony #4 was chosen for further experiments on the role of BID in oxidative cell death 
paradigms. 
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Remarkably, Bid KO in HT22 cells led to a full and sustained protection against glutamate- or 
erastin-induced cell death comparable to BI-6c9-mediated rescue demonstrated by MTT assay, 
Annexin V/PI FACS analysis and real-time impedance measurements. However, this 
protection by Bid knockout was independent of GSH depletion which occurred upstream of 
BID transactivation. In contrast, Bid KO led to the complete abrogation of lipid peroxidation 
and mitochondrial ROS formation. Moreover, Bid knockout preserved the mitochondrial 
membrane potential, mitochondrial energy metabolism as well as healthy morphology, thus 
exposing BID as a key link of death signaling pathways starting with disrupted GPX4 redox 
homeostasis and culminating in mitochondrial damage in neuronal cells. Since the effects of 
Bid knockout were circumvented by reintroduction of either full-length or active truncated BID 
and the fact that the CRISPR knockout cells were still susceptible to cell death induction by 
staurosporine, the protection against glutamate and erastin toxicity can be specifically 
attributed to Bid knockout while excluding general resistance to cell death.  
Taken together, these results strongly suggest BID being transactivated in the course of 
glutamate- and erastin-mediated oxidative death in neuronal cells, thus contrasting the 
previous observations in cancer cells by Dixon et al., where BID was not involved in erastin-
induced ferroptosis demonstrated by using an shRNA library targeting most known genes 
encoding mitochondrial proteins [38]. In addition, the presented involvement of BID is in good 
agreement with earlier studies providing evidence for a key role of BID in models of oxytosis, 
glutamate excitotoxicity and oxygen glucose-deprivation, and in in vivo models of cerebral 
ischemia and brain trauma [14,15,31,72,103,140,186], where BID was shown to mediate 
mitochondrial fragmentation, ROS production and release of apoptosis inducing factor. Hence, 
the concept of BID-mediated mitochondrial damage is transferrable to mechanisms of 
ferroptosis in neuronal cells. 
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For further clarification of merged pathways of oxytosis and ferroptosis, the commonly used 
ferroptosis inhibitor liproxstatin-1 [53,167,227] was analyzed with respect to potential 
protection against glutamate-induced cell death in HT22 cells. Liproxstatin-1, a 
spiroquinoxalinamine derivative initially believed to act through LOX inhibition, is now 
recognized as a radical-trapping antioxidant (RTAs) in lipid bilayers being able to suppress 
ferroptosis in vitro, in Gpx4−/− mice and in a pre-clinical model of ischemia/reperfusion-
induced hepatic damage [53].  
In HT22 cells, liproxstatin-1 completely prevented cell death by both erastin and 
glutamate up to 6 hours post-treatment independent of GSH depletion, suggesting a critical 
amount of accumulating lipid peroxides reached at this time-point. In addition, liproxstatin-1 
was effective in rescuing lipid peroxidation, mitochondrial ROS formation, loss of 
mitochondrial membrane potential and alterations of mitochondrial morphology when applied 
in combination with glutamate or erastin, respectively providing compelling evidence for joint 
cell death pathways of oxytosis and ferroptosis. 
In conclusion, these data suggest that ferroptosis in neurons is merged with previously 
separated pathways of oxytosis through BID transactivation to mitochondria, thereby 
underlining mitochondrial damage as the crucial point of decision for neuronal function and 
survival. Such BID-dependent mitochondrial death pathways involve fragmentation of the 
organelles, impaired ATP synthesis, and loss of mitochondrial membrane potential and 
mitochondrial membrane integrity. Subsequently, mitochondrial damage results in the release 
of pro-apoptotic factors such as AIF and Cytc providing potential new therapeutic intervention 
strategies in preventing neuronal death at different levels of cellular stress. Such approaches 
may include ferroptosis inhibitors, inhibitors of lipid peroxidation and strategies of 
mitochondrial protection through inhibition of BID. 
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In light of this discussion, the exact mechanisms underlying BID activation by ROS and the 
precise biochemical pathway of BID-mediated mitochondrial damage upon oxidative stress 
require further investigation. During apoptosis, BID is activated to tBID by cleavage via 
caspases or calpains. However, this potential mechanism of BID activation was excluded in 
oxidative death in HT22 cells, as pan caspase inhibitors, such as z-VAD-fmk, or calpain 
inhibitors were not able to rescue the cells from glutamate toxicity [54,103,194]. In addition, to 
date, tBID was not detectable following glutamate challenge by Western blot analysis. Instead, 
full-length BID was observed translocating to the mitochondria after glutamate or erastin 
challenge, suggesting a cleavage-independent activation machinery already proposed by König 
et al. in excitotoxic death in hippocampal rat neurons [99]. Therefore, ROS seem to activate 
BID in a different way than in apoptosis. Garcia-Perez et al. previously revealed involvement of 
ROS in the progression of tBID-induced Cytc release by sensitizing the mitochondria for OMM 
permeabilization [61]. Vice versa, tBID stimulated mitochondrial ROS production to 
coordinate the permeabilization of mitochondria using an inter-mitochondrial amplification 
mechanism to propagate Cytc release and to establish an all-or-none response of OMM 
permeabilization. Similarly, Ding et al. linked BID to mitochondrial ROS generation by 
demonstrating that BID-deficient hepatocytes exhibited significantly less mitochondrial ROS 
upon induction of apoptosis [37].  
In this context, several BID-receptors at the mitochondria have been suggested, such as 
BAX [18], cardiolipin ([68,112]) or MTCH2 [92,146], all of which are not sufficiently analyzed 
yet regarding their specific contribution to oxidative death in HT22 cells. At least for BAX an 
upregulation after glutamate-induced cell death in HT22 cells has been described [107,224], 
however, the necessity of BAX for oxidative death in HT22 cells is still not settled. On the other 
hand, mechanisms of tBID directly re-arranging the inner mitochondrial membrane associated 
with mobilization of Cytc are known, which do not depend on BAK [161]. 
In summary, BID was exposed as a key mediator of mitochondrial damage in neuronal 
ROS-associated regulated cell death, however, the exact underlying biochemical pathways 
inducing BI transactivation and mitochondrial damage require further research. 
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4.2 Mitochondrial rescue prevents GPX4-dependent ferroptosis 
Ferroptosis is defined to occur as a consequence of lethal lipid peroxidation owing to disrupted 
GPX4 redox homeostasis [180]. Glutamate and erastin indirectly mediate such oxidative cell 
death by GSH depletion and have been intensively studied in HT22 cells in particular in the 
context of mitochondrial damage. However, ferroptosis induction by direct GPX4-inhibition 
has not yet been reported in this neuronal cell-line. Therefore, 1S, 3R-RSL3 was exploited as a 
validated GPX4-inhibiting compound. In recent publications, 1S, 3R-RSL3 was established as 
a potent inactivator of GPX4 in a variety of cells through covalent binding by its electrophilic 
chloroacetamide moiety to selenomethionine being specific for this isomeric form [211,212].  
Analogous to these findings, the 1S, 3R-RSL3 isomer induced cell death in HT22 cells 
in a very low nanomolar range whereas the RSL3 isomers exhibited unspecific toxicity with 
1000-fold less potency which underlines the specific toxicity of RSL3 attributed to its unique 
spatial conformation and which is in general agreement with earlier reports by Yang and co-
workers [211]. Interestingly, MEF cells and primary murine and rat cortical neurons were less 
sensitive to 1S, 3R-RSL3 treatment requiring low micromolar concentrations for cell death 
induction, which may be attributed to cell-specific oxidative stress vulnerability by individual 
redox defense mechanisms and different levels of proteins involved in redox homeostasis. 
Notably, 1S, 3R-RSL3 treatment not only inactivated GPX4 but also led to a remarkable 
reduction in GPX4 protein levels after 9-10 hours of treatment which may be caused by protein-
degradation via proteases once GPX4 is inactivated [53]. More interestingly, even at high 
micromolar concentrations, the corresponding des-chloro-derivative 1S, 3R-RSL3-Cl was no 
longer active, supporting the conclusion that chlorine is an indispensable chemical feature for 
covalent GPX4 active site binding and subsequent inactivation.  
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Analyzing the detailed time-course of biochemical events following RSL3-induced disruption 
of the redox homeostasis, it was shown that lipid peroxidation as well as mitochondrial ROS 
formation already occur 2 hours after RSL3 treatment in HT22 and MEF cells, underlining the 
potent redox homeostasis disruption following GPX4 inhibition. The observed ROS 
production was closely followed by loss of mitochondrial membrane potential, reduced energy 
metabolism, excessive mitochondrial fragmentation, and cell death occurred 6-8 hours after 
RSL3 challenge. These data match those of erastin by demonstrating mitochondrial damage as 
a prerequisite for cell death, however, cell death by RSL3 is much faster than by erastin given 
the fact that RSL3 directly targets GPX4 while erastin targets xCT-mediated cystine import, 
which is necessary for GSH synthesis, thereby indirectly affecting GPX4 activity which is 
essential for maintenance of the cell’s redox defense by catalyzing the detoxification of oxidative 
12/15-LOX products and inhibition of 12/15-LOX activity. The observed results confirm 
findings from prior work in various different cell types which documented specific hallmarks 
of erastin, RSL3 or GPX4 KO induced ferroptosis, such as toxic iron overload, disturbed 
GSH/GPX4 redox homeostasis and lipid peroxidation through 12/15-LOX or autoxidation 
[38,41,90]. 
In order to verify BID involvement in this additional paradigm of oxidative cell death, 
CRISPR Bid knockout cells were exposed to RSL3 and the BID inhibitor BI-6c9 was tested. Bid 
KO cells were at least 1000-fold less sensitive compared to HT22 wildtype cells and the BID 
inhibitor was again able to abrogate cell death and mitochondrial damage-associated 
parameters, such as lipid peroxidation, mitochondrial ROS formation and loss of the 
mitochondrial membrane potential, suggesting a vital role for BID in the execution of RSL3-
induced cell death. The BID inhibitor and the commonly known ferroptosis inhibitors 
liproxstatin-1, ferrostatin and deferoxamine, were potent in preventing RSL3-induced cell 
death until 4 to 6 hours of post-treatment, rendering them promising therapeutics in future 
approaches against ferroptosis. However, these results also imply the point of no return to occur 
earlier than in glutamate- or erastin-induced oxidative death.  
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Seiler et al. already demonstrated AIF to be crucially involved in GPX4-mediated oxidative cell 
death [162], which was supposed to apply to RSL3-induced GPX4 disruption as well. Indeed, 
siRNA-mediated knockdown of AIF led to a significant reduction of RSL3-toxicity in HT22 
cells. Similar to other pathways of caspase-independent programmed cell death, mitochondrial 
damage and the subsequent AIF release is considered a hallmark of the ultimate steps leading 
to lethal signaling cascades. The present finding on protective effects of AIF siRNA is, thus, well 
in line with earlier studies demonstrating cell death involving AIF after oxidative damage 
induced by Xc- inhibition or genetic GPX4 deletion and AIF depletion-mediated 
preconditioning effects at the mitochondrial site [31,103,162]. In line with Öxler et al. [133], in 
RSL3-induced mitochondrial damage it can be assumed that preconditioning by siRNA-
mediated AIF knockdown also protects from oxidative cell death through stabilized 
mitochondria and reduced complex I activity. 
Oxidative stress induced mitochondrial damage has been described as a key decision 
point in neuronal cells undergoing cell death. Assuming that protecting mitochondria, similar 
to what has been shown for AIF depletion, might prevent ferroptosis, significant protection was 
found by application of the radical scavenger MitoQ which is targeted to the mitochondria 
[94,95]. This mitochondrial accumulation is facilitated via the positive charge which is spread 
over a large, hydrophobic surface area, allowing these cations to pass easily through membranes 
and to accumulate in the mitochondrial matrix in response to the membrane potential [151]. 
This accumulation was revealed to be 1000-fold more efficient than with the more hydrophobic 
molecule coenzyme Q10, which has received increasing attention as therapeutic and preventive 
intervention for neurodegenerative disorders [214]. However, in the treatment of Parkinson’s 
patients, Q10 did not improve motor symptoms although well-tolerated and safe as assessed by 
meta-analysis of randomized controlled trials [226]. In addition, a clinical study of Q10 in 
Huntington’s disease also failed to slow the progressive functional decline [121]. 
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Despite a considerable amount of studies investigating MitoQ [94,95], no evidence was 
available for the detailed protective mechanism in regulated oxidative cell death. The results 
presented here show that the cytoprotective effect of MitoQ was indeed mediated by selective 
attenuation of mitochondrial ROS formation during oxidative cell death through reduced 
mitochondrial respiration and concomitantly enhanced glycolytic function, which has been 
already described by Fink et al. in isolated mitochondria and in bovine aortic endothelium cells 
(BAE) [52]. It was further revealed that MitoQ significantly protected from RSL3-induced lipid 
peroxidation, mitochondrial ROS formation, loss of mitochondrial membrane potential and 
cell death, and that its protective potential was lost upon glycolysis inhibition by 2-
desoxyglucose. Notably, at low cytoprotective concentrations MitoQ rescued only 
mitochondrial parameters of oxidative cell death but did not affect RSL3-mediated increases in 
lipid peroxidation detected upstream of mitochondrial damage which proves selective ROS 
scavenging within the mitochondria. This finding thereby implies a mechanism of action 
through increased tolerance to oxidative stress at the level of mitochondria without affecting 
non-mitochondrial ROS formation, which the cells can overcome. Such mitochondrial 
protection by MitoQ was sufficient for cell survival despite GPX4 inhibition and pronounced 
lipid peroxidation. Of note, MitoQ application alone rapidly led to a modest mitochondrial 
fragmentation which may be attributed to architectural changes of the mitochondrial 
membrane upon absorption of MitoQ to the matrix surface of the inner membrane and might 
contribute to reduced respiratory chain function which has been established by Roginsky and 
co-workers [150]. The reduced respiratory chain function and simultaneously enhanced 
glycolysis might also contribute to a preconditioning effect rendering mitochondria resistant 
to oxidative stress. 
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Notably, the neuroprotective concentrations of commercially available MitoQ were limited to 
a small range of 0.5 to 1 μM. Concentrations below 0.5 μM did not provide protection, while 
concentrations higher than 1.0 μM had cytotoxic effects which limited the maximum 
protection during oxidative stress in the model system of cultured neuronal HT22 cells. 
Although at low protective concentrations, the ROS scavenger MitoQ rescued mitochondrial 
morphology, respiratory function and cell viability, MitoQ treatment induced opposite effects 
at higher concentrations, i.e. enhanced ROS production and accelerated loss of mitochondrial 
membrane potential [141]. Pro-oxidant properties of MitoQ can be explained by redox cycling 
with superoxide production by its semiquinone form at two sites of the mitochondrial complex 
I, which has been observed by several groups [44,130], and has been eliminated in optimized 
molecules SkQn [172] with a greater therapeutic window. Increased ROS production upon 
MitoQ application has been published to cause the upregulation of autophagy in several cancer 
cell lines in an ATG7- and KEAP1/NRF2-dependent manner, thereby sensitizing cancer cells 
to MitoQ-induced cell death. Vice versa, autophagy acted as an antioxidant feed-back triggered 
by toxic levels of MitoQ [67,148]. The findings on reduced mitochondrial respiration and the 
according increases in glycolysis activity after MitoQ exposure are in line with earlier findings 
showing MitoQ mediated mtDNA damage in MDA-MB-231 and H23 cancer cells, thereby 
decreasing expression of mitochondrial-encoded respiratory chain subunits, which was also 
compensated by increased glycolytic activity [141]. As a consequence of glycolytic shift, MitoQ 
displayed chemotherapeutic effects in combination with 2-DG, which synergistically sensitized 
cancer cells to cell death as they, to some extent, already shifted their energy metabolism 
towards glycolysis (Warburg effect), which can be intensified by MitoQ [22]. 
In this thesis, further investigation on the potential mechanism of MitoQ revealed no 
rescue activity against tBID-induced cell death. TBID overexpression, which mediates 
mitochondrial disruption and release of pro-apoptotic factors to the cytosol in HT22 cells, was 
unaffected by MitoQ which rather harmed the cells even more.  
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In the development of MitoQ as a pharmaceutic drug for human application, it passed through 
conventional animal toxicity and oral bioavailability was determined at about 10% [173]. In 
human phase I trials MitoQ was demonstrated to have adequate pharmacokinetic properties 
with oral dosing at 80 mg (1 mg/kg) resulting in a maximum plasma concentration of 
~33 ng/mL after one hour. Currently, oral MitoQ supplementation with 40- 80 mg per day is 
evaluated in clinical phase II studies on Parkinson’s disease [174], hepatitis C virus (HCV) 
mediated rise in liver enzymes [60], non-alcoholic fatty liver disease (NAFLD), fatigue in 
multiple sclerosis (MS), chronic kidney disease, and ageing. The study on PD included newly 
diagnosed untreated patients in a double-blind study of 40 and 80 mg doses of MitoQ over 12 
months, however, no difference between MitoQ and placebo on any measure of PD progression 
was found. This might not necessarily imply ineffectiveness of MitoQ but rather result from 
insufficient accumulation in the brain and/or the fact that upon diagnosis of PD more than 
50 % of dopaminergic neurons are already lost so that treatment at this stage fails. In contrast, 
in non-responder or unsuitable standard-of-care HCV patients a significant effect of 40 and 80 
mg oral MitoQ for 28 days with respect to serum alanine transaminase (ALT) was found.  
Unfortunately, the remaining studies have been either terminated due to poor 
participant recruitment or they are still in the recruitment process. Importantly, these studies 
provide safety data for the long-term administration of MitoQ in humans. Despite mild dose-
dependent nausea, no severe adverse events were reported in either study. However, these 
studies present heterogeneous results requiring more in-depth investigation for targeted 
therapy of oxidative mitochondrial diseases. 
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In conclusion, the present study provides convincing evidence for the substantial involvement 
of mitochondrial impairment in GPX4-dependent oxidative death (Figure 90) and exposes the 
protection upstream of mitochondria by BID inhibition or by targeted mitochondrial 
antioxidants as essential therapeutic strategies for diseases featuring ferroptosis as an 
underlying mechanism of cell death. However, the exact molecular mechanisms orchestrating 
mitochondrial damage in the respective pathologic conditions, such as AD, PD or ischemic 
stroke, have to be elucidated first before predicting the response to targeted mitochondrial 
therapy. In particular, the activation of BID triggered by oxidative stress and the mode of action 
how exactly BID mediates mitochondrial damage require further investigation. 
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Figure 90. GPX4-dependent oxidative cell death 
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4.3 BID crystallization for structure-based design of BID inhibitors 
Having outlined the great significance of BID transactivation during oxidative cell death 
mechanisms, BID inhibition became a sensible therapeutic option for treating 
neurodegenerative disorders involving oxidative stress. To date, solution NMR structures for 
human and mouse BID have been presented [26,120] suggesting eight α-helices arranged in a 
compact fold of which helices H6 and H7 are arranged in an antiparallel manner in the core of 
the protein. The remaining six helices are amphipathic and packed around the two core helices. 
In addition, a flexible unstructured intramolecular loop and N-terminus were observed sharing 
significant similarity with other BCL2 family members, such as BCL-XL [124]. Despite these 
NMR structures, crystal structures of just the BID BH3 peptide in complex with BCL-XL [147] 
or BAX [32] are available. However, high-resolution atomic X-ray data of full-length BID are 
still desirable for in silico optimization of existing lead structures of BID inhibitors 
[10,13,14,131,131] improving specificity and application as future therapeutics.  
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In the course of this thesis, a variety of BID constructs and crystallization screens were 
performed based on previously established protocols [132]. Initial crystals obtained of purified 
Bid3 lacking the flexible N-terminus and intracellular unstructured loop were optimized by 
cysteine-to-serine mutations (CCSS) thereby preventing unspecific GSH binding and 
increasing protein homogeneity after purification. Indeed, Bid3 CCSS crystals grew larger and 
in a reproducible fashion. Crystallization conditions comprising PEGs or MPD and divalent 
cations, such as magnesium, cobalt and calcium, facilitated crystal growth and led to an 
improvement of crystal size. Unfortunately, crystal analysis at the synchrotron microfocus 
beamline in Grenoble displayed insufficient resolution for solving the atomic structure and 
molecular replacement did not work with the electron density data either. Although additional 
heavy-atom exchange approaches were successful in terms of reliable purification and crystal 
growth, these data could not aid structural elucidation of Bid3 crystals. These results might be 
attributed to insufficient crystal quality which should be optimized for future structural 
analyses. As purification and crystallization condition optimization has been almost exhausted 
and is reaching its limits, strategies for improving crystal growth quality would comprise 
altering Bid constructs by mutation rather than testing further crystallization conditions. 
Ideally, the constructs should be mutated back in the direction of full-length Bid including parts 
of the flexible loop as this would reduce the chance of artificially altered protein folding. 
Co-crystallization attempts of BID constructs with different BID inhibitors mostly 
resulted in precipitation of BID inhibitors alone or Bid-inhibitor complex at the time of adding 
the inhibitor to the protein solution, however, some small crystals were obtained, which might 
be composed of the respective Bid construct and the inhibitor in a co-crystal. Unfortunately, 
these crystals need further improvement in their quality as their diffraction properties with 
~3 Å were insufficient to solve their 3D structure. Hence, a diffraction resolution of less than 
2-3 Å would be ideal. 
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Full-length BID purification, which was desirable to prevent artificial protein crystal structures, 
unfortunately, did not result in any crystal growth presumably due to unspecific cleavage 
resulting in a heterogeneous protein solution of BID fragments. As crystal growth is more likely 
in conditions of homogeneous proteins, future approaches should aim at preventing unspecific 
protein cleavage by cloning of full-length Bid constructs that do not require thrombin cleavage. 
For instance, TEV proteases could be used to remove His- or GST-tags by insertion of TEV 
protease cleavage sites (ENLYFQ\S motifs) into the protein constructs [136].  
In addition to mouse Bid constructs, using human Bid constructs would be a reasonable 
strategy to obtain altered and ideally well-diffracting crystals. Another approach for improving 
diffraction properties by stabilizing protein crystals is to fuse T4 lysozyme to the flexible N-
terminus of the protein by cloning as Zou et al. described for facilitating crystallogenesis of the 
β2 adrenergic receptor [230]. T4 lysozyme is a well-folded protein forming crystals under a 
variety of conditions thus stabilizing flexible protein regions upon fusion. Other fusion partners 
for the stabilization and crystallization of G protein-coupled receptors, such as rubredoxin, 
xylanase, flavodoxin and thermostabilized apocytochrome b562 (BRIL), have been described 
by Chun et al. [27] and would be worthwhile in testing for the purpose of stabilizing the Bid 
protein during crystallization. These fusion techniques for crystallization in the presence of 
detergent could be used for tBID crystallization, which has not been successful to date owing 
to low bacterial expression and due to hydrophobicity leading to amorphous protein 
precipitation.  
In conclusion, a promising basis for further optimization of Bid crystallography has 
been established in this thesis, thus facilitating future approaches in solving the 3D structure of 
BID. 
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5 Summary 
Age-related neuropathologies, such as Alzheimer’s and Parkinson’s disease as well as acute 
brain injury commonly involve oxidative stress-induced disruption of the intracellular calcium 
homeostasis, disturbed redox balance and impaired energy metabolism attributed to 
mitochondrial damage which eventually drives neuronal cells to death. Thus, identifying 
biochemical features underlying the detrimental impairment of mitochondrial integrity and 
function is key to develop therapeutic strategies preventing neuronal loss. To date, a great 
variety of regulated cell death modalities has been established in neuronal death. In particular, 
apoptosis, excitotoxicity and regulated necrosis were shown to play a prominent role, and tight 
crosstalk between these paradigms of cell death exists, especially via convergence at the 
mitochondria. Despite increasing knowledge on cell death pathways, for many 
neurodegenerative diseases no curative treatment is available, so far. 
Over the last decades, a number of publications proposed the involvement of BCL-2-
family proteins like BID and BAX in mediating mitochondrial cell death. For the protein BID, 
the contribution to neuronal apoptosis during ischemia has been widely established in vivo, 
exposing BID inhibition as a promising future therapy option. However, in non-apoptotic 
models of oxidative cell death, for instance ferroptosis, the role of BID and involvement of 
mitochondrial damage in cell death execution remained to be elucidated. In addition, the exact 
mechanisms how lipid ROS formation triggers BID activation and mitochondrial demise are 
still unknown. Due to high energy utilization for the maintenance of the membrane potential, 
neurotransmitter synthesis and restoring intracellular ion pools after action potentials, neurons 
strongly rely on oxygen and functional energy metabolism, thus being vulnerable to loss of 
mitochondrial function. 
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The aim of this study was to determine hallmarks of regulated oxidative cell death pathways 
with respect to their time-dependent progression, involvement of BID as well as mitochondrial 
damage. Therefore, CRISPR/Cas9 technology was applied to generate neuronal HT22 cell lines 
lacking BID in order to analyze their sensitivity to oxidative stress induced by erastin and RSL3. 
Further, protective effects of MitoQ were investigated to evaluate the therapeutic potential of 
this mitochondria-targeted ROS scavenger in models of ferroptosis. Additionally, this work 
aimed to improve BID crystallization with novel recombinant protein constructs and optimized 
crystallization conditions. 
The first part of the thesis reports on the involvement of mitochondrial damage in 
oxidative death signaling in neuronal HT22 cells and mouse embryonic fibroblasts. In the 
model of glutamate-induced oxytosis, which is concentration- and cell density-dependent, 
impairment of mitochondrial respiration occurred in a time-dependent manner. In this cell 
death paradigm mitochondrial damage was represented the point of no return in the cell’s 
commitment to die as the well-established BID inhibitor BI-6c9 could rescue the cells within a 
time window of up to 8 hours after onset of glutamate exposure when massive mitochondrial 
damage was observed. The comprehensive analysis of erastin-induced oxidative death revealed 
a close interconnection of the previously separated cell death pathways of oxytosis and 
ferroptosis. In a time-dependent manner, erastin induced loss of mitochondrial membrane 
potential and lipid peroxidation followed by cell death 8 to 10 hours after treatment onset. 
Mitochondrial ROS production and loss of mitochondrial function was observed after 6 hours, 
and was tightly connected to severe mitochondrial fission thereby underlining the major 
finding of mitochondrial damage as the converging point of death signaling in neural and MEF 
cells in this paradigm of erastin-induced ferroptosis. In addition, siRNA-mediated AIF 
knockdown mitigated cell death in HT22 cells exposed to erastin, revealing a significant role 
for AIF release from mitochondria in ferroptosis similar to earlier findings in glutamate-
induced oxytosis. 
  5 Summary 
 
180 
 
The second part of the thesis focused on the involvement of BID in mitochondrial cell death 
pathways. SiRNA approach and CRISPR/Cas9 Bid knockout in HT22 cells revealed a significant 
contribution of BID in mediating mitochondrial demise upon oxidative stress. BID deprived 
cells were not only protected against glutamate- or erastin-induced cell death but also their 
mitochondrial parameters, such as membrane potential, ROS production and morphology 
were preserved at control levels. In contrast, tBID overexpression in Bid KO cells reversed the 
protective effects of BID absence and led to a significant increase in lipid ROS formation and 
cell death. In addition to shared BID involvement, mechanistic overlap of oxytosis and 
ferroptosis could be shown by the comparable cell protection against glutamate and erastin 
challenge by the ferroptosis inhibitor liproxstatin. Direct GPX4 inhibition by 1S, 3R-RSL3 and 
protection mediated by the mitochondria-targeted antioxidant MitoQ further established 
significant contribution of ROS formation to mitochondrial damage and again highlighted a 
role for BID as Bid KO cells were less sensitive to RSL3-mediated ferroptosis. Overall, these 
findings highlight a key role for BID in both paradigms of oxytosis and ferroptosis and expose 
BID transactivation to the mitochondria, mitochondrial oxidative damage and AIF-release as 
common mechanistic hallmarks linking these pathways.  
Finally, the 3D structure of BID should be elucidated by X-ray crystallography and, 
therefore, novel recombinant Bid constructs were established. For the first time, BID crystals 
could be obtained in a reproducible manner and were optimized by improving protein 
constructs and crystallization conditions. In order to solve the phase problem, 
selenomethionine crystals were grown, however, the resolution of electron density data was not 
sufficient to solve the molecular 3D structure of BID but provide a promising basis for further 
optimization.   
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6 Zusammenfassung 
Altersbedingte neuronale Erkrankungen, wie Alzheimer oder Parkinson sowie akute 
Hirnschädigungen nach Schlaganfall oder Schädel-Hirn-Trauma sind durch nachhaltige 
Störungen der zellulären Homöostase in Neuronen gekennzeichnet. Dies ist in der Regel 
verbunden mit einer Entgleisung der intrazellulären Calciumhomöostase, einem gestörten 
Redoxgleichgewicht und Energieverlust, was über die Schädigung der Mitochondrien weiter 
verstärkt wird und schließlich zum Zelltod führt. Folglich ist die Aufklärung biochemischer 
Signalkaskaden des neuronalen Zelltods eine wesentliche Voraussetzung dafür, neue und 
effektive therapeutische Konzepte zu entwickeln. Bislang konnten verschiedene Modalitäten 
des regulierten Zelltods in Neuronen identifiziert werden, darunter Mechanismen der 
Apoptose, Exzitotoxizität sowie regulierten Nekrose. Diese verschiedenen Mechanismen 
münden wahrscheinlich alle in einer Schädigung der Mitochondrien, die damit in der 
Regulation des neuronalen Zelltods eine entscheidende Rolle einnehmen. Trotz zunehmender 
Erkenntnisse über spezifische Signalwege des regulierten Zelltods steht bislang keine kurative 
Therapie für neurodegenerative Erkrankungen zur Verfügung. 
Frühere Arbeiten haben aufgezeigt, dass pro-apoptotische BCL-2 Proteine wie BID und 
BAX eine entscheidende Rolle bei mitochondrialen Mechanismen des Zelltods spielen. In vivo 
konnte nachgewiesen werden, dass BID an der neuronalen Apoptose entscheidend beteiligt ist, 
so dass die Hemmung dieses Proteins einen vielversprechenden Ansatz für zukünftige 
Therapien darstellt. Hingegen sind die Beteiligung von BID und die Schädigung der 
Mitochondrien in nicht-apoptotischen Zelltodmodellen, wie z.B. der Ferroptose, weitgehend 
unklar. Neurone sind auf einen funktionierenden Energiestoffwechsel angewiesen, da sie für 
die Aufrechterhaltung des Membranpotentials, die Neurotransmittersysnthese sowie für die 
Wiederherstellung der Ionenhomöostase nach einem Aktionspotential  viel Energie brauchen, 
was sie wiederum für Schäden durch Sauerstoff- und Energiemangel anfällig macht. 
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Das Ziel dieser Studie war es, die Schlüsselmechanismen des regulierten oxidativen Zelltods 
aufzuklären sowie den Zeitverlauf entsprechend darzustellen und hier insbesondere die Rolle 
von BID bei der Schädigung der Mitochondrien zu charakterisieren. Dafür wurden mithilfe der 
CRISPR/Cas9 Technik Bid knockout Zellen generiert und deren Empfindlichkeit gegen die 
Ferroptose-Induktoren Erastin und RSL3 untersucht. Als weitere therapeutische Strategie 
wurde die Behandlung mit MitoQ analysiert, das reaktive Sauerstoffmoleküle spezifisch in den 
Mitochondrien abfängt. Ferner sollte die BID Kristallisation durch Entwicklung neuer 
rekombinanter Bid Konstrukte und Kristallisierungskonditionen optimiert werden. 
Im ersten Teil der Studie wurde die Regulation des oxidativen Zelltods in MEF und 
neuronalen HT22 Zellen untersucht. Im Modell der Glutamat-induzierten Oxytose konnte ein 
zeitabhängiger Verlust der mitochondrialen Atmung beobachtet werden. In diesem Modell 
konnte mithilfe des BID-Inhibitors BI-6c9 nachgewiesen werden, dass die mitochondriale 
Schädigung durch BID den kritischen Punkt im oxidativen Zelltod darstellt. Nach funktioneller 
und struktureller Schädigung der Mitochondrien kann der Zelltod nicht mehr aufgehalten 
werden. Die Analyse des Erastin-induzierten Zelltods ergab mechanistische Überschneidungen 
der bislang separat betrachteten Zelltod-Modalitäten von Oxytose und Ferroptose. Erastin 
verursachte ähnlich zur Oxytose den Verlust des mitochondrialen Membranpotentials und die 
Produktion von Lipidperoxiden. Diesen folgte der Zelltod innerhalb von ca. 8-10 Stunden. Das 
Auftreten mitochondrialer reaktiver Sauerstoffspezies und der Verlust der mitochondrialen 
Funktion wurde 6 Stunden nach Erastinexposition beobachtet, und trat zeitgleich mit 
morphologischen Veränderungen der Mitochondrien auf. Des Weiteren konnte gezeigt 
werden, dass der Apoptose-induzierender Faktor AIF ebenfalls eine wichtige Rolle in der 
Erastin-induzierten Ferroptose spielt. Die siRNA-vermittelte Depletion von AIF verminderte 
den ferroptotischen Zelltod analog zu früheren Befunden aus dem Modell der Glutamat-
induzierten Oxytose. 
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Der zweite Teil befasste sich mit der Beteiligung des BCL-2 Proteins BID in mitochondrialen 
Prozessen des oxidativen Zelltods. Die Depletion von BID mittels siRNA oder CRISPR/Cas9 
schützte die Zellen vor einer Schädigung der Mitochondrien und Ferroptose. Dies unterstreicht 
die entscheidende Rolle der BID-Aktivierung bei den Schlüsselmechanismen der 
Mitochondrienschädigung im oxidativen Zelltod. Folgerichtig führte die Reexpression von 
aktiviertem tBID zu einer Auslöschung des protektiven Effekts durch die BID-Depletion und 
induzierte wiederum Lipidperoxidation, mitochondriale Schädigung und Zelltod.  
Abgesehen von der gemeinsamen Beteiligung von BID in Oxytose und Ferroptose 
konnten die mechanistischen Übereinstimmungen zudem dadurch nachgewiesen werden, dass 
der Ferroptoseinhibitor Liproxstatin HT22 Zellen auch gegen Oxytose schützte. Die direkte 
Inaktivierung des Enzyms GPX4 mithilfe von 1S, 3R-RSL3 und die gleichzeitige Protektion der 
Mitochondrien mithilfe von MitoQ belegen ebenfalls die signifikante Bedeutung der 
Mitochondrienschäden im Zelltod durch oxidativen Stress. Dieser Teil der Studien 
untermauerte auch die entscheidende Rolle von BID, da Bid KO Zellen auch hier weniger 
sensibel auf die RSL3-Behandlung reagierten. Zusammengefasst unterstreichen diese 
Ergebnisse eine besondere Beteiligung von BID in den beiden Zelltodmodellen Oxytose und 
Ferroptose und belegen, dass die Aktivierung von BID, die Mitochondrienschädigung und 
AIF-Abhängigkeit in diesen bislang getrennt betrachteten Zelltodmodalitäten identisch sind. 
Abschließend sollte die 3D-Struktur von BID mittels Röntgenstrukturanalyse 
untersucht werden. Dazu wurden neuartige rekombinante Bid Konstrukte und deren 
Reinigung etabliert. Zum ersten Mal konnten Kristalle reproduzierbar erzeugt und optimiert 
werden, in dem die Bid Konstrukte und Kristallisationsbedingungen sukzessive verbessert 
wurden. Um das Phasenproblem zu lösen, wurden Selenomethionin-Kristalle gezüchtet, deren 
errechnete Elektronendichten am Ende nicht ausreichten, um die molekulare Struktur 
abschießend zu klären. Dennoch bieten die erhobenen Daten eine vielversprechende 
Grundlage für weitere Optimierungsversuche.   
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7 Abbreviations 
°C Degree Celsius 
μL Microliter 
μM Micromolar 
12/15 LOX 12/15 Lipoxygenase 
2-DG 2-Desoxyglucose 
AA Antimycin A 
ACSL4 Long-chain-fatty-acid—CoA ligase 4 
AD Alzheimer’s Disease 
AIF Apoptosis inducing factor 
ALS Amyotrophic lateral sclerosis 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AMR ATP monitoring reagent 
ANOVA Analysis of variance 
APAF-1 Apoptotic protease-activating factor 1 
APOE Apolipoprotein E 
APP Amyloid precursor protein 
ATP Adenosinetriphosphate 
BAD Bcl-2 antagonist of cell death 
BAK Bcl-2 antagonist killer 1 
BAX Bcl-2 associated x protein  
BCA Bicinchonic acid 
BCL-2 B-cell lymphoma-2 
BCL-XL Bcl-2 related gene, long isoform 
BH Bcl-2 homology 
BI BID inhibitor 
BID Bcl-2 interacting domain death antagonist 
BIK Bcl-2-interacting killer 
BIM Bcl-2-interacting mediator of cell death 
BODIPY 4,4-Difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora 3a,4a-diaza-s-
indacene-3-undecanoic acid 
BOK Bcl-2 related ovarian killer 
Bp Base pairs 
BSA Bovine serum albumin 
Ca2+ Calcium 
Cas9 CRISPR associated protein 9 
Casp Caspase 
cBid Caspase-8 cleaved Bid 
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CCCP Carbonyl cyanide chlorophenyl hydrazone 
CCI Controlled cortical impact 
CD95 Cluster of differentiation 95 
CL Cardiolipin 
Cl- Chloride 
CLSM Confocal laser scanning microscopy 
CNS Central nervous system 
CO2 Carbon dioxide 
COX Cyclooxygenase 
CRISPR Clustered regularly-interspaced short palindromic repeats 
Cu+ Copper 
Cytc Cytochrome C 
DAMP Damage-associated molecular pattern 
DAPI 4',6-Diamidino-2-phenylindole 
DCF Dichlorodihydrofluoresceinediacetate 
Def Deferoxamine 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Desoxyribonucleic acid 
DRP1 Dynamin-related protein 1 
DSB Double-strand break 
DTT DL- Dithiothreitol 
EBSS Earl’s balanced salt solution 
EC50 Half maximal effective concentration 
ECAR Extracellular acidification rate 
EDTA Ethylenediamine-tetra-acetic acid 
EGFP Green fluorescent protein 
EGTA Ethylene glycol-bis(2-aminoethylether)- 
N,N,N’,N’- tetraacetic acid 
EndoG Endonuclease G 
FACS Fluorescence-activated cell sorting 
FADD Fas-associated protein with death domain 
FasL Fas ligand 
FCCP Carbonyl cyanide-4-(trifluoromethoxy)phenyl- 
hydrazone 
FCS Fetal calf serum 
Ferro Ferrostatin-1 
FLIP FLICE-inhibitory proteins 
FT Flow-through 
GAPDH Glyceraldehyde-3-phosphatedehydrogenase 
GFP Green fluorescent protein 
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Glu Glutamate 
GPX4 Glutathione peroxidase 4 
GSH Hydrochloric acid 
h Hour 
H2O2 Hydrogen peroxide 
HBSS Hank’s balanced salt solution 
HCl Hydrogen chloride 
HD Huntington’s disease 
HDR Homology-directed repair 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HRP Horseradish peroxidase 
IAP Inhibitors of apoptosis proteins 
IMM Inner mitochondrial membrane 
IMS Mitochondrial intermembrane space 
IP3 Inositol trisphosphate 
iPSC Induced pluripotent stem cells 
IPTG Isopropyl-β-D-thiogalactopyranosid 
kDa Kilo Dalton 
KO Knockout 
Lip Liproxstatin-1 
LOX Lipoxygenase 
LPCAT3 Lysophospholipid acyltransferase 5 
MALDI-TOF Matrix-assisted laser desorption/ionization time of flight 
MCAO Middle cerebral artery occlusion 
MCL-1 Induced myeloid leukemia cell differentiation protein 
MEF Mouse embryonic fibroblast 
MEM+ Eagle’s minimum essential medium 
MIF Macrophage migration inhibitory factor 
min Minute 
mL Milliliter 
mM Millimolar 
MNNG Methylnitronitrosoguanidine 
MOM Mitochondrial outer membrane 
MOMP Mitochondrial outer membrane permeabilization 
MOPS 3-(N-morpholino) propanesulfonic acid 
mPTP Mitochondrial permeability transition pore 
mtDNA Mitochondrial DNA 
MTCH2 Mitochondrial carrier homolog 2 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
N2 Nitrogen 
NAC N-acetyl-L-cysteine 
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NADH Nicotinamide adenine dinucleotide 
NADPH Nicotinamide adenine dinucleotide phosphate 
NaHCO3 Sodium hydrogen carbonate 
NaOH Sodium hydroxide 
NCX Na+/Ca2+ exchanger 
NHEJ Non-homologous end joining 
nM Nanomolar 
nm Nanometer 
NMDA N-methyl-D-aspartic acid 
NMR Nuclear magnetic resonance 
NO Nitrogen monoxide 
NO+ Nitrosium ion 
NOS Nitrogen monooxide synthethase 
NOXA Phorbol-12-myristate-13-acetate-induced protein 1 
OCR Oxygen consumption rate 
OGD Oxygen-glucose deprivation 
OMI/HrtA2 High temperature acquired protein A2 
ORAI1 Calcium release-activated calcium channel protein 1 
PAM Protospacer adjacent motif 
PBS Phosphate buffered saline 
PC Phosphatidylcholin 
PCD Programmed cell death 
PCR Polymerase chain reaction 
PD Parkinson’s Disease 
PDB Protein data bank 
PE Phosphatidylethanolamin 
PEG Polyethyleneglycole 
PEI Polyethylenimine 
Pen/Strep Penicillin + Streptomycin 
PFA Paraformaldehyde 
pH Potentia hydrogenii 
PI Propidium iodide 
PL Phospholipid 
PLL Poly-L-Lysine 
PMSF phenylmethylsulfonyl fluoride 
PSEN Presenelin 
PTP Permeability transition pore 
PUFA Polyunsaturated fatty acid 
PVDF Polyvinylidenfluorid 
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RCD Regulated cell death 
RIP Receptor-interacting serine/threonine-protein 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
Rot Rotenone 
RSL3 RAS-selective lethal compound 3 
RT Room temperature 
s Second 
Scr Scrambled 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SeMet Selenomethionine 
siRNA Small interfering ribonucleic acid 
SMAC/DIABLO Second mitochondria – derived activator of 
caspase/direct IAP binding protein with low pI 
SOD Superoxide dismutase 
STS Staurosporine 
TBE Tris/borate/EDTA 
TBI Traumatic brain injury 
tBID Truncated BID 
TBS Tris-buffered solution 
TBST Tris-buffered solution with Tween 20 
TC Thrombin-cleavage 
TCEP Tris (2-carboxyethyl) phosphine 
TE Trypsin-EDTA 
TEMED Tetramethylenethylendiamine 
TL Total lysate 
TMRE Tetramethylrhodamin ethyl ester 
TNF Tumor necrosis factor 
TRADD Tumor necrosis factor receptor type 1-associated DEATH 
domain protein 
TRAF2 TNF receptor-associated factor 2 
TRAIL TNF-related apoposis-inducing ligand 
U Unit(s) 
UV Ultra-violet 
V Volt 
VDAC Voltage-dependent anion channel 
w/o Without 
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WB Western-blot 
WT Wildtype  
xCT Glutamine-cystine antiporter 
XIAP X-chromosomal linked inhibitor of apoptosis 
ZFN Zinc finger nuclease 
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